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Abstract 
Thrombosis  is  associated  with  the  occlusion  of  a  blood  vessel  and  can  be  
triggered  by  a  number  of  types  of  injury,  such  as  the  rupture  of  an  atherosclerotic  plaque  
on  the  artery  wall,  changes  in  blood  composition,  or  blood  stasis.    The  resulting  
thrombosis  can  cause  major  diseases  such  as  myocardial  infarction,  stroke,  and  venous  
thromboembolic  disorders  that,  collectively,  account  for  the  most  common  cause  of  
death  in  the  developed  world.    Anticoagulants  are  used  to  treat  and  prevent  these  
thrombotic  diseases  in  a  number  of  clinical  and  surgical  settings.    Although  commonly  
prescribed,  currently  approved  anticoagulants  have  a  major  limitation  of  severe  drug-­‐‑
induced  bleeding,  which  contributes  to  the  high  levels  of  morbidity  and  mortality  
associated  with  use.  The  “holy  grail”  for  antithrombotic  therapy  is  to  identify  a  drug  
that  inhibits  thrombus  formation  without  promoting  bleeding.    Understanding  the  
differences  between  thrombosis  and  hemostasis  in  the  vascular  system  is  critical  to  
developing  these  safe  and  effective  anticoagulants,  as  this  depends  on  striking  the  
correct  balance  between  inhibiting  thrombus  formation  (efficacy)  and  reducing  the  risk  
of  severe  bleeding  (safety).    While  it  is  commonly  thought  that  the  same  factors  play  a  
similar  role  in  hemostasis  and  thrombosis,  recent  evidence  points  to  differing  functions  
for  FXI  and  FXII  in  each  of  these  settings.    Importantly,  these  factors  seem  to  contribute  
to  pathological  thrombus  formation  without  being  involved  in  normal  hemostasis.  
     v  
The  overall  goal  of  this  project  was  to  evaluate  the  inhibition  of  the  intrinsic  
pathway  of  coagulation  as  a  potential  anticoagulant  strategy  utilizing  the  aptamer  
platform.  Aptamers  are  short,  highly  structured  nucleic  acids  that  act  as  antagonists  by  
binding  to  large  surface  areas  on  their  target  protein  and  thus  tend  to  inhibit  protein-­‐‑
protein  interactions.    High  affinity  binding  aptamers  have  been  isolated  that  specifically  
target  a  diverse  range  of  proteins,  including  transcription  factors,  proteases,  viral  
proteins,  and  growth  factors,  as  well  as  other  coagulation  factors.    As  synthetic  
molecules,  aptamers  have  a  small  molecular  weight,  are  highly  amenable  to  
modifications  that  can  control  their  bioavailability,  and  have  not  been  found  to  elicit  an  
immune  response,  thus  making  them  ideal  drug  candidates.  Importantly,  aptamers  can  
be  rapidly  and  effectively  reversed  with  either  a  sequence  specific  antidote  that  
recognizes  the  primary  sequence  of  the  aptamer  or  a  universal  antidote  that  binds  to  
their  backbone  and  reverses  all  aptamer  activity  independent  of  sequence.  This  ability  
lends  itself  well  to  their  therapeutic  application  in  coagulation,  as  rapid  reversal  of  a  
drug  upon  the  onset  of  bleeding  is  a  key  property  for  increasing  the  safety  of  this  class  of  
drugs.  
Aptamers  targeting  FXI/FXIa  and  FXII/FXIIa  were  isolated  in  two  separate  
SELEX  (systematic  evolution  of  ligands  by  exponential  enrichment)  procedures:  the  FXII  
aptamer  was  isolated  in  a  convergent  SELEX  approach  and  the  FXIa  aptamer  was  
isolated  from  a  purified  protein  selection.  In  both  processes,  2’fluoropyrimidine  
     vi  
modified  RNA  with  a  40-­‐‑nucleotide  random  region  was  incubated  with  either  the  
plasma  proteome  (in  initial  rounds  of  the  convergent  SELEX)  or  the  purified  protein  
target  (FXII  or  FXIa).    The  nucleic  acids  that  did  not  bind  to  the  target  were  separated  
from  those  that  bound,  and  these  molecules  were  then  amplified  to  generate  an  enriched  
pool  with  increased  binding  affinity  for  the  target.    This  process  was  repeated  under  
increasingly  stringent  conditions  to  isolate  the  aptamer  that  bound  with  the  highest  
affinity  to  the  purified  target  protein.    Utilizing  biochemical  and  in  vitro  coagulation  
assays,  specific,  high-­‐‑affinity  binding  and  functional  anticoagulant  aptamers  were  
identified  for  both  protein  targets,  and  the  mechanism  of  anticoagulation  was  
ascertained  for  each  aptamer.    
Overall,  both  aptamers  bound  to  an  exosite  on  their  target  protein  that  was  able  
to  inhibit  downstream  activation  of  the  next  protein  in  the  coagulation  cascade.    In  order  
to  specifically  examine  aptamer  effects  on  several  parameters  of  thrombin  generation,  a  
new  assay  was  developed  and  fully  characterized  using  aptamer  anticoagulants  
targeting  other  coagulation  factors.    Aptamer  inhibition  of  both  FXI  and  FXII  was  able  to  
decrease  thrombin  generation  in  human  plasma.    However,  limited  cross-­‐‑reactivity  in  
other  animal  species  by  both  aptamers  hindered  our  ability  to  assess  aptamer  inhibition  
in  an  in  vivo  setting.    The  further  characterization  and  use  of  these  aptamers  in  plasma  
and  blood  based  settings  will  allow  us  to  study  the  diverging  functions  of  the  intrinsic  
pathway  in  thrombosis  and  hemostasis.  
     vii  
A  critical  need  exists  for  safe  and  effective  anticoagulants  to  treat  and  prevent  
numerous  thrombotic  procedures  and  diseases.    An  ideal  anticoagulant  is  one  that  
strikes  the  correct  balance  between  inhibiting  thrombus  formation  and  reducing  drug-­‐‑
induced  bleeding.    Inhibition  or  depletion  of  factors  XI  and  XII  of  the  intrinsic  pathway  
of  coagulation  have  shown  reduced  thrombus  formation  without  interruption  of  normal  
hemostasis  in  several  models  of  thrombosis.    By  developing  novel  RNA  aptamer  
anticoagulants  to  these  factors,  we  have  set  the  stage  for  evaluating  the  net  therapeutic  
benefit  of  intrinsic  pathway  inhibition  to  effectively  control  coagulation,  manage  
thrombosis,  and  improve  patient  outcome.    As  well  as  developing  a  safe  anticoagulant,  
these  agents  can  lead  to  important  biological  discoveries  concerning  the  fundamental  
difference  between  hemostasis  and  thrombosis.    
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1. Introduction  
1.1 Coagulation 
1.1.1 Thrombosis and Hemostasis 
   Hemostasis  is  the  process  that  occurs  to  maintain  the  integrity  of  the  vascular  
system  after  injury  by  keeping  blood  contained  within  the  circulatory  system  and  to  
sustain  patency  of  a  blood  vessel.    This  process  is  crucial  for  life  and  is  highly  conserved  
throughout  organisms,  from  worms  to  zebrafish  to  humans  (1).  Thrombosis,  or  the  
formation  of  a  blood  clot  which  can  grow  to  occlude  or  partially  occlude  a  blood  vessel,  
is  thought  to  result  from  pathological  processes  that  ultimately  overwhelm  the  normal  
regulatory  systems  of  hemostasis  (2).    Thrombosis  is  responsible  for  the  three  most  
common  vascular  diseases:  myocardial  infarction  (MI),  ischemic  stroke,  and  venous  
thromboembolism  (VTE),  which  collectively  include  deep  venous  thrombosis  (DVT)  and  
pulmonary  embolism  (PE).    Including  other  abnormalities  in  blood  coagulation  (such  as  
inherited  bleeding  disorders)  and  other  coronary  diseases,  cardiovascular  disease  (CVD)  
is  the  leading  cause  of  death  worldwide  (3).    
The  process  of  thrombosis  is  often  described  using  Virchow’s  triad,  which  states  
that  changes  in  blood  flow,  blood  composition,  or  the  endothelial  cell  lining  of  the  vessel  
walls  all  contribute  to  thrombosis  (4).    In  the  development  of  a  thrombus,  reduced  blood  
flow,  stasis,  and  the  resulting  decreased  oxygen  tension  can  allow  for  the  buildup  of  
procoagulant  proteases  and  mechanisms  that  can  overcome  the  natural  anticoagulant  
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processes  present  at  that  site.    A  number  of  disease  states  and  environmental  and  genetic  
risk  factors,  such  as  age,  cancer,  pregnancy,  obesity,  and  the  use  of  hormone  
replacement  therapy  or  contraceptives,  which  can  all  result  in  thrombophilia,  can  alter  
the  composition  of  blood.    Thrombophilia  is  a  blood  disorder  in  which  blood  has  an  
increased  tendency  to  clot,  generally  caused  by  either  an  increase  in  clotting  proteins,  
procoagulant  mutations  in  clotting  proteins,  decreases  in  natural  anticoagulant  proteins,  
or  decreased  fibrinolysis.      The  endothelial  cells  lining  the  vessel  walls  are  normally  
found  in  an  anticoagulant  state,  with  the  expression  of  protein  anticoagulants  and  a  
dampened  ability  to  attach  to  proteins  and  cells  present  in  flowing  blood.    Changes  in  
the  endothelial  cells,  upon  reduced  oxygen  tension  or  mechanical  injury,  can  drastically  
alter  their  ability  in  adhering  to  and  activating  inflammatory  cells,  platelets,  and  
coagulation  proteases  and  thus  initiate  clotting.    While  a  defect  in  one  of  these  elements  
can  go  unnoticed,  the  addition  of  a  second  abnormality  could  be  additive  or  even  
synergistic  in  causing  thrombosis,  and  effective  clinical  diagnosis  and  treatment  relies  on  
the  simultaneous  consideration  of  all  soluble,  cellular,  and  physiological  markers  (5).      
1.1.2 Coagulation Cascade 
The  ability  of  blood  to  coagulate,  or  form  clots,  has  been  documented  from  the  time  
of  Hippocrates,  where  it  was  noted  that  blood  removed  from  the  body  congealed  upon  
cooling  (6).    This  view  was  widely  accepted  until  the  mid  1850’s,  when  scientists  showed  
that  blood  clotting  could  be  accelerated  in  the  body  with  the  addition  of  foreign  
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substances,  therefore,  the  ability  of  blood  to  clot  was  “intrinsic”  to  itself.    Throughout  the  
next  century,  the  various  components  of  the  clotting  cascade  were  discovered,  beginning  
with  the  four  basic  factors:  fibrinogen,  prothrombin,  thromboplastin  (now  called  tissue  
factor),  and  calcium.    At  the  turn  of  the  century,  Paul  Morawitz  first  described  the  
“classic  theory”  of  coagulation,  whereby,  in  the  presence  of  tissue  factor  (TF)  and  
calcium,  prothrombin  was  converted  to  thrombin,  which  would  then  convert  fibrinogen  
to  fibrin  to  achieve  clotting  (6).    Throughout  the  next  century,  the  other  clotting  factors  
were  discovered,  mainly  through  the  examination  of  coagulopathic  patients  deficient  in  
one  of  these  factors.      
By  the  mid-­‐‑1960s,  a  “waterfall”(7)  or  “cascade”(8)  schematic  of  coagulation  was  
organized,  whereby  an  activated  serine  protease  sequentially  activates  the  next  zymogen  
in  the  overall  sequence,  culminating  in  thrombin  production  and  fibrin  clot  formation.    
These  processes  were  known  to  proceed  in  the  presence  of  a  lipid  and  calcium  (Factor  
IV).  This  cascade  has  become  slightly  more  defined  since  the  publication  of  those  
seminal  papers,  as  the  discovery  of  the  action  of  cofactors,  naturally  occurring  inhibitors,  
feedback  loops,  and  multiple  ways  to  activate  the  cascade  have  slightly  altered  the  
original  format.    
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Figure  1.    The  cascade  model  of  coagulation  
Adapted  from  Hoffman  and  Monroe,  Hematol  Oncol  Clin  North  Am,  2007  (9)  
  
Today,  this  model  describes  two  converging  pathways  initiated  by  either  
exposure  of  TF  on  the  vessel  wall  at  the  site  of  injury  (extrinsic  pathway)  or  by  activation  
of  blood-­‐‑borne  components  in  the  vasculature  (intrinsic,  or  contact  activation,  pathway)  
(Figure  1).  The  extrinsic  pathway  is  essential  for  localized  fibrin  clot  formation  at  the  site  
of  injury,  and  is  triggered  by  the  binding  and  subsequent  activation  of  factor  VII  (FVII)  
to  exposed  endothelial  TF,  thus  forming  the  extrinsic  tenase  complex.    The  intrinsic,  or  
‘contact’  pathway,  is  activated  when  factor  XII  (FXII)  is  exposed  to  negatively  charged  
surfaces,  causing  autoactivation  of  FXII  to  FXIIa.  FXIIa  then  activates  factor  XI  (FXI),  
which  can  then  activate  factor  IX  (FIX).    FIXa  can  then  complex  with  its  cofactor,  
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activated  factor  VIII  (FVIIIa),  leading  to  the  formation  of  the  intrinsic  tenase  complex.    
The  extrinsic  and  intrinsic  pathways  converge  with  the  activation  of  factor  X  (FX)  by  
either  the  extrinsic  tenase  or  the  intrinsic  tenase.    FXa  then  binds  to  its  cofactor  factor  Va  
(FVa),  forming  the  prothrombinase  complex,  which  can  then  activate  prothrombin  to  
thrombin,  leading  to  the  conversion  of  fibrinogen  to  fibrin  (1).  
While  this  cascade  models  elegantly  depicts  the  series  of  reactions  necessary  to  
form  a  clot,  it  does  not  explain  several  clinical  observations.    First,  this  model  does  not  
depict  why  patients  with  hemophilia  A  or  B  (FVIII  or  FIX  deficiency)  have  severe  
bleeding  phenotypes,  even  though  the  extrinsic  pathway  in  these  patients  is  intact.    In  
addition,  patients  with  deficiencies  of  the  two  initiating  members  of  the  intrinsic  
pathway,  FXII  and  FXI  (hemophilia  C),  either  have  no  bleeding  tendencies  or  an  injury-­‐‑
related  variable  bleeding  tendency,  respectively.    Thus,  the  extrinsic  pathway  could  
seemingly  compensate  for  the  loss  of  FXII  or  FXI,  but  not  FIX  or  FVIII,  an  observation  
that  the  current  cascade  model  did  not  explain  (9).    
   To  address  these  and  other  observations  regarding  platelet  and  endothelial  cell  
interactions  with  coagulation  factors,  a  revised,  cell-­‐‑based  model  of  coagulation  was  
presented  in  which  TF-­‐‑bearing  cells  and  activated  platelets  serve  as  a  scaffold  for  
procoagulant  proteins  to  interact  and  ultimately  form  a  localized  fibrin  clot  to  repair  the  
vessel  wall  (10).    In  this  system,  coagulation  occurs  in  three  overlapping  stages:  
initiation,  amplification,  and  propagation  (Figure  2).    




Figure  2.  The  cell-­‐‑based  model  of  coagulation  
Adapted  from  Hoffman  and  Monroe,  Hematol  Oncol  Clin  North  Am,  2007  (9)  
  
Initiation  occurs  primarily  through  the  exposed  TF/VIIa  extrinsic  complex  on  the  
surface  of  an  endothelial  cell  at  the  site  of  injury.    This  complex  can  then  activate  FIX,  
thus  linking  the  extrinsic  and  intrinsic  pathways,  which  can  then  diffuse  from  the  
surface  of  the  cell  and  localize  on  the  platelet  surface.    The  extrinsic  tenase  can  also  
activate  FXa  on  the  surface  of  the  TF-­‐‑bearing  cell.    This  activation  is  localized  by  TF  
pathway  inhibitor  (TFPI)  or  antithrombin  (AT),  which  rapidly  inhibits  any  FXa  that  
diffuses  away  from  the  site  of  injury.    FXa  then  combines  with  FVa  on  the  surface  of  the  
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TF-­‐‑bearing  cell  to  form  the  prothrombinase  complex.    In  this  stage,  FV  can  become  
activated  by  two  ways:  1)  by  FXa  or  non-­‐‑coagulation  proteases  and  2)  the  release  of  FVa  
from  α-­‐‑granules  of  partially  activated  platelets.    The  resulting  prothrombinase  complex  
on  the  surface  of  exposed,  TF-­‐‑bearing  cells  then  activate  low  levels  of  thrombin  (9).      
In  the  amplification  stage,  this  small  amount  of  thrombin  can  feedback  and  
prime  the  coagulation  cascade  for  rapid  thrombin  generation.    Thrombin  has  several  
roles  in  this  stage.    First,  thrombin  can  bind  to  receptors  on  the  platelet  surface,  thus  
accelerating  platelet  activation.    In  addition,  thrombin  activates  FVIII,  FXI,  and  
additional  FV  in  feedback  loops  that  result  in  high  levels  of  activated  coagulation  
proteases  on  the  platelet  surface.    It  is  this  augmentation  and  activation  of  various  
cofactors  (FVIII,  FV)  that  leads  into  the  propagation  stage,  where  activated  FIX,  formed  
from  both  FXIa  and  TF/VIIa,  can  complex  with  FVIIIa  to  activate  FX  on  the  surface  of  the  
platelet.    The  resulting  prothrombinase  complex  can  then  produce  the  burst  of  thrombin  
necessary  to  form  a  stable  fibrin  clot.    This  generated  thrombin  can  also  activate  other  
mechanisms  (platelet  receptors,  FXIII,  inhibitors  of  fibrinolysis)  to  stabilize  the  clot  (10).      
With  this  model,  it  is  clear  that  the  extrinsic  and  intrinsic  pathways  are  not  
redundant;  in  fact,  the  extrinsic  pathway  initiates  thrombin  generation  on  exposed  TF  
bearing  cells,  whereas  the  intrinsic  pathway  amplifies  thrombin  generation  on  the  
surface  of  the  platelet  to  form  and  stabilize  the  clot.    A  notably  absent  coagulation  factor  
in  this  scheme  is  FXII,  as  thrombin  feedback  of  FXI  on  the  surface  of  platelet  provides  
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sufficient  amounts  of  FXIa  to  boost  the  production  of  FIX  (11).    These  observations  fit  
with  clinical  data,  as  FXII  does  not  seem  to  be  essential  for  hemostasis.    However,  recent  
observations,  discussed  in  more  detail  later  in  this  chapter,  suggest  that  FXII  might  have  
a  mechanism  in  thrombus  formation,  as  continued  FXIa  and  subsequent  thrombin  
generation  on  the  surface  of  a  clot  may  contribute  to  continued  thrombus  stability.    
While  the  numerous  coagulation  proteases  work  primarily  to  generate  thrombin  
and  form  a  fibrin  clot,  platelets,  which  are  anuclear  cells  circulating  at  high  
concentration  in  the  blood,  also  become  activated  at  the  site  of  vascular  injury  and  form  
an  integral  part  of  the  clot  that  seals  the  vasculature.    At  the  site  of  vessel  wall  injury,  
there  is  numerous  crosstalk  between  coagulation  proteases,  platelets,  and  endothelial  
cells.    While  platelet  activation  is  a  complex  topic  reviewed  extensively  (1,  12),  platelets  
offer  a  procoagulant  surface  for  coagulation  proteases  to  generate  thrombin,  as  well  as  
providing  stable  adhesion  to  the  vessel  wall  and  mediating  signaling  activities  to  
enhance  thrombus  formation.    That  platelets  are  essential  for  coagulation  is  evident  by  
the  severe  bleeding  phenotypes  in  patients  with  thrombocytopenia  (decreased  amount  
of  platelets  in  the  blood)  or  genetic  disorders  affecting  platelet  pathways.      
While  the  process  described  above  outlines  how  coagulation  occurs  to  repair  
injury  to  the  vascular  system,  an  important  physiological  concept  includes  the  process  of  
anticoagulation,  which  continually  works  to  regulate  and  localize  coagulation  to  the  site  
of  injury,  and  also  fibrinolysis,  which  breaks  down  the  clot  once  it  is  no  longer  needed  in  
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order  to  keep  blood  vessels  patent.    While  these  two  mechanisms  will  not  be  outlined  in  
detailed,  a  brief  mention  of  these  systems  is  important  in  understanding  the  entire  
hemostatic  system.      
Natural  anticoagulant  mechanisms  are  critical  in  preventing  widespread  clot  
formation.    This  is  evident  by  the  fact  that  mice  lacking  one  of  the  three  major  
anticoagulant  pathways,  protein  C  (inhibiting  FVIIa  and  FVa),  TFPI  (inhibiting  FXa),  and  
AT  (inhibiting  FIXa,  FXa  and  thrombin),  are  not  compatible  with  life  (13).    Protein  C  
becomes  activated  by  increasing  amounts  of  thrombin  binding  to  thrombomodulin  (TM)  
on  the  surface  of  endothelial  cells,  which  can  then  cleave  protein  C  held  in  complex  with  
the  endothelial  protein  C  receptor  (EPCR).    Activated  protein  C  (APC)  can  then  complex  
with  Protein  S  to  effectively  inhibit  the  action  of  the  important  cofactors  FVIIIa  and  FVa.    
Dysfunction  of  this  pathway  is  implicated  in  disseminated  intravascular  coagulation  
(DIC),  which  results  in  widespread  clotting  and  subsequent  bleeding  from  consumption  
of  coagulation  factors.    TFPI  limits  the  initiation  of  coagulation  by  directly  inhibiting  free  
FXa,  and  also  interacting  with  the  TF/FVIIa/FX  complex.  TFPI  function  seems  to  be  
partially  dependent  on  Protein  S.    AT  inhibits  three  key  coagulation  proteases,  FIXa,  
FXa,  and  thrombin,  and  is  as  such  is  one  of  the  more  important  inhibitors  of  thrombin  
generation.    True  AT  deficiency  has  never  been  observed  in  humans,  while  homozygous  
deficient  mice  die  in  utero,  suggesting  that  AT  deficiency  is  lethal  (1).    
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In  order  to  maintain  blood  flow,  the  fibrinolytic  pathway  degrades  fibrin  clots  
once  they  are  no  longer  needed  to  seal  a  site  of  injury.    Plasminogen,  the  protease  that  
degrades  fibrin  into  soluble  fibrin  degradation  products,  is  activated  by  tissue  
plasminogen  activator  (tPA)  and  urokinase  plasminogen  activator  (uPA).    While  tPA  
actually  binds  to  fibrin  and  aids  in  the  lysis  of  clots,  uPA  acts  on  the  cellular  level.    There  
are  several  inhibitors  of  fibrinolysis,  including  plasminogen  activator  1  (PAI-­‐‑1),  α2-­‐‑
antiplasmin,  and  thrombin  activated  fibrinolysis  inhibitor  (TAFI).    The  importance  of  
these  proteins  are  evident,  as  patients  deficient  in  plasminogen  have  an  increased  
likelihood  of  clotting,  and  deficiencies  of  PAI-­‐‑1  result  in  an  increased  tendency  to  bleed  
(14).    A  more  complete  view  of  the  coagulation  cascade,  including  anticoagulant  and  
fibrinolytic  mechanisms,  are  detailed  in  Figure  3.    
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Figure  3.  The  coagulation  cascade,  including  the  anticoagulant  and  fibrinolytic  
systems  
Adapted  from  Mackman,  Arterioscler  Thromb  Vasc  Biol.  2005.  (13)  
  
1.2 Contact Pathway/Intrinsic pathway 
Portions  of  this  section  have  been  adapted  from  the  manuscript  entitled  “The  many  faces  of  the  
contact  pathway  and  their  role  in  thrombosis”  published  in  the  Journal  of  Thrombosis  and  
Thrombolysis  on  July  2011,  32(1):  9-­‐‑20  and  authored  by  Rebecca  Woodruff,  Bruce  Sullenger,  and  
Richard  Becker,  as  well  as  a  second  manuscript  entitled  “Antithrombotic  therapy  in  acute  
coronary  syndrome:  how  far  up  the  coagulation  cascade  will  we  go?”  published  in  Current  
Cardiology  Reports  on  July  2010,  12(4):  315-­‐‑20  and  authored  by  Rebecca  Woodruff,  Bruce  
Sullenger,  and  Richard  Becker.    
     12  
1.2.1 FXII 
Human  FXII  is  an  80kDa  glycoprotein  that,  upon  activation,  forms  α-­‐‑FXIIa  
comprised  of  a  50kDa  amino  acid  heavy  chain  and  a  30kDa  light  chain  linked  by  a  
disulfide  bond  (15).    While  the  light  chain  contains  the  catalytic  domain  capable  of  
activating  FXI  and  prekallikrein  (PK),  the  heavy  chain  consists  of  several  conserved  
domains  that  mediate  binding  to  other  proteins  and  surfaces,  including  fibronectin  type  
I  and  II  domains,  two  EGF-­‐‑like  domains,  a  kringle  domain,  and  a  proline  rich  region  
(16).    The  gene  for  FXII  (F12)  is  closely  related  to  human  growth  factor  activator  (HGFA)  
(17),  and  contains  considerable  homologous  structural  regions,  including  epidermal  
growth  factor  domains,  with  the  fibrinolytic  proteins  tPA  and  uPA  (18-­‐‑20).  
Binding  by  the  heavy  chain  to  a  negatively  charged  surface,  such  as  dextran  
sulfate  or  kaolin,  induces  a  conformational  change  that  allows  FXII  to  be  more  
susceptible  to  cleavage  (21,  22).    This  cleavage  can  occur  slowly  by  FXII  autoactivation  or  
more  efficiently  by  kallikrein  in  a  feedback  loop  (23,  24).    Biologically,  a  number  of  
negatively  charged  substances,  including  polyphosphates,  nucleic  acids,  mast  cell  
heparin,  and  collagen,  among  others,  have  been  found  to  activate  FXII  in  vivo  (25-­‐‑28).   
Once  activated,  surface  bound  α-­‐‑FXIIa  can  cleave  FXI  and  PK,  and  plasma  
kallikrein  can  then  reciprocally  activate  FXII  in  a  positive  feedback  loop  (29,  30).    Further  
cleavage  of  FXII  leads  to  a  smaller  30kDa  fragment,  β-­‐‑FXII,  which  retains  catalytic  
activity  for  PK  but  not  FXI,  and  can  diffuse  away  from  the  activating  surface  (22,  31).    
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FXII  has  also  been  shown  to  bind  to  the  surface  of  endothelial  cells  (mediated  through  
the  urokinase  plasminogen  activator  receptor  (uPAR)  (32),  as  well  as  platelets  (32,  33),  
and  can  thus  affect  other  systems  aside  from  coagulation.    Binding  of  zymogen  FXII  to  
uPAR  on  endothelial  cells  can  stimulate  angiogenesis  (34).    FXII-­‐‑mediated  activation  of  
PK  leads  to  activation  of  the  bradykinin  (BK)  proinflammatory  signaling  pathway  that  
can  induce  vasodilation,  chemotaxis  of  neutrophils,  and  increase  vascular  permeability.    
In  addition,  FXII  can  activate  the  complement  pathway  through  activation  of  the  C1  
esterase  (35),  as  well  as  trigger  the  fibrinolytic  system  through  urokinase  activation.  The  
main  physiologic  inhibitor  for  FXII  is  the  C1  esterase  inhibitor  (36),  although  FXII  
activation  by  platelets  seems  to  be  regulated  by  antithrombin  (37).    While  FXII  can  
influence  a  number  of  systems  in  vitro,  FXII’s  contribution  to  these  systems  in  vivo  is  
unclear.    
Recognition  that  thrombin  can  directly  activate  FXI  and  bypass  the  need  for  FXII-­‐‑
mediated  activation  may  explain  the  absence  of  a  bleeding  phenotype  in  FXII-­‐‑deficient  
patients  and  also  supports  an  emerging  theory  that  FXII-­‐‑mediated  thrombin  generation  
and  fibrin  formation  is  not  an  absolute  prerequisite  for  normal  hemostasis  (38,  39).    
However,  FXII-­‐‑deficient  mice  are  protected  against  thrombus  formation  in  several  
models  of  arterial  and  venous  thrombosis,  but  maintain  normal  hemostatic  capacity.  
Intravital  microscopy  and  blood  flow  monitoring  suggest  that  while  thrombus  initiation  
proceeds  following  vascular  injury,  the  thrombi  themselves  are  unstable  and  disperse  
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rather  developing  to  the  point  of  occlusion  (40).    Infusion  of  human  FXII  into  these  mice  
recovers  the  wild  type  phenotype,  suggesting  that  the  observed  effects  are  highly  
dependent  on  plasma  levels  of  FXII  (40).    Protection  from  thrombosis  is  not  limited  to  
arterial  injury,  as  FXII-­‐‑deficient  mice  have  reduced  brain  infarct  volume  following  
transient  middle  cerebral  artery  stroke  model  (tMCAO)  model  without  an  increase  in  
hemorrhage  (41).    Therefore,  in  mice,  it  is  evident  that  FXII  plays  a  role  in  pathological  
thrombus  formation.  A  search  for  the  primary  (or  dominant)  activator  in  vivo  has  been  
challenging,  as  a  number  of  negatively  charged  substances  commonly  found  at  the  site  
of  a  thrombus,  such  as  polyphosphates,  nucleic  acids,  sulfatides,  fatty  acids,  protein  
aggregates,  and  activated  platelets  have  each  been  found  to  activate  FXII  in  vitro  (27,  42-­‐‑
44).    It  is  well  known  that  activated  platelets  can  accelerate  FXII-­‐‑mediated  fibrin  
formation,  and  the  discovery  that  platelet  released  polyphosphate  can  directly  activate  
FXII  may  serve  as  this  link  (45).    
While  FXII  deficiency  in  mice  confers  thrombotic  protection,  full  deficiency  of  
FXII  is  rare,  and  thus  not  well  described.    However,  there  is  a  history  of  anecdotal  
reports  suggesting  that  complete  deficiency  of  FXII  is  prothrombotic,  including  the  first  
recorded  FXII  deficient  patient,  John  Hageman,  who  died  from  a  pulmonary  embolism  
(46).    Other  studies  have  argued  against  FXII  as  an  independent  risk  factor  for  
thromboembolism,  but  cite  other  risk  factors  in  a  FXII  deficient  background  (47).  
Interestingly,  a  large  Viennese  patient  study  (n=8936)  showed  that  all-­‐‑cause  mortality  of  
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patients  severely  deficient  in  FXII  (<10%)  was  similar  to  patients  with  100%  FXII  plasma  
levels,  suggesting  a  dual  role  of  FXII  in  thrombosis  (48).  Because  FXII  deficiency  causes  
unstable  thrombi  in  mice,  it  may  interfere  with  thrombosis  in  areas  with  high  shear  
stress  that  can  break  apart  the  thrombus  before  it  grows  to  a  larger  size.    However,  
venous  thrombi  can  still  develop  in  areas  with  low  shear  stress,  and  perhaps  have  a  
larger  tendency  to  embolize  during  FXII  deficiency.  In  addition,  other  functions  of  FXII,  
such  as  its  growth  factor  activity  or  role  in  inflammation,  could  also  affect  mortality  
rates  in  severely  deficient  patients.  Future  epidemiologic  studies  will  need  to  be  carried  
out  to  further  elucidate  FXII’s  role  in  humans.    
1.2.2 FXI 
Human  FXI(a)  is  a  160-­‐‑kDa  serine  protease  glycoprotein  that  circulates  as  a  
disulfide  linked  homodimer  of  two  identical  607  amino  acid  subunits.    Each  polypeptide  
consists  of  a  35-­‐‑kDa  C-­‐‑terminal  light  chain  containing  the  trypsin-­‐‑like  catalytic  domain,  
and  an  N-­‐‑terminal  45-­‐‑kDa  heavy  chain  with  four  ~90  amino  acid  tandem  repeats  termed  
apple  domains  (49).    These  apple  domains  confer  binding  to  other  proteins:  A1  contains  
binding  sites  to  high  molecular  weight  kininogen  (HK)  and  thrombin  (50),  A2  &  A3  to  
FIX  (51),  A3  to  the  platelet  receptor  GP1bα  and  heparin  (52),  and  A4  to  FXII  and  the  
other  subunit  of  FXI  (53,  54).    FXI  circulates  in  complex  with  HK,  and  is  structurally  
related  to  PK,  as  both  are  hallmarked  by  the  PAN-­‐‑related  apple  domains  forming  a  disc-­‐‑
like  structure  around  the  base  of  the  catalytic  domain  (55)  (Figure  4).      
     16  
  
  
Figure  4.  A  crystal  structure  of  dimerized  zymogen  FXI  
In  this  topology  diagram,  the  catalytic  domain  is  in  white,  and  sites  of  interactions  are  
highlighted.  H1  and  H2  denote  heparin  binding  sites,  T  is  thrombin,  HK  is  high  
molecular  weight  kininogen,  Gp1b  is  the  platelet  receptor  GP1bα,  FIX  is  factor  IX,  AL  is  
the  activation  loop  cleavage  site,  and  AS  is  the  active  site  residues.    This  figure  is  
adapted  from  Emsley,  Blood,  2010  (55).    
  
FXI  can  be  activated  by  FXIIa  and  thrombin,  both  of  which  cleave  at  the  same  site  
on  FXI,  and  activation  proceeds  through  an  intermediate  structure  with  one  activated  
subunit  (1/2FXIa)  which  can  be  detected  in  plasma  and  may  represent  the  predominant  
active  species  (56).    FXIa  subsequently  activates  FIX  to  FIXαβ  by  the  sequential  cleavage  
of  two  activation  sites  on  FIX  (56-­‐‑59).  Dimerization  seems  to  be  required  for  FXI  
activation,  as  it  is  thought  that  the  proteases  bind  to  one  subunit  while  activating  the  
other  (60).    In  addition,  dimerization  might  be  important  in  tethering  FXI  to  the  site  of  
injury,  as  the  zymogen  subunit  can  bind  to  the  platelet  receptor  GP1bα,  and  leave  the  
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active  subunit  free  to  bind  to  and  activate  FIX.    Zymogen  FXI  binds  to  platelets  better  
than  FXIa,  with  approximately  1500  binding  sites  per  platelet  (61).    Whereas  optimal  
binding  requires  HK,  zinc  ions,  residues  in  the  apple  3  domain  of  FXI,  and  the  N-­‐‑
terminal  domain  of  GP1bα,  recent  work  has  suggested  that  FXI  binds  to  the  platelet  
receptor  ApoER2,  which  colocalizes  with  GP1bα  (55).    FXIa  also  binds  to  platelets,  but  
with  a  much  lower  frequency  of  250  binding  sites  per  platelet  (62).    FXI  and  FXIa  bind  to  
platelets  through  a  separate  binding  site  and  mechanism,  as  FXIa  binding  to  platelets  
seemingly  requires  the  catalytic  domain,  but  not  the  apple  3  domain,  whereas  the  apple  
3  domain  is  required  for  FXI  binding  (55).  
Early  observations  revealed  that  FXI  could  be  activated  by  thrombin  as  well  as  
FXIIa  and  suggested  that  this  route  of  bioamplification  was  favored  in  vivo  over  FXII-­‐‑
mediated  activation  (38).  Subsequent  experiments  revealed  that  FXI-­‐‑mediated  activation  
of  thrombin  was  essential  for  continued  thrombin  generation  in  the  presence  of  low  
levels  of  TF,  but  not  when  higher  levels  of  TF  were  present,  such  as  that  found  at  the  
endothelial  cell  sites  of  injury  (63).    This  continued  thrombin  generation  is  important  for  
the  activation  of  TAFI,  which  can  protect  the  clot  from  fibrinolysis  degradation  (63).  In  
addition,  the  GP1bα  receptor  on  the  surface  of  platelets  contains  binding  sites  for  FXII,  
thrombin  and  FXI,  bringing  these  proteins  into  close  proximity  on  the  platelet  surface  
and  allowing  FXI  to  be  activated  and  subsequently  activate  FIX  in  the  presence  of  
calcium  ions,  thus  amplifying  coagulation  and  thrombin  generation  (56-­‐‑59).    
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The  effect  of  FXI  concentration  on  thrombin  kinetics  varies  widely  among  
individuals  (64),  likely  reflecting  the  several  unique  functional  characteristics  of  the  
protease,  as  well  as  the  dependency  on  the  levels  of  other  procoagulant  proteases,  and  
mirroring  the  variable  bleeding  phenotype  seen  in  FXI  deficient  patients.    In  a  cell  based  
model  system,  as  little  as  5%  of  normal  plasma  levels  of  FXI  led  to  some  thrombin  
generation,  with  a  maximal  amount  of  thrombin  generated  at  50%  of  normal  FXI  
levels(59).    These  observations  lend  to  the  fact  that  FXI  deficiency,  or  hemophilia  C,  has  
historically  been  difficult  to  predict  bleeding  tendency  as  there  has  been  a  poor  
correlation  between  bleeding  phenotype  and  plasma  FXI  levels.  Hemophilia  C  is  a  rare  
bleeding  disorder  that  affects  approximately  one  in  10,000  people  worldwide,  but  is  
more  common  in  distinct  populations,  such  as  Ashkenazi  Jews  (65).    While  hemophilia  C  
does  not  normally  result  in  spontaneous  bleeding,  it  is  a  mild  to  moderate  bleeding  
disorder  with  increased  bleeding  tendencies  in  tissues  with  high  fibrinolytic  activity.    
With  over  190  reported  mutations  in  the  F11  gene  (www.factorxi.com),  there  are  two  
main  types  of  mutation:  CRM-­‐‑  (Type  I)  are  mutations  causing  low  FXI  plasma  levels  
while  CRM+  (Type  II)  are  mostly  functional  mutations  correlating  with  normal  FXI  
levels  but  reduced  coagulant  activity.    
Studies  on  human  patients  with  FXI  deficiency  have  been  similarly  muddled.  
While  severe  deficiency  of  FXI  is  rare,  there  is  some  evidence  that  these  patients  may  be  
protected  against  VTE  and  even  ischemic  stroke  (66,  67).    The  Leiden  Thrombophilia  
     19  
study,  a  large,  population  based  study,  identified  high  FXI  activity  levels  as  a  risk  factor  
for  DVT  (68).    In  addition,  a  retrospective  analysis  of  patients  reported  that  FXI  activity  
above  95%  was  associated  with  a  heightened  risk  of  ischemic  stroke  (68,  69).    Patients  
with  acute  coronary  syndrome  (ACS),  compared  to  patients  with  stable  angina  pectoris,  
have  higher  levels  of  FXIa-­‐‑C1  inhibitor  complexes,  reflecting  acute  activation  of  FXI  (70).  
Overall,  while  FXI  is  considered  a  “procoagulant”  and  elevated  levels  have  been  
associated  with  prothrombotic  phenotypes,  FXI  plasma  activity  in  humans  correlates  
poorly  with  bleeding  risk  (71).  
The  potential  uncoupling  of  FXI’s  role  in  thrombosis  and  hemostasis  is  
supported  by  observations  from  several  models  of  arterial  thrombosis,  venous  
thrombosis  and  stroke  in  FXI-­‐‑  deficient  mice  and  higher  species.    FXI  deficient  mice  
exhibit  prolonged  aPTT  clotting  times  and  reduced  FXI  plasma  activity  levels,  but  had  
no  evidence  of  a  bleeding  phenotype.  Several  studies  using  a  ferric  chloride  model  of  
arterial  injury  with  these  mice  demonstrated  that  FXI  deficiency  protected  from  
thrombus  occlusion  at  a  level  comparable  to  FIX  deficiency  or  high  concentrations  of  
unfractionated  heparin,  but  without  uncontrolled  bleeding  as  measure  by  a  tail  vein  
bleeding  assay  (40,  72,  73).  The  thrombi  that  did  form  were  unstable  and  failed  to  
occlude  the  vessel  (40).    FXI  deficiency  also  conferred  a  thromboprotective  effect  in  a  
tMCAO,  with  a  lower  volume  of  infarcted  brain  tissue  and  less  fibrin  deposition  in  distal  
microvessels  compared  to  wild  type  mice  without  any  detectable  hemorrhage  (41).    The  
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potential  antithrombotic  effect  of  FXI  depletion  or  inhibition  has  also  been  observed  in  
species  other  than  mice.    Antibody-­‐‑mediated  FXI  inhibition  in  rabbits  increased  clot  lysis  
in  jugular  veins  and  reduced  thrombus  propagation  on  injured  neointima  of  the  iliac  
artery  (74,  75),  while  infusion  of  FXI  antibodies  in  baboons  prevented  growth  of  
occlusive  thrombi  in  arterio-­‐‑venous  shunt  and  vascular  graft  occlusion  models(76,  77).    
Administration  of  a  FXI  specific  antisense  oligonucleotide  in  mice  reduced  levels  of  FXI  
while  conferring  an  antithrombotic  effect  similar  to  warfarin  without  abnormal  bleeding  
times  (78).  
1.2.3 The roles of the contact pathway 
The  relevance  of  the  contact  activation  pathway  in  vivo  for  maintaining  
hemostatic  capacity  has  been  debated  as  patients  deficient  in  FXII,  PK,  or  HK  do  not  
typically  present  with  a  bleeding  phenotype,  and  FXI  deficiency  (hemophilia  C),  is  a  
mild  to  moderate,  tissue-­‐‑specific  bleeding  disorder.    In  contrast,  patients  deficient  in  the  
downstream  intrinsic  pathway  factors,  such  as  FIX  or  FVIII,  demonstrate  more  severe  
bleeding  tendencies,  including  spontaneous  bleeding,  while  patients  completely  
deficient  in  TF,  FX  or  FII  have  not  been  described.      Upholding  these  observations,  it  is  
widely  accepted  that  activation  of  the  extrinsic  pathway  is  the  main  pathway  
responsible  for  hemostasis.    In  addition,  the  actions  of  FXII  can  be  bypassed  by  other  
constituents  of  the  coagulation  pathway,  including  thrombin,  which  can  directly  activate  
FXI,  leading  to  continued  thrombin  generation  (38,  79).    This  mechanism  is  thought  to  be  
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increasingly  important  in  settings  where  extrinsic  activation,  or  the  amount  of  TF  
present,  is  low,  such  as  on  the  surface  of  a  growing  clot.    
In  the  past  decade,  in  vitro  and  animal  model  studies  have  suggested  a  larger  role  
in  FXII-­‐‑mediated  activation  of  FXI  in  contributing  to  stable  thrombus  formation  from  
continued  thrombin  generation  on  the  surface  of  a  growing  thrombus.    In  thrombosis,  
substances  that  are  present  at  a  developing  thrombus,  such  as  aggregated  proteins,  
extracellular  RNA  or  other  nucleotides,  collagen,  and  polyphosphate,  could  contribute  
to  the  continued  activation  of  FXII  and  FXI,  leading  to  excessive  thrombin  generation  
and  platelet  activation  to  attenuate  the  growth  of  the  thrombus.  The  role  of  FXII  and  FXI  
in  thrombosis  could  vary  depending  on  the  event,  and  while  the  contact  pathway  might  
play  a  large  role  in  thrombus  formation  where  or  when  the  extrinsic  pathway  has  been  
inhibited,  such  as  on  the  extended  surface  of  a  platelet  rich  thrombus,  FXII  and  FXI  
might  not  be  required  for  thrombosis  at  a  ruptured  plaque,  where  a  large  amount  of  TF  
can  trigger  thrombin  generation  independently  (80).  
The  procoagulant  environment  contributing  to  thrombus  formation  is  not  solely  
influenced  by  activation  of  the  coagulation  cascade  and  platelets,  but  is  also  affected  by  
the  activity  of  other  systems,  including  inflammatory  or  fibrinolytic  systems,  that  FXI  
and  FXII  can  also  influence.    Full  understanding  of  the  systems  that  the  contact  pathway  
affects  is  essential  as  many  vascular  disorders,  such  as  atherosclerosis,  are  influenced  by  
a  number  of  these  processes.    In  fact,  activated  FXII  is  found  at  the  site  of  an  early  
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atherosclerotic  lesion,  and  could  contribute  to  the  inflammatory  and  angiogenic  
processes  that  help  to  develop  an  atherosclerotic  plaque  (81).    Additional  fibrinolytic  
and/or  inflammatory  properties  of  FXII  and  FXI  could  also  play  a  role  in  pathological  
thrombus  formation.    Therefore,  a  detailed  exploration  into  all  of  the  contributions  of  the  
contact  pathway  can  provide  insight  into  the  mechanisms  of  thrombosis  and  guide  
future  drug  development.      
1.2.3.1  The  Evolution  of  the  Contact  Pathway  
It  is  widely  thought  that  a  series  of  gene  duplications  throughout  evolution  led  to  
the  complete  clotting  cascade  as  it  is  seen  in  humans.  Thus,  all  clotting  factors  contain  
many  of  the  same  conserved  domains  and  are  closely  related  to  one  another  (19).    A  
simple  version  of  the  clotting  cascade  appeared  in  the  earliest  vertebrates,  and  as  
vertebrates  themselves  have  become  more  complex  with  more  intricate  and  contained  
cardiovascular  systems,  the  clotting  cascade  has  evolved  similarly.    While  thrombin  was  
the  first  coagulation  factor  to  emerge  before  the  appearance  of  the  first  vertebrates,  the  
contact  pathway  was  the  last  to  evolve,  as  genes  for  HK,  FXII  and  a  single  paralog  of  
PK/XI  are  found  later  in  vertebrate  development  (19).    A  duplication  event  of  the  FXI/PK  
predecessor  gene  led  to  the  separation  of  these  factors  during  the  development  of  early  
mammals,  with  all  placental  mammals  carrying  two  distinct  genes  for  PK  and  FXI  (18).    
Because  of  this  late  emergence,  these  proteins  are  58%  similar  with  the  same  overall  
domain  structure  (82,  83).      Interestingly,  the  gene  for  FXII  has  been  lost  in  some  species  
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during  evolution  as  some  marine  mammals,  such  as  whales  and  dolphins,  as  well  as  
birds,  lack  a  gene  for  FXII,  supporting  the  view  that  this  protein  is  not  needed  for  
hemostasis  (19,  84).    Similarly,  the  gene  for  FXI  is  absent  in  birds,  such  as  the  chicken,  
duck,  and  vulture  (85).    
1.2.3.2  Hemostasis  and  Thrombosis  
In  the  coagulation  cascade,  FXI  can  be  activated  either  by  FXIIa  or  in  a  feedback  
loop  by  thrombin,  and  these  two  routes  may  have  diverging  functions.    FXI-­‐‑mediated  
activation  of  thrombin  is  essential  for  continued  thrombin  generation  in  the  presence  of  
low  levels  of  TF,  but,  when  higher  levels  of  TF  are  present,  thrombin  generation  is  FXI,  
and  also  FXII,  independent  (63,  86).    To  this  end,  preliminary  studies  show  that  low  
TF/FXI  deficient  mice  die  in  utero,  while  FXI  deficient  nice  have  no  bleeding  phenotype,  
suggesting  that  FXI  is  essential  for  hemostasis  while  the  extrinsic  pathway  is  impaired  
(87).      Because  the  thrombin-­‐‑mediated  FXI  activation  pathway  seems  to  be  favored  in  
vivo  over  FXII-­‐‑mediated  activation  it  is  widely  considered  that  FXII-­‐‑mediated  thrombin  
formation  did  not  have  a  significant  role  in  maintaining  normal  hemostasis  (38,  88).      
The  site  at  a  growing  thrombus,  however,  is  quite  different  from  a  hematological  
challenge,  and  could  differ  from  thrombus  to  thrombus.    A  number  of  negatively  
charged  substances  found  in  the  body  and  at  sites  of  vascular  injury,  such  as  
polyphosphates  (26,  45),  extracellular  oligonucleotides  (27,  89),  collagen  (25),  laminin  
(90),  and  aggregated  proteins  (44),  have  been  found  to  activate  FXII.    While  all  of  these  
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substances  could  contribute  the  FXII  activation,  the  main  in  vivo  physiological  activator  
of  FXII,  if  there  is  just  one,  has  not  been  fully  elucidated.  Polyphosphate  released  from  
activated  platelets  is  a  logical  FXII  activator  contained  to  the  site  of  thrombus  formation.    
However,  polyphosphate  can  act  as  a  cofactor  to  augment  thrombin’s  ability  to  activate  
FXI  itself  and  therefore  bypass  the  requirement  for  FXII.    However,  there  is  mounting  in  
vivo  evidence  that  FXII-­‐‑mediated  FXI  activation  contributes  to  thrombus  formation.    
A  growing  clot  at  the  site  of  a  ruptured  plaque  could  be  exposed  to  larger  
amounts  of  inflammatory  proteins  or  the  contents  of  dead  and  dying  cells,  all  which  
could  contribute  the  activation  of  FXII.    To  this  end,  while  mice  deficient  in  FXI  or  FXII  
do  not  exhibit  spontaneous  or  abnormal  bleeding,  these  mice  are  protected  against  
thrombus  formation  in  several  models  of  arterial  and  venous  thrombosis,  as  well  as  
stroke.  In  several  models  of  thrombotic  injury,  intravital  microscopy  work  and  blood  
flow  monitoring  suggest  that,  while  thrombus  initiation  is  not  interrupted  on  the  vessel  
wall  in  both  FXI  and  FXII  deficient  mice,  thrombi  that  are  formed  are  unstable  and  break  
up  before  occlusion  of  a  blood  vessel  can  occur  (40,  72,  73,  91).      Protection  from  
thrombosis  is  not  limited  to  arterial  injury,  as  FXII  and  FXI  deficiency  also  confer  a  
thromboprotective  effect  in  a  tMCAO,  with  a  lower  volume  of  infarcted  brain  tissue  and  
less  fibrin  deposition  in  distal  microvessels  without  any  hemorrhaging  detected  (41).  
MRI’s  performed  in  FXII  deficient  mice  undergoing  tMCAO  found  that,  while  both  
groups  show  severe  hypoperfusion  in  the  first  two  hours  after  removing  the  occluding  
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thread,  the  FXII  deficient  mice  show  an  increase  in  cerebral  blood  flow  from  2  –24  hours  
compared  to  wild  type  mice  (92).    The  antithrombotic  effect  of  FXI  deficiency  is  also  seen  
across  species,  as  inhibition  of  FXI  with  antibodies  in  rabbits  resulted  in  increased  clot  
lysis  in  jugular  veins  and  reduced  thrombus  propagation  on  injured  neointima  of  the  
iliac  artery  (74,  75).    In  addition,  infusion  of  FXI  antibodies  in  baboons  prevented  the  
growth  of  occlusive  thrombi  in  arterio-­‐‑venous  shunts  and  vascular  graft  occlusion  (76,  
77).      Even  at  low  shear  rates  in  an  endothelial  denudation  rabbit  jugular  vein  model,  FXI  
was  found  to  contribute  to  platelet  aggregation  and  fibrin  formation  (93).    
Activation  of  FXII  can  lead  to  activation  of  FXI,  and  thus  coagulation,  but  FXIIa  
can  also  activate  PK.  PK  circulates  in  plasma  bound  to  HK,  and  once  activated,  kallikrein  
cleaves  the  nonapeptide  BK  from  HK.    BK  is  a  vasoactive  peptide  that  mediates  several  
inflammatory  responses,  including  vasodilation  and  vascular  permeability.    In  order  to  
elucidate  which  pathway,  FXII-­‐‑mediated  FXI  activation  or  FXII-­‐‑mediated  PK  activation,  
plays  a  larger  role  in  thrombosis,  thrombosis  models  with  animals  deficient  in  these  
contact  pathway  proteins  were  undertaken.    In  murine  studies  with  deletions  of  other  
constituents  of  the  contact  pathway,  BK  B2  receptor  (the  main  receptor  for  BK)  and  
kininogen  gene  1  (encodes  for  HK)  knockout  mice  caused  a  delayed  time  to  vessel  
occlusion  in  a  Rose  Bengal/laser  injury  carotid  artery  thrombosis  model  (94,  95).    This  
model  causes  less  endothelial  damage  and  collagen  exposure  than  a  applying  the  free  
radical  FeCl3.    While  FXI  and  FXII  deficient  mice  were  able  to  prolong  the  time  to  vessel  
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occlusion  in  this  model  (96),  pharmacologic  inhibition  of  plasma  kallikrein  was  shown  to  
be  prothrombotic,  as  shorter  occlusion  times  in  the  carotid  artery  after  laser  injury  were  
observed  (97).    Conversely,  BK2  knockout  mice  in  different  strain  backgrounds  
demonstrated  opposing  phenotypes  in  an  experimental  stroke  model,  with  one  having  
reduced  infarct  volumes  and  improved  motor  skills  (98),  whereas  another  study  showed  
an  increase  in  infarct  volumes  and  mortality  rates  (99).    While  the  role  of  some  of  the  
contact  pathway  proteins  in  thrombosis  has  not  completely  been  elucidated,  the  in  vivo  
evidence  suggests  that  FXII  and  FXI,  though  not  involved  in  initiating  fibrin  formation,  
are  involved  in  stabilizing  occlusive  thrombi  in  several  animal  models.  
If  FXI  and  FXII  deficiency  protect  from  thrombosis  in  an  animal  model,  than  
human  should  follow  suite.    In  fact,  either  FXI  or  FXII  deficient  humans  present  with  a  
more  complex  phenotypic  picture.    Elevated  levels  of  FXI  have  been  found  to  be  
prothrombotic,  as  FXI  levels  are  considered  to  be  a  risk  factor  for  deep  venous  
thrombosis  and  ischemic  stroke  (68,  69),  and  FXI  deficiency  reduced  the  incidence  of  
ischemic  stroke  (67).    FXI  deficiency  does  not  seem  to  offer  protection  against  acute  
myocardial  infarction  (100),  but  high  FXI  levels  were  found  to  increase  the  risk  of  
myocardial  infarction.    Interestingly,  in  this  same  study,  low  levels  of  FXII  increased  the  
risk  of  myocardial  infarction.  FXII  plasma  activity  has  been  found  to  exhibit  a  U-­‐‑shaped  
curve  with  respect  to  mortality,  with  the  lowest  10%  of  plasma  levels  associated  with  
mortality  rates  comparable  to  100%  FXII  levels  (48).    However,  FXII  has  not  been  found  
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to  be  an  independent  prothrombotic  risk  factor,  and  no  studies  have  been  conducted  to  
determine  if  FXII  deficiency  offers  thromboprotection  (101).    These  findings  highlight  
the  difference  between  mice  and  human,  and  also  point  to  the  probable  importance  of  
other  functions  of  the  contact  pathway  in  modulating  thrombosis.    
1.3.2.3  Fibrinolysis  
In  addition  to  its  role  in  the  coagulation  cascade,  the  contact  pathway  has  also  
been  shown  to  influence  fibrinolysis.    In  vitro,  it  was  recognized  that  the  presence  of  FXI  
was  able  to  inhibit  clot  lysis  in  plasma  (63).    Further  studies  found  that  thrombin  
mediated  feedback  activation  of  FXI  contributes  to  sustained  thrombin  generation  and  
TAFI  production,  thus  stabilizing  and  protecting  the  clot  from  fibrinolysis  (102,  103).    
TAFI  inhibits  fibrinolysis  of  the  formed  clot  by  removing  carboxy-­‐‑terminal  lysine  
residues  from  fibrin,  thereby  altering  the  ability  of  plasminogen  to  bind  to  fibrin,  and  
thus  preventing  the  breakdown  of  the  fibrin  clot  (104).  The  importance  of  FXI-­‐‑mediated  
continued  TAFI  production  is  evident  from  the  increased  risk  of  bleeding  in  FXI  
deficient  patients  undergoing  surgeries  in  tissues  with  high  local  fibrinolytic  activity.    
Additionally,  inhibition  of  FXI  in  a  rabbit  jugular  vein  model  caused  a  two-­‐‑fold  increase  
in  endogenous  thrombolysis  and  clot  lysis,  presumably  through  reduced  activation  of  
TAFI  (74).    
While  FXI  acts  indirectly  as  an  antifibrinolytic  by  attenuating  thrombin  mediated  
TAFI  activation,  FXII  has  been  shown  to  directly  and  indirectly  promote  fibrinolysis.  
     28  
FXII  structurally  resembles  the  fibrinolytic  proteins  tPa  and  uPa,  and  FXIIa  and  
kallikrein  can  activate  plasminogen  directly  in  plasma  to  contribute  to  wound  healing  
and  tissue  remodeling  (105,  106).    Kallikrein  can  also  directly  activate  uPa  and  tPa,  and  
enhance  the  activation  of  tPa  on  endothelial  cells  by  releasing  BK,  which  stimulates  tPa  
release  (107).    In  addition,  a  recent  study  showed  that  FXII  could  bind  to  and  inactivate  
PAI-­‐‑1  to  enhance  fibrinolysis  in  an  in  vitro  assay  (108).    Overall,  the  contact  pathway  
seems  to  be  involved  in  both  pro  and  antifibrinolytic  mechanisms,  although  the  relative  
efficiency  and  importance  of  each  system  in  vivo  has  yet  to  be  determined.      
1.3.2.4  Platelets  
Activated  platelets  are  known  to  promote  FXII  activation  and  FXII-­‐‑  mediated  
thrombin  generation,  although  the  mechanism  of  activation  in  vivo  has  been  debated  (43,  
109).    Polyphosphates  released  from  the  dense  granules  of  activated  platelets  can  
directly  activate  FXII,  trigger  coagulation  and  inflammation,  and  delay  clot  lysis,  
possibly  through  FXI-­‐‑mediated  TAFI  activation  (26,  43,  45).    Mice  deficient  in  FXII  were  
protected  from  a  lethal  pulmonary  embolism  model  triggered  by  infusion  of  
polyphosphates  and  exhibited  reduced  fibrin  formation  in  the  lungs,  while  infusion  of  
human  FXII  protein  corrected  thrombosis  susceptibility  in  this  model  (45).    Collagen,  a  
strong  platelet  activator  itself,  is  also  able  to  independently  bind  to  and  activate  FXII  to  
induce  thrombin  generation  and  clotting  in  a  FXI-­‐‑dependent  manner  (25,  40).  Under  
flow  conditions,  collagen-­‐‑initiated  thrombin  formation  in  reconstituted  platelet  rich  
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plasma  was  highly  dependent  on  the  presence  of  FXII  and  FXI,  and  this  dependence  was  
abolished  by  adding  tissue  factor,  suggesting  that  FXII-­‐‑  and  FXI-­‐‑  mediated  thrombin  
generation  is  particularly  important  in  conditions  where  the  extrinsic  pathway  has  been  
impaired  (25).    The  relative  importance  of  polyphosphate-­‐‑mediated  activation  of  FXII  
versus  collagen  activation,  as  well  as  the  possibility  of  FXII  activation  from  other  
materials  present  in  a  developing  thrombus  such  as  RNA  and  aggregated  proteins,  will  
require  detailed  investigation,  although  the  unstable  thrombi  in  FXII  deficient  mice  
suggest  that  one  or  possibly  all  of  these  factors  effect  FXII-­‐‑  mediated  coagulation  (26,  27,  
40).    
Binding  to  platelets  serves  as  an  important  mechanism  for  FXI-­‐‑mediated  FIX  
activation,  as  thrombin  can  activate  enough  FXI  on  the  platelet  surface  without  any  FXII  
contribution  to  sustain  thrombin  generation  (59).    A  naturally  occurring  FXI  mutant  that  
cannot  bind  platelets  has  a  severely  reduced  rate  of  activation  by  thrombin  (110),  
whereas  thrombin  activates  FXI  at  a  5-­‐‑10,000  fold  enhancement  when  bound  to  the  
platelet  surface  (61).      This  enhancement  could  be  due  to  the  recent  finding  that  
polyphosphates  release  from  activated  platelets  serve  a  cofactor  to  greatly  increase  
thrombin  activation  of  FXI  (111).  While  there  are  ~1500  binding  sites  for  FXI  on  the  
surface  of  the  platelet  (61),  FXIa  binds  to  only  ~250  sites  (112),  suggesting  that  FXI  and  
FXIa  bind  in  a  different  mechanism.    In  fact,  FXI  and  FXIa  do  not  compete  for  binding  on  
the  platelet  surface  (62),  and  biochemical  studies  suggest  that  FXI  binds  to  GP1bα  in  
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complex  with  either  HK  or  prothrombin  through  its  exposed  A3  domain,  but,  once  
activated,  residues  in  the  catalytic  domain  are  required  for  binding  (112).  Dimeric  FXI  
seems  to  be  required  for  binding,  as  monomeric  FXI  has  a  reduced  activity  in  activated  
platelet  dependent  clotting  assays,  suggesting  that  FXI  binds  to  GP1bα  with  one  subunit  
and  to  FIX  with  the  other  (58).    In  addition,  FXI  has  recently  been  shown  to  bind  to  
ApoER2,  a  receptor  that  co-­‐‑localizes  with  GP1bα  on  the  platelet  surface,  and  FXI  or  FXIa  
can  induce  platelet  aggregation  and  intracellular  signaling  events  on  wild  type,  but  not  
ApoER2-­‐‑deficient  platelets  (113).    Binding  of  FXI  to  the  platelet  surface  can  help  to  
localize  hemostasis  to  only  the  site  of  injury,  as  the  FXI  inhibitor  protein  nexin  2  released  
from  activated  platelets  inhibits  only  free  FXIa  (112,  114).    Thus,  platelets  can  accelerate  
the  activation  of  both  FXII  and  FXI  in  several  respects,  and  may  serve  as  important  
mediator  of  intrinsic  pathway  activation  at  the  site  of  a  growing  thrombus.  
1.3.2.5  Inflammation  
Activation  of  the  contact  system  can  induce  inflammatory  reactions  through  
activation  of  the  classical  cascade  of  the  complement  system,  leading  to  anaphylatoxin  
production  causing  smooth  muscle  cell  contraction,  enhanced  vascular  permeability  and  
recruitment  of  inflammatory  cells  to  produce  a  local  immune  response.    Mast  cells  are  
commonly  found  at  sites  of  infection,  and  are  associated  with  increased  vascular  
permeability  in  host  defense  of  allergic  reactions.    Heparin  released  by  these  mast  cells  
has  been  shown  to  activate  FXII,  thus  leading  to  release  of  BK,  a  small  peptide  that  is  
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cleaved  from  HK  by  kallikrein  which  induces  vascular  permeability  (28,  35).    BK  can  also  
bind  to  its  receptor  on  endothelial  cells  to  promote  nitric  oxide  and  prostacyclin  release,  
inducing  smooth  muscle  cell  relaxation  and  vasodilation  (115).    FXII  seems  to  play  an  
integral  part  of  contact-­‐‑stimulated  BK  generation,  as  plasma  levels  of  BK  are  reduced  in  
FXII  deficient  mice,  even  though  kallikrein  can  be  activated  independent  of  FXII  by  
other  proteins  (heat  shock  protein  90,  prolylcarboxypeptidase)  (116).    Activation  of  both  
of  these  systems  causes  the  signs  and  symptoms  seen  in  septic  shock  and  hereditary  
angioedema.      In  septic  shock,  FXII  can  be  activated  by  bacterial  cell  walls,  endotoxin,  
polyphosphate,  and  various  microbial  proteases  present  from  bacteria  in  the  blood,  
leading  to  a  rapid  decrease  in  blood  pressure  and  possibly  disseminated  intravascular  
coagulation,  a  thrombotic  and  hemorrhagic  disorder  resulting  from  widespread  
misregulation  of  the  clotting  and  fibrinolytic  systems  (117-­‐‑120).    Unregulated  contact  
pathway  and  complement  activation  is  also  implicated  in  hereditary  angioedema  (HAE),  
a  condition  caused  by  a  deficiency  or  defect  in  the  main  inhibitor  of  these  two  pathways,  
C1-­‐‑inhibitor  (121).    HAE  is  marked  by  the  recurrent  episodes  of  acute,  localized  increase  
in  vascular  permeability  in  the  skin  and  various  mucosal  tissues,  mediated  through  the  
action  of  BK  and  complement  anaphylatoxin.    HAE-­‐‑TypeIII  is  caused  by  a  mutation  in  
the  FXII  gene,  however,  plasma  concentrations  and  aPTT  clotting  times  are  both  normal  
in  these  patients  (101).      Kallikrein  and  BK  may  also  be  involved  in  cross-­‐‑talk  with  the  
renin-­‐‑angiotensin  system  involved  in  regulating  blood  pressure  and  fluid  balance.  
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Constituents  of  the  contact  system  can  also  bind  to  and  activate  immune  cells  
directly,  as  kallikrein  can  induce  neutrophil  homing,  aggregation,  and  degranulation  
(115,  122,  123),  and  FXII  mobilizes  leukocytes  to  the  site  of  injury  by  activating  the  
chemoattractant  chemerin  (124).  FXII  also  stimulates  monocytes  to  produce  the  cytokine  
interleukin-­‐‑1  (125).    In  addition,  activated  HK  can  bind  to  receptors  on  monocytes  and  
neutrophils,  stimulating  the  release  of  cytokines  and  inhibiting  their  migration,  keeping  
them  at  the  site  of  injury,  and  contributing  to  a  chronic  inflammatory  response  (115).    
Overall,  these  studies  indicate  that  all  of  the  contact  factors,  except  FXI,  may  play  an  
important  role  in  modulating  the  inflammatory  response  pathway.  Thus,  inhibition  of  
FXI  is  touted  to  have  less  potential  off-­‐‑target  effects,  and  therefore  be  a  more  attractive  
therapeutic  target.  
1.3.2.6  Angiogenesis  
Binding  of  contact  pathway  proteins  to  endothelial  cells  can  also  induce  
angiogenesis,  and  this  generation  of  new  blood  vessels  can  be  important  in  tumor  
progression  and  wound  healing.  HK  and  PK  bind  to  endothelial  cells  through  a  
multiprotein  receptor  complex,  including  complement  receptor  gC1qR,  uPAR,  and  
cytokeratin  1  (126).    While  activation  of  PK  can  occur  on  the  surface  of  endothelial  cells  
without  FXII  by  the  enzyme  prolylcarboxypeptidase  (95),  FXII  can  bind  to  gC1qR  and  
increase  the  rate  of  kallikrein  formation  (127).  Assembly  of  contact  factors  in  the  
presence  of  Zn2+  ions  on  endothelial  cells  results  in  the  release  of  BK,  which,  through  the  
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action  of  its  receptors,  stimulates  cell  migration  and  proliferation  by  increasing  the  
concentration  of  angiogenic  mediators  (32,  128,  129).    In  addition,  BK  was  recently  
shown  to  enhance  the  homing  of  circulating  endothelial  progenitor  cells,  a  mechanism  
also  important  in  forming  new  blood  vessels  (130).      
Zymogen  FXII  is  also  directly  implicated  in  angiogenesis,  as  FXII  can  bind  to  
uPAR  and  induce  cell  proliferative  intracellular  signaling  events  at  levels  just  12.5%  of  
its  normal  plasma  concentration  (34,  128).    In  addition,  FXII  induced  aortic  sprouting  in  
mice  at  concentrations  as  low  as  3.2%  of  normal  levels,  and  FXII  deficient  mice  had  
fewer  vessels  in  skin  biopsies  compared  to  wild  type  (34).    While  FXII  is  not  essential  for  
developmental  angiogenesis  as  FXII  deficiency  is  not  lethal,  it  could  contribute  to  the  
repair  process  after  injury  or  inflammation.    HK  and  FXII  compete  for  the  same  binding  
region  on  the  gC1qR-­‐‑uPAR-­‐‑cytokeratin  1  complex,  and  plasma  concentrations  of  HK  
inhibit  FXII  binding  and  thus  inhibit  FXII-­‐‑  mediated  signaling.    Activated  HK  itself  
inhibits  angiogenesis  by  preventing  endothelial  cell  migration  and  adhesion  through  
disruption  of  the  uPA-­‐‑uPAR  signaling  complex  that  regulates  these  processes  (32,  34,  
131).  
1.3.2.7  Inhibitors  of  the  contact  pathway  
Inhibition  strategies  aimed  at  FXIa  include  antisense  oligonucleotides,  
neutralizing  antibodies,  and  peptide  and  small  molecule  inhibitors.    Several  antibodies  
have  been  tested  in  higher  animals,  including  rabbits  and  baboons,  and  all  were  
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efficacious  in  preventing  thrombus  occlusion  without  any  reported  effects  on  bleeding  
times  (76,  77,  96).    Administration  of  a  FXI  specific  antisense  oligonucleotide  in  mice  
reduced  levels  of  FXI  while  conferring  an  antithrombotic  effect  similar  to  warfarin  
without  abnormal  bleeding  times  (78).  A  selective  small  molecule  inhibitor  has  recently  
been  described  that  prevents  activation  of  FIX  and  prolongs  clotting  times  (132).  
Novel  3-­‐‑carboxamide-­‐‑coumarin  inhibitors  were  developed  to  be  potent  and  
selective  inhibitors  of  FXIIa  (133);  however,  they  did  not  protect  mice  from  ischemic  
stroke  in  a  tMCAO  at  the  given  concentration  (134).    D-­‐‑Pro-­‐‑Phe-­‐‑Arg  chloromethyl  
ketone  (PCK)  inhibits  the  amidolytic  activity  of  FXIIa,  was  able  to  increase  clotting  time  
in  a  dose-­‐‑dependent  manner,  and  protect  mice  against  ischemic  brain  stroke  in  a  
tMCAO  (41).    However,  PCK  is  not  completely  selective  for  FXIIa,  as  it  is  a  more  potent  
inhibitor  of  kallikrein  (135),  and  PCK  treatment  was  prothrombotic  in  a  Rose  Bengal  
murine  thrombosis  model    (97).    The  fourth  domain  of  a  specific  thrombin  inhibitor,  
infestin,  that  was  isolated  from  the  insect  Triatoma  infestans,  can  specifically  inhibit  FXIIa  
(136).    This  protein,  termed  infestin-­‐‑4,  was  fused  to  recombinant  human  albumin,  and  
was  highly  specific  for  FXIIa.    This  compound  protected  mice  from  ischemic  stroke  and  
protected  rats  and  mice  from  arterial  thrombosis  without  affecting  hemostasis  (136).    
Several  inhibition  strategies  against  both  proteins  mirror  the  data  seen  with  factor  
deficient  mice  and  encouragingly  protect  against  thrombosis  without  affecting  bleeding.    
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1.3 Antithrombotics 
1.3.1 Cardiovascular Disease 
CVD  includes  any  disease  of  the  heart  or  blood  vessels  and  is  the  leading  cause  
of  morbidity  and  mortality,  accounting  for  one  in  three  deaths  in  the  United  States.    
While  mortality  trends  have  declined  since  2000,  CVD  has  accounted  for  more  deaths  
that  any  other  major  cause  of  death  since  the  early  1900s.  Currently  one  in  three  adults  
have  one  or  more  types  of  CVD,  with  the  prevalence  higher  amongst  men  and  
increasing  with  age.    Thus,  CVD  costs  more  than  any  other  major  diagnostic  group  and  
currently  constitutes  over  17%  of  overall  national  health  expenditures.    Unfortunately,  
by  2030,  40.5%  of  the  population  is  predicted  to  have  a  CVD,  with  direct  medical  costs  
expected  to  triple  to  an  estimated  $818  billion  (3,  137).  
The  three  most  common  CVDs  include  acute  coronary  syndromes  (ACS),  stroke,  
and  VTE.    ACS  includes  an  array  of  symptoms  relating  to  an  obstruction  of  the  coronary  
arteries,  including  MI  and  unstable  angina.  In  coronary  artery  disease  (CAD),  
insufficient  amounts  of  oxygen  are  reaching  the  myocardium,  most  commonly  due  to  
arteriosclerosis,  or  the  buildup  of  a  lipid-­‐‑filled  plaque  in  the  endothelium  of  one  or  up  to  
all  three  coronary  arteries.    This  plaque  can  slowly  grow  over  the  course  of  years  to  
occlude  the  blood  vessel,  or  rupture,  thus  immediately  forming  a  thrombus  that  can  
occlude  blood  flow,  and  thus  oxygenation  of  the  myocardial  tissue.    Prolonged  occlusion  
can  cause  death  of  the  myocardium,  resulting  in  an  MI.  Angina  pectoris  is  chest  pain  
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associated  with  temporary  myocardial  ischemia  that  does  not  occur  long  enough  for  
death  of  the  heart  tissue  to  occur.    While  stable  angina  is  associated  with  chest  pain  due  
to  increased  oxygen  requirements  of  the  myocardium  when  coronary  blood  flow  is  
reduced,  most  likely  due  to  an  atherosclerotic  plaque,  unstable  angina  is  associated  with  
a  partially  occlusive  thrombus  and  can  lead  to  MI.      
Atrial  Fibrillation  (AF)  is  the  most  common  heart  arrhythmia  and  can  be  caused  
by  a  number  of  different  risk  factors,  including  hypertension  and  CAD.    In  AF,  the  left  
atrium  is  not  contracting  properly,  leading  to  blood  stasis  and  an  increased  probability  
for  thrombus  formation.    AF  greatly  increases  the  risk  of  stroke,  as  thrombi  formed  in  
the  atrium  can  travel  to  the  cerebral  artery  to  result  in  an  ischemic  event.    Ischemic  
strokes  account  for  85%  of  all  strokes,  and  stroke,  as  a  whole,  is  the  leading  cause  of  
severe  disability  (137).    
VTE  occurs  with  blood  clots  forming  in  the  large  veins,  oftentimes  in  the  legs,  a  
process  termed  deep  vein  thrombosis  (DVT).    While  there  are  approximately  1-­‐‑3  cases  
per  1000  people  per  year,  the  prevalence  of  VTE  increases  with  age,  with  approximately  
1  in  every  100  people  per  year  over  the  age  of  50  presenting  with  a  VTE  (4).    Long  
periods  of  immobilization,  such  as  that  which  occurs  on  long  plane  flights  or  leading  a  
sedentary  lifestyle,  results  in  blood  stasis,  which  can  increase  the  risk  for  VTE.    In  
addition,  orthopedic  surgery,  such  as  hip  or  knee  replacements,  can  increase  the  risk  for  
VTE  up  to  two  months.    A  pulmonary  embolism  (PE)  is  an  embolized  thrombus,  
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oftentimes  from  a  DVT,  that  travels  to  and  blocks  the  pulmonary  artery.    PE  is  the  third  
most  common  cause  of  hospital-­‐‑related  death,  and  one-­‐‑quarter  of  PE’s  result  in  sudden  
death  (137).    
While  arterial  thrombosis  is  largely  responsible  for  ACS,  including  MI,  stroke,  
and  peripheral  artery  disease  (PAD),  which  occlude  obstructions  in  other  large  arteries  
(excluding  coronary,  aortic  or  brain),  venous  thrombosis  is  primarily  responsible  for  
VTE,  including  DVT  and  PE.      These  two  types  of  thrombosis  differ  in  mechanism,  as  
outlined  below,  and  thus  in  the  types  of  agents  used  to  treat  them  (Figure  5).    
     




Figure  5.  A  depiction  of  two  types  of  thrombosis  
The  differences  between  (A)  arterial  and  (B)  venous  thrombosis.    Adapted  from  
Mackman,  Nature  2008  (138).  
  
Arterial  thrombosis  is  associated  with  atherosclerosis,  and  often  occurs  on  the  
surface  of  a  ruptured  atherosclerotic  plaque.    Exposure  of  procoagulant  material,  such  as  
collagen,  von  willebrand  factor  (VWF),  lipid-­‐‑rich  macrophages,  TF  and  subendothelial  
cells  in  the  high  shear  arterial  environment  rapidly  recruits  platelets  to  the  site  of  injury  
and  activates  procoagulant  proteases,  thus  forming  platelet-­‐‑rich  “white”  clots.    These  
clots  can  grow  to  occlude  an  artery,  where  they  can  cause  disrupted  blood  flow  to  the  
tissue  supplied  by  the  artery.    Arterial  thrombi  are  the  most  common  cause  of  MI  and  
stroke,  collectively  the  most  common  cause  of  death  in  the  world.      Risk  factors  
associated  with  arterial  thrombi  include  hypertension,  diabetes,  smoking,  and  
hypercholesterolemia.    Interestingly,  the  risk  factors  for  arterial  thrombosis  only  
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modestly  increase  VTE  risk,  and  vice  versa,  thus  supporting  that  these  thrombotic  
disorders  have  different  mechanisms  (5).    
Venous  thrombosis  usually  occurs  with  “red”  clots  in  the  large  veins  in  the  legs,  
where  part  or  all  of  this  thrombus  can  break  away  and  travel  to  the  lungs,  possibly  
forming  a  PE  and  disrupting  the  flow  of  blood  in  the  pulmonary  artery.    Prolonged  
immobilization,  such  as  that  which  occurs  during  bed  rest  after  surgery  or  prolonged  
periods  of  sitting,  can  cause  blood  stasis  and  decreased  oxygen  tension,  especially  in  
sinus  valve  pockets  in  the  large  leg  vein.  Decreased  oxygen  tension  can  induce  
endothelial  cell  stress  response  systems,  resulting  in  activation  of  cell  adhesion  
molecules  on  the  surface  of  the  cell  that  recruit  platelets,  microparticles,  and  
inflammatory  cells,  all  of  which  carry  low  levels  of  TF.    This  local  increase  in  TF,  in  
addition  to  a  higher  number  of  procoagulant  proteases  present  due  to  blood  stasis,  leads  
to  activation  of  the  coagulation  cascade,  thrombin  generation  and  fibrin  clot  formation.    
In  addition,  inflammatory  cells  release  neutrophil  extracellular  traps  (NETs),  DNA,  
RNA,  and  platelet-­‐‑released  polyphosphate,  thus  activating  the  intrinsic  pathway  
through  FXII,  and  contributing  to  more  thrombin  generation  (139).    While  
immobilization  alone  might  not  cause  DVT,  genetic  factors  including  deficiencies  in  
anticoagulant  proteases  or  prothrombotic  mutations,  and  other  acquired  risk  factors  
such  as  age,  surgery,  hormone  replacements  or  contraceptives,  and  obesity,  can  increase  
the  risk  for  developing  a  DVT.      
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In  general,  arterial  thrombosis  is  treated  with  a  class  of  drugs  called  antiplatelets,  
which  prevent  platelet  activation  and  aggregation,  while  venous  thrombosis  is  treated  
with  anticoagulants,  which  prevent  fibrin  clot  formation.  Collectively,  these  two  classes  
of  drugs  are  called  antithrombotics,  and  are  divided  into  classes  based  on  their  
mechanism  of  action.    Antithrombotics  are  also  used  to  prevent  blood  coagulation  in  
surgical  settings,  where  catheter  insertions,  stent  placements,  extracorporeal  circuits  or  
orthopedic  surgery  can  present  a  highly  thrombogenic  environment.    
1.3.2 Anticoagulant agents 
Anticoagulants  are  generally  used  to  prevent  the  generation,  growth  and  
embolization  of  a  thrombus,  although  they  do  not  dissolve  an  already  present  clot.    
There  are  several  classes  of  anticoagulants,  including  the  vitamin  K  antagonists  (VKA),  
FXa  inhibitors,  and  direct  and  indirect  thrombin  inhibitors.  A  partial  list  of  the  currently  
approved  anticoagulants,  including  their  targets,  mechanism  of  action,  and  indication,  
are  outlined  in  Table  1.    
     
     41  
Table  1.    Current  anticoagulant  agents  
























Heparin   Heparin   Glycosamino-­‐‑
glycan  
Parental   Prophylaxis  &  Treatment  of  
DVT;  PCI;  CABG  
Enoxaparin   Lovenox   Glycosamino-­‐‑
glycan  
Parental   Prophylaxis  &  Treatment  of  
DVT  






Warfarin   Coumadin   Small  Molecule   Oral   Prophylaxis  &  Treatment  of  
DVT;  Prophylaxis  &  Treatment  
of  VTE  in  valve  replacement  &  

















Argatroban   Acova   Small  Molecule   Parental   Prophylaxis  &  Treatment  of  
DVT;  PCI  
Bivalirudin   Angiomax   Peptide   Parental   Prophylaxis  &  Treatment  of  
DVT;  PCI  













   Apixaban   Eliquis   Small  Molecule   Oral   Prophylaxis  of  VTE  &  stroke  in  
nonvalvular  AF  
Rivaroxaban   Xarelto   Small  Molecule   Oral   Prophylaxis  &  Treatment  of  
DVT;  Prophylaxis  of  stroke  in  
nonvalvular  AF  
  
There  are  two  routes  of  administration  of  anticoagulants:  parental  or  oral.    
Parental  anticoagulants  are  traditionally  used  in  acute  care  settings  when  a  rapid  onset  
is  necessary,  such  as  a  patient  presenting  with  unstable  angina  or  MI,  during  cardiac  
operations,  or  for  short-­‐‑term  prophylaxis  of  VTE  after  orthopedic  surgery  (140).    The  
indirect  thrombin  inhibitor  heparin  is  a  glycosaminoglycan  that  enhances  antithrombin’s  
inhibition  of  thrombin  and  FXa.    Heparin  has  been  a  mainstay  of  anticoagulation  since  
the  1940s.    Because  of  its  rapid  and  predictable  mode  of  action,  heparin  is  oftentimes  
used  to  initiate  anticoagulant  therapy.    In  addition,  heparin  is  commonly  used  in  
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surgical  settings,  such  as  cardiopulmonary  bypass  (CPB),  because  of  its  strong  
anticoagulant  effect  and  its  ability  to  be  reversed  by  a  small,  positively  charged  protein,  
protamine.    Heparin,  while  affective,  is  associated  with  several  complications,  including  
heparin-­‐‑induced  thrombocytopenia  (HIT)  or  heparin-­‐‑induced  thrombocytopenia  with  
thrombosis  (HITT),  which  results  when  heparin  interacts  with  other  extracellular  
proteins,  such  as  platelet  factor  4,  to  cause  immune  reactions  (138).    Lower  molecular  
weight  heparins,  such  as  enoxaparin  (Lovenox)  or  fondaparinux  (Arixtra),  are  safer  and  
easier  to  administer  and  monitor,  and  have  thus  replaced  heparin  for  prophylactic  
treatment  of  VTE.    However,  these  heparin  derivatives  cannot  be  reversed  by  protamine,  
and  are  thus  not  used  for  surgical  procedures  (141).    The  parental  direct  thrombin  
inhibitors,  such  as  argatroban  (Acova)  and  bivalirudin  (Angiomax),  have  recently  been  
introduced  to  replace  the  indirect  thrombin  inhibitors  in  patients  with  or  at  risk  of  
developing  HIT  or  HITT,  who  cannot  be  given  heparin,  during  percutaneous  coronary  
intervention  (PCI,  or  “angioplasty”)  surgery  or  as  a  prophylactic  treatment  of  VTE.      
While  these  parental  anticoagulants  are  effective,  they  all  confer  a  high  risk  of  bleeding,  
with  no  direct  antidote  available  to  reverse  their  action.  
For  long-­‐‑term  anticoagulation  therapy,  an  oral  anticoagulant  is  administered  
after  initial  treatment  with  a  rapidly  acting  parental  anticoagulant.    In  general,  oral  
anticoagulants  are  easier  to  administer  and  have  higher  patient  compliance  for  chronic  
therapy,  as  parental  anticoagulants  require  repeated  injections.    The  oral  VKA,  warfarin  
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(Coumadin),  has  been  the  mainstay  of  oral  anticoagulant  therapy  for  the  past  65  years.    
While  effective,  warfarin  has  several  drawbacks  that  have  led  for  a  search  for  new  oral  
anticoagulants.    Namely,  warfarin  has  numerous  food  and  drug  interactions,  a  narrow  
therapeutic  window,  and  is  difficult  to  dose  and  monitor,  with  over  half  of  patients  
failing  to  maintain  an  acceptable  level  of  anticoagulation  (140).    This  puts  a  high  number  
of  patients  at  risk  for  bleeding  events  (over-­‐‑anticoagulation)  or  thrombotic  events  
(under-­‐‑anticoagulation).      
Recent  advances  have  led  to  emergence  of  new  oral  anticoagulants  directly  
targeting  either  thrombin  or  FXa  that  will  likely  begin  to  replace  warfarin.      These  
compounds  include  rivaroxaban  (Xarelto),  apixaban  (Eliquis)  and  dabigatran  (Pradaxa),  
which  all  show  efficacy  in  preventing  short-­‐‑term  VTE  for  surgical  indications  such  as  
hip  or  knee  replacement.  These  oral  anticoagulants  have  also  shown  efficacy  in  long-­‐‑
term  anticoagulant  therapy  for  the  life-­‐‑long  prevention  of  stroke  in  patients  with  AF,  
which  represent  a  large  and  growing  population  (142).    While  dabigatran  has  already  
been  licensed  for  this  indication,  other  direct  FXa  inhibitors  are  in  advanced  stages  of  
development.    These  new  anticoagulants  show  comparable  efficacy  to  warfarin  with  less  
bleeding  incidents,  indicating  that  the  field  has  made  a  large  step  in  replacing  warfarin  
in  this  at-­‐‑risk  population  (142).    
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1.3.3 Antiplatelet agents 
   Chronic  antiplatelet  therapy  is  used  to  treat  a  range  of  cardiovascular  diseases  
associated  with  arterial  thrombosis,  including  treating  patients  with  MI,  stroke,  or  
angina,  as  well  as  prevention  in  patients  at-­‐‑risk  for  these  events  and  others,  such  as  PAD  
or  AF.    In  addition,  antiplatelet  agents  are  also  used  as  a  rapid  onset  anticoagulant  in  
cardiac  surgeries,  especially  PCI,  where  insertion  of  foreign  bodies,  such  as  a  catheter  or  
a  stent,  can  cause  thrombosis.    Several  of  the  currently  used  antiplatelet  agents  are  
summarized  in  Table  2.    
Table  2.  Current  antiplatelet  agents    
All  information  was  obtained  from  www.fda.gov  




Type  of  Drug   Route   Use  
PD
E  
Cilostazol   Pletal   Small  Molecule   Oral   Treatment  of  PAD  






Prasugrel   Effient   Small  Molecule   Oral   Prophylaxis  of  thrombotic  CV  
events  in  ACS;  Prophylaxis  of  
stent  thrombosis  
Clopidogrel   Plavix   Small  Molecule   Oral   Prophylaxis  of  thrombotic  CV  
events  in  ACS;  Prophylaxis  of  
stroke,  MI,  or  PAD  
Ticagrelor   Brilinta   Small  Molecule   Oral   Prophylaxis  of  thrombotic  CV  
events  in  ACS  
Ticlopidine   Ticlid   Small  Molecule   Oral   Prophylaxis  of  stroke;  







Abciximab   ReoPro   Monoclonal  
Antibody  
Parental   PCI  
Eptifibatide   Integrilin   Peptide   Parental   Prophylaxis  of  thrombotic  CV  
events  in  ACS;  PCI  
Tirofiban   Aggrastat   Small  Molecule   Oral   Prophylaxis  of  thrombotic  CV  




   Aspirin   Aspirin   Small  Molecule   Oral   Low  Dose:  Long  term  
prophylaxis  of  MI  &  stroke  
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Aspirin  has  been  the  gold  standard  for  chronic  oral  antiplatelet  agent  use,  as  it  is  
effective  in  reducing  the  incidence  of  MI  and  stroke  without  increasing  the  risk  of  
bleeding  (142).    Clopidogrel  (Plavix)  is  more  recent  antiplatelet  agent  that  has  shown  
widespread  tolerance  across  patient  populations  with  ACS,  as  well  as  slightly  more  
efficacy  than  aspirin  in  reducing  serious  vascular  events.    However,  both  of  these  agents  
were  only  able  to  reduce  the  incidence  of  these  events  by  approximately  20%,  leaving  a  
wide  proportion  of  the  population  at  risk,  and  a  high  probability  for  breakthrough  
thrombotic  events  (12,  142).      
   The  limited  efficacy  of  aspirin  and  clopidogrel,  which  only  target  one  receptor  on  
the  platelet  surface,  respectively,  suggests  that  the  redundancy  of  the  platelet  activation  
pathway,  where  any  number  of  pathways  can  be  activated  by  different  stimuli  and  lead  
to  platelet  aggregation,  is  important,  and  that  only  inhibiting  one  pathway  or  receptor  
might  not  be  efficacious  (142).    To  this  end,  combination  therapy,  either  combining  an  
antiplatelet  and  an  anticoagulant  agent,  or  two  antiplatelet  agents  (such  as  aspirin  and  
clopidogrel),  is  hampered  by  an  increase  in  major  bleeding,  thus  not  leading  to  a  clinical  
benefit  for  chronic  use.    This  type  of  therapy  is  reserved  for  use  in  high-­‐‑risk  populations,  
as  well  as  inhibitors  against  the  platelet  receptor  GPIIb-­‐‑IIIa,  which  is  the  key  receptor  in  
mediating  platelet  aggregation.    These  inhibitors  exhibit  high  bleeding  risk,  but  are  still  
used  in  certain  settings,  such  as  in  PCI  to  inhibit  catheter  and  stent-­‐‑mediated  
thrombosis,  where  their  use  can  be  highly  monitored  and  controlled  (12).    
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   Newer  antiplatelet  agents  have  been  developed  that  have  higher  potency  than  
clopidogrel,  but  target  the  same  pathway.    Prasugrel  (Effient)  is  P2Y12  receptor  
antagonist  that  exhibits  more  potent  and  consistent  inhibition  of  platelet  aggregation  
(142).  Unlike  clopidogrel,  ticagrelor  (Brilinta)  does  not  have  to  be  metabolized,  and  thus  
has  a  fast  onset  of  action,  a  characteristic  that  lends  itself  well  to  surgery,  where  
anticoagulation  needs  to  occur  quickly.    The  challenge  of  both  of  these  agents,  however,  
is  their  increased  risk  of  bleeding  compared  to  clopidogrel  (142).    
Overall,  antiplatelet  therapy  has  suffered  due  to  a  narrow  therapeutic  window,  
where  too  much  inhibition  can  cause  bleeding  and  too  little  inhibition  can  cause  
breakthrough  thrombotic  events.    Another  problem  with  antiplatelet  therapy  is  that  
irreversible  inhibitors  are  present  for  the  life  of  a  platelet,  so  a  patient  on  antiplatelet  
drugs  ideally  should  stop  therapy  for  several  days  before  surgery  to  decrease  the  risk  of  
bleeding.      Oftentimes,  this  is  not  possible  for  this  subset  of  the  population,  as  urgent  
surgery  in  ACS  patients  is  often  necessary  (141).    The  combination  of  the  correct  dose  
and  target  is  important,  and  further  studies  into  the  inhibition  of  alternative  platelet  
receptors  has  been  underway  to  attempt  to  identify  new,  safer  antiplatelet  agents.      
  
1.3.4 Ideal Antithrombotic Agents 
   While  cardiovascular  disease  is  already  the  leading  cause  of  death  in  many  
westernized  countries,  the  global  incidence  of  cardiovascular  disease  is  expected  to  
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continue  to  increase,  as  more  cultures  are  changing  their  lifestyle  to  lead  more  sedentary  
lives  and  eat  higher  fat  diets.    As  such,  the  antithrombotic  market  is  expected  to  increase  
from  approximately  4  billion  in  2010  to  12  billion  in  2016  in  the  United  States  alone,  from  
a  combination  of  increased  patient  population  for  long  term  therapy  due  to  rising  
incidence  of  obesity  and  atherosclerosis,  and  an  increase  of  cardiac  procedures  
performed  in  the  aging  population  (143).    While  a  number  of  new  agents  have  been  
introduced  into  the  market  that  have  more  favorable  profiles  than  the  standard  of  care,  
there  is  still  a  large  unmet  need  for  convenient  and  effective  antithrombotics  that  do  not  
incur  a  bleeding  risk.    This  risk  of  bleeding  associated  with  antithrombotic  drug  therapy  
can  be  caused  by  many  factors,  including  narrow  therapeutic  windows  (the  balance  
between  inhibiting  thrombosis  and  causing  bleeding),  patient  drug  metabolism  
variability,  an  undefined  threshold  of  anticoagulation  needed  for  clinical  benefit,  
complex  interactions  between  the  drug  and  multiple  hemostatic  factors,  and  limited  
control  of  the  drug’s  pharmacodynamics  (144).    As  in  the  example  of  antiplatelet  
therapy,  increased  potency  does  not  always  mean  increased  efficacy,  and  increased  risks  
of  bleeding  can  actually  decrease  the  clinical  benefit  of  a  more  potent  therapeutic.  
There  are  several  ways  to  design  an  antithrombotic  with  a  more  favorable  safety  
profile.    The  first  strategy  is  to  formulate  a  drug  that  has  a  rapid  onset  and  offset  of  
action.  After  drug  administration  is  halted,  the  compound  is  rapidly  cleared  from  the  
body  and  anticoagulation  values  quickly  return  to  baseline  in  the  absence  of  drug  
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administration.    This  strategy  requires  a  large  amount  of  compound,  and  is  not  viable  
for  a  chronic  therapy  setting.  An  alternative  drug  design  strategy  is  to  develop  a  stable  
compound  that  can  be  rapidly  controlled  with  an  antidote.    Antidote  reversal  of  
stabilized  drugs  reduces  the  amount  of  compound  required  (and  therefore  the  cost),  
increases  the  number  of  indications  that  the  drug  can  be  used  for,  and  enhances  the  
safety  profile  (145).    In  addition,  an  active  antidote  can  be  appropriately  dosed  to  reverse  
some,  but  not  all,  of  the  circulating  drug,  allowing  for  a  higher  level  of  anticoagulant  
control.    This  ability  of  antidotes  to  modulate,  rather  than  completely  neutralize  the  
therapeutic  compound  offers  clinicians  the  ability  to  fine-­‐‑tune  the  drug’s  titratability  and  
the  level  of  clinical  anticoagulation  in  real  time  (145).    Currently,  the  only  antidote-­‐‑
reversible  antithrombotic  available  is  the  heparin/protamine  pair,  which  is  the  standard  
for  clinical  anticoagulation  despite  dangerous  side  effects  and  complex  and  
unpredictable  pharmacodynamics  that  make  dosing  a  challenge.    Other,  newer  
anticoagulant  agents  that  have  potentially  less  bleeding  risk  than  heparin,  such  as  
enoxaparin  or  argatroban,  do  not  have  an  antidote,  making  their  clinical  use  limited  
(146).  
Because  of  the  wide  range  of  cardiovascular  events  and  the  different  mechanism  
contributing  to  each,  a  “magic  bullet”  therapy  that  is  universally  effective  is  not  likely  
(12).    Instead,  therapeutics  designed  to  treat  closely  related  cardiovascular  events  and  
settings  are  needed.    For  example,  cardiologists  in  a  hospital  setting  need  an  effective  
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antithrombotic  for  highly  thrombogenic  settings,  including  cardiology  procedures  and  
critical  care  settings,  where  the  risk  of  bleeding  might  not  offset  the  clinical  benefit.    This  
antithrombotic  ideally  has  a  rapid  onset  of  action,  is  most  often  parentally  administered,  
is  highly  effective  at  anticoagulation,  and  can  be  instantly  reversed  after  surgery  or  if  
bleeding  complications  arise.  In  contrast,  a  parental  antithrombotic  for  a  long  term  
chronic  setting  might  not  be  feasible  (141).    A  long-­‐‑term  antithrombotic  must  be  
conveniently  administered,  is  most  often  orally  administered,  be  highly  tolerable  in  a  
wide  range  of  patient  populations,  have  a  predictable  pharmacokinetic  and  
pharmacodynamics  response,  have  compatibility  with  other  reagents,  and  be  effective  
without  causing  bleeding  or  have  an  antidote  readily  available  if  bleeding  complications  
arise.    While  there  are  similarities  between  these  two  strategies,  in  general,  the  most  
important  characteristics  involved  in  designing  a  successful  antithrombotic  is  reliability,  
convenience,  and  safety  (143).    
Another  strategy  in  striking  the  balance  between  inhibiting  thrombus  formation  
(efficacy)  and  reducing  the  risk  of  severe  bleeding  (safety)  of  an  antithrombotic  includes  
inhibiting  the  correct  target.    While  most  of  the  factors  involved  in  hemostasis  and  
thrombosis  are  conserved,  determining  the  differences  between  these  two  states,  and  
subsequently  only  inhibiting  those  factors  involved  in  thrombosis,  can  lead  to  an  
effective  antithrombotic  with  a  reduced  bleeding  risk.    In  general,  targeting  of  the  
downstream,  essential  coagulation  factors  interrupts  both  thrombosis  and  hemostasis  to  
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ensure  that  blood  clotting  cannot  occur.    In  these  settings,  an  antidote  is  needed  in  order  
to  control  potential  bleeding  for  this  strategy  to  be  safely  administered.  While  most  of  
the  currently  approved  antithrombotics  target  these  downstream  factors,  their  use  is  
limited  due  to  the  high  risk  of  bleeding  associated  with  therapy,  and  no  antidote  to  
reverse  it.    However,  recent  studies  have  suggested  that,  at  least  in  animal  models,  
inhibition  of  the  upstream,  intrinsic  coagulation  factors  XI  and  XII  can  hinder  
thrombosis  without  affecting  normal  hemostatic  events.    While  these  factors  are  
associated  with  the  stability  of  a  pathological  thrombus,  they  are  not  essential  for  
hemostasis  in  humans,  as  deficiencies  of  FXI  and  FXII  do  not  confer  a  severe  bleeding  
phenotype.  Therefore,  pharmacological  inhibition  of  FXI  and  FXII,  or  other  factors  not  
involved  in  hemostasis,  could  produce  an  effective  anticoagulant  to  treat  and  prevent  
thromboembolic  disorders  without  a  high  risk  of  bleeding.  
  
1.4 Aptamers and SELEX 
Portions  of  this  section  have  been  adapted  from  the  manuscript  entitled  “Antidote-­‐‑control  
of  aptamer  therapeutics:  The  road  to  a  safer  class  of  drug  agents”  published  in  Current  
Pharmaceutical  Biotechnology  on  August  2012,  13(10):1924-­‐‑34  and  co-­‐‑authored  by  Kristin  
Bompiani  and  Rebecca  Woodruff,  as  well  as  Richard  Becker,  Shahid  Nimjee,  and  Bruce  Sullenger.    
Other  portions  of  this  section  were  adapted  from  the  manuscript  entitled  “Application  of  
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aptamers  for  targeted  therapeutics”  published  in  Arch  Immunol  Ther  Exp  (Warsz)  on  April  
2013,  and  co-­‐‑authored  by  Partha  Ray,  Kristi  Viles,  Erin  Soule  and  Rebecca  Woodruff.      
1.4.1 Emergence of Aptamers & SELEX 
The  central  dogma  of  molecular  biology  states:  “DNA  makes  RNA  makes  
protein.”    While  the  oligonucleotides  in  this  equation  are  responsible  for  information  
storage  and  transfer,  proteins  actually  carry  out  all  the  functions  of  the  cell.    A  clue  that  
this  might  not  precisely  be  the  case  was  discovered  when  the  structure  of  tRNA  was  
solved,  and  it  was  determined  that  highly  structured  RNA’s  serve  a  function  other  than  
information  storage  in  the  translation  process.    The  discovery  of  catalytic  RNAs  was  so  
groundbreaking  that  it  was  later  awarded  the  Nobel  Prize.  Out  of  this  oligonucleotide  
revolution  came  the  idea  of  an  RNA  world,  where  more  diverse  oligonucleotides  than  
what  is  present  today  could  have  been  able  to  both  encode  and  carry  out  complex  
functions  until  amino  acids  took  over  part  of  their  job.    To  do  this,  oligonucleotides  
would  have  needed  to  evolve  diverse  shapes  and  affinities  towards  different  substrates,  
and  this  information  inherently  would  have  been  encoded  by  their  linear  sequence.    By  
screening  large  libraries  of  single  stranded  oligonucleotides,  scientists  can  identify  the  
exact  sequences  responsible  for  binding  to  molecules,  including  nucleic-­‐‑acid  binding  
proteins  (147).    
The  process  of  SELEX  (systematic  evolution  of  ligands  by  exponential  
enrichment)  was  first  developed  to  quickly  discover  the  specific  nucleotide  sequence(s)  
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essential  for  binding  to  a  DNA  or  a  single  stranded  RNA  binding  protein.    In  their  
groundbreaking  paper,  Tuerk  and  Gold  demonstrated  that  large  libraries  of  randomized  
oligonucleotide  (RNA  or  DNA)  sequences  could  be  screened  in  vitro  for  ligands  that  
bind  with  the  highest  affinity  to  T4  DNA  polymerase  (148).    Using  this  process,  their  
group  discovered  that  T4  DNA  polymerase  recognizes  eight  specific  nucleotides.    Two  
aptamers,  or  specific  sequences  of  DNA,  dominated  the  finished  pool  and  bound  with  
equal  affinity:  one  with  the  exact  nucleotide  sequence  of  its  natural  DNA  binding  site  
and  one  with  four  differences.    These  binding  sequences  were  termed  “aptamer”  after  
the  Greek  aptus,  meaning  “to  fit”  (149).    Early  on,  it  was  determined  that  SELEX  could  
actually  select  sequences  that  bind  with  higher  affinity  than  those  that  are  present  in  
nature  (150).      Because  the  in  vitro  SELEX  process  is  not  constrained  by  biological  fitness,  
these  additional,  and  sometimes  truncated,  sequences  that  bind  with  higher  affinity  can  
be  isolated.    This  process  was  therefore  exploited,  and  during  the  last  twenty  years,  has  
been  used  to  isolate  aptamers  to  a  diverse  number  of  proteins,  including  transcription  
factors,  proteases,  viral  proteins,  growth  factors  and  cell  adhesion  molecules,  among  
others.      
The  starting  pool  of  a  selection  is  a  combinatorial  nucleic  acid  library  containing  
a  certain  number  of  randomized  nucleotides,  flanked  on  either  end  with  constant  
regions  to  aid  with  molecular  biology  techniques.  The  randomized  region  is  essential  for  
library  diversity,  and  can  range  from  a  few  nucleotides  up  to  hundreds  of  nucleotides,  
     53  
and  can  be  continuous  or  found  in  blocks.  Importantly,  enough  randomization  of  the  
library  needs  to  occur  in  order  to  form  enough  unique  stable  aptamer  structures  (or  
oligonucleotide  sequences)  to  perform  the  selection.    A  library  with  approximately  25  
randomized  nucleotides  yields  ~1015  different  aptamer  sequences,  which  allows  for  
almost  all  sequences  present  in  the  starting  pool  to  be  examined  (147).    
Traditionally,  the  SELEX  process  begins  by  incubating  this  nucleic  acid  library  
with  a  purified  protein  target  or  molecule.    Oligonucleotides  that  bind  to  the  protein  or  
molecule  are  separated  from  the  unbound  aptamers  through  various  techniques  
(nitrocellulose  filtration,  column  chromatography,  immunoprecipitation,  etc.)  and  are  
subsequently  amplified  to  generate  an  enriched  pool  with  increased  binding  affinity  for  
the  target.    The  entire  process  of  incubation,  partitioning,  elution,  and  amplification  
completes  one  round  of  SELEX.    This  process  is  repeated  under  increasingly  stringent  
conditions  to  isolate  a  pool  of  oligonucleotide  sequences  that  bind  with  the  highest  
affinity  for  the  target.      Increased  stringency  is  generated  by  creating  greater  competition  
for  binding  to  the  target  in  a  round;  this  is  facilitated  by  either  increasing  the  RNA  to  
protein  ratio,  increasing  salt  concentrations,  or  decreasing  the  overall  amount  of  protein  
used.    The  number  of  rounds  required  to  drive  a  selection  to  completion  depends  on  
both  the  innate  ability  of  the  target  to  bind  to  the  library  oligonucleotide  and  how  much  
stringency  is  increased  in  each  round.    Importantly,  stringency  is  often  kept  minimal  
during  the  beginning  rounds  to  reduce  the  risk  of  loosing  a  high  affinity  binder  when  
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there  are  many  aptamer  sequences  present  and  limited  number  of  areas  on  the  protein  to  
bind.    After  significant  increases  in  binding  affinity  by  the  pool  are  made,  and  weak  or  
non-­‐‑binders  have  been  selected  out,  stringency  can  be  increased  to  quickly  drive  the  
selection  to  completion  (147).    
Several  variations  on  the  traditional  SELEX  procedure  have  since  been  derived  
from  the  original  method  described  by  Tuerk  and  Gold.    For  example,  “toggle”  SELEX  
was  developed  to  isolate  an  aptamer  that  can  bind  to  conserved  regions  on  two  
homologous  proteins,  primarily  between  a  protein  from  two  different  species  (151).    This  
method  was  developed  to  facilitate  aptamer  cross-­‐‑reactivity  for  pre-­‐‑clinical  studies.    
“Complex”  selection  is  used  to  create  a  pool  of  aptamers  that  can  bind  to  multiple  
targets  in  a  complex  mixture,  such  as  the  plasma  proteome  or  red  blood  cell  membranes,  
to  create  a  focused  library  (152,  153).    This  focused  pool  can  be  amplified  and  used  to  
isolate  aptamers  from  nearly  any  protein  found  in  the  complex  mixture  in  
approximately  half  the  number  of  rounds  compared  to  traditional  SELEX  (152).    Other  
types  of  SELEX  have  been  developed  with  cells  or  a  whole  organism  as  the  target,  not  
just  soluble  proteins  or  molecules.    Cell-­‐‑based  SELEX  can  be  employed  in  the  cancer  
biomarker  setting  to  discover  aptamers  that  selectively  bind  to  cancer  cells,  but  not  
normal  cells  (154).      Similarly,  aptamers  have  been  isolated  that  can  detect  differences  
between  pancreatic  cancerous  cell  secretomes  versus  non-­‐‑cancerous  secretomes  (155).    In  
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addition,  SELEX  has  been  performed  in  vivo  in  a  mouse  to  identify  aptamers  that  bound  
specifically  to  cancer  metastases  (156).  
   The  SELEX  process  generates  an  enriched  pool  of  aptamer  sequences  that  
demonstrate  high  affinity  binding  toward  the  target.    After  completion  of  SELEX,  the  
oligonucleotide  pool  is  cloned  and  sequenced,  yielding  individual  aptamer  sequences.    
Enriched  pools  at  the  end  of  a  selection  often  have  “structural  families”,  or  sequences  
that  share  common  stretches  of  nucleotide  composition  or  common  structural  motifs.    If  
SELEX  has  been  driven  to  completion,  the  final  pool  is  comprised  of  a  single  aptamer  
sequence.    While  SELEX  completion  produces  an  obvious  candidate  compound  for  
further  testing,  generation  of  sequence  families  can  yield  valuable  information  as  
conserved  structural  domains  across  structural  families  may  indicate  a  region  of  
sequence  that  is  important  for  target  binding  and/or  functionality.  
Once  several  aptamer  sequences  have  been  identified,  in  vitro  studies  are  used  to  
compare  the  individual  aptamer  sequences  for  their  binding  affinity  and  intended  
functionality  toward  the  therapeutic  target  (enzyme  inhibition,  receptor-­‐‑mediated  
signaling,  etc.).    The  aptamer  with  a  combination  of  the  tightest  binding  and  most  potent  
functionality  is  selected  for  optimization  and  further  studies.  
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1.4.2 Aptamers as Therapeutics 
In  essence,  aptamers  are  designer  ligands  that  can  be  made  toward  theoretically  
any  target  molecule  of  interest.  As  a  novel  class  of  compounds  that  has  rapidly  gained  
clinical  interest  over  the  past  twenty  years,  aptamers  combine  the  best  characteristics  of  
small  molecules  and  antibodies  and  have  some  additional  unique  characteristics  of  their  
own.    
As  small,  single-­‐‑stranded  oligonucleotides,  aptamers  form  specific  three-­‐‑
dimensional  structures  that  allow  them  to  bind  to  their  targets  with  high  affinity  and  
specificity.    Crystal  structures  of  aptamer-­‐‑protein  binding  have  shown  that  aptamers  
fold  into  a  tertiary  structure  and  present  an  extended  conformational  surface  that  is  
complementary  to  the  target  protein,  thus  binding  and  concealing  a  large  surface  area  on  
the  protein  (157).    There  are  numerous  electrostatic,  hydrophilic,  and  van  der  Waals  
interactions  within  the  extended  aptamer/protein  binding  interface,  including  hydrogen  
and  pi-­‐‑bond  stacking  with  the  amino  side  chains  of  the  proteins.    Because  of  these  
specific  interactions,  aptamers  often  bind  their  targets  with  dissociation  constants  (Kds)  
that  are  typically  in  the  low  nanomolar  (10-­‐‑9)  to  high  picomolar  range  (10-­‐‑12).    The  unique  
surface,  shape,  and  charge  of  the  aptamer-­‐‑binding  region  on  the  target  profoundly  
influences  the  affinity  of  aptamer-­‐‑target  binding  and  thus  dictates  specificity.    A  single  
substitution  of  an  amino  acid  or  nucleic  acid  base  in  the  binding  region  can  completely  
disrupt  aptamer  binding  and  thus  function  (158).  Since  a  large  part  of  the  target  protein  
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is  concealed  by  aptamer  binding,  aptamers  tend  to  act  as  antagonists  by  blocking  
protein-­‐‑protein  interactions.  
Unlike  small  molecules  or  antibodies,  aptamers  can  easily  be  
pharmacokinetically  manipulated,  thus  controlling  their  duration  of  action  from  a  few  
hours  to  days.  Unmodified  oligonucleotides,  especially  RNA,  are  rapidly  degraded  in  
biological  fluids  by  endogenous  endonucleases.    Therefore,  internal  modification  
strategies  with  chemically  synthesized  bases  are  oftentimes  utilized  to  increase  
resistance  to  enzymatic  hydrolysis.  Modified  bases  are  typically  introduced  at  the  
beginning  of  the  SELEX  process,  since  a  change  in  chemical  structure  can  influence  
aptamer  folding  and  target  binding.    Commonly,  the  2’  ribose  position  of  the  pyrimidine  
nucleotides  is  modified  to  include  functional  groups  such  as  an  amine  (2’N),  O-­‐‑methyl  
(2’OMe)  or  fluoro  (2’F),  as  substitutions  at  this  position  are  effective  at  increasing  
nuclease  resistance  (159).    These  modifications  can  easily  be  incorporated  during  in  vitro  
transcription  by  using  a  mutant  form  of  RNA  polymerase  (RNAP)  that  can  recognize  its  
respective  modified  base.    While  all  of  these  modifications  greatly  increase  the  half-­‐‑life  
of  an  aptamer  in  biological  fluids,  there  are  subtle  unique  advantages  and  disadvantages  
to  each  type  of  modification.    Overall,  many  aptamers  have  been  generated  with  
2’fluropyrimidines,  as  higher  transcription  yields  incorporating  this  modification  makes  
the  development  process  easier.      However,  2’OMe  modifications  have  traditionally  been  
less  expensive  than  any  of  the  other  common  modifications,  and  are  thus  attractive  in  
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clinical  development  of  aptamers  (159).    Although  internal  modification  of  the  aptamer  
sequence  protects  against  endonuclease  cleavage,  a  3’end  cap  of  deoxythimidine  is  often  
incorporated  to  protect  the  end  of  the  aptamer  from  exonuclease  cleavage.      
Because  aptamers  are  relatively  small  (8-­‐‑15  kDa)  and  thus  are  rapidly  cleared  by  
the  kidneys,  bulky,  inert  moieties,  such  as  cholesterol  or  polyethylene  glycol  (PEG),  are  
typically  conjugated  to  the  5’  end  of  an  aptamer  to  increase  the  molecular  weight,  
thereby  decreasing  the  clearance  rate  and  increasing  the  half-­‐‑life  of  an  aptamer  in  vivo.  
Cholesterol  conjugation  of  an  aptamer  can  increase  the  half-­‐‑life  to  several  hours  (160),  
while  PEG  conjugation  can  extend  the  half-­‐‑life  to  days  or  even  weeks,  depending  on  the  
mode  of  administration  (161).    Therefore,  the  bioavailability  of  a  specific  aptamer  can  be  
easily  manipulated.    
Similar  to  small  molecule  therapeutics,  aptamers  can  be  chemically  synthesized  
by  solid-­‐‑phase  oligonucleotide  synthesis  to  generate  large,  homogenous  and  highly  
purified  quantities  of  compound.    Shorter  aptamers,  like  other  custom  oligonucleotides,  
have  higher  yields  and  are  most  cost  effective  to  produce;  thus,  aptamers  are  typically  
truncated  to  less  than  50  nucleotides  or  the  smallest  functional  sequence  possible.  
Additionally,  as  synthetic  molecules,  the  chemical  composition  of  individual  bases  in  the  
aptamer  sequence  can  be  altered  to  increase  the  yield  or  decrease  the  cost  of  
manufacturing,  as  long  as  the  changed  modification  does  not  disrupt  the  aptamer’s  
structure  or  function.    Previously,  2’F  modified  nucleotides  could  often  be  substituted  
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with  the  less  expensive  2’OMe  nucleotides,  resulting  in  a  functional  aptamer  that  is  
more  cost  effective  to  produce  in  high  quantities.    However,  the  cost  of  2’F  modified  
nucleotides  has  recently  been  reduced  to  a  similar  cost  as  2’OMe  nucleotides,  allowing  
for  the  feasibility  of  developing  a  therapeutic  2’F  modified  aptamer.  
In  addition  to  being  chemically  synthesized,  aptamers  have  a  stable  shelf  life  and  
can  recover  their  folded  structure  after  wide  temperature  fluctuations.    Moreover,  
aptamers  are  well  tolerated  in  the  body,  and  can  thus  be  repeatedly  administered  (162).    
Overall,  ribonucleic  acids  are  non-­‐‑immunogenic,  with  extensive  analysis  in  clinical  
trials.    The  incidence  of  allergic  reactions  have  been  low,  and  thought  to  be  caused  by  
antibody  generation  to  the  PEG  group  appended  to  the  aptamer  (163).      
While  the  above  properties  of  aptamers  highlight  their  flexibility  and  utility  as  
potential  therapeutics,  the  most  unique  characteristic  of  aptamers  over  antibodies  or  
small  molecules  is  their  ability  to  be  functionality  controlled  with  antidotes.    Two  types  
of  antidote  control  have  been  developed:  a  sequence  specific  antidote  that  recognizes  the  
primary  sequence  of  the  aptamer  and  disrupts  the  aptamer’s  structure,  and  a  universal  
antidote  that  nonspecifically  binds  to  an  oligonucleotide  and  can  reverse  the  activity  of  
any  aptamer,  independent  of  sequence  or  shape  (164,  165).      
A  matched  oligonucleotide  aptamer  antidote  takes  advantage  of  the  fact  that  
aptamers  form  stable  secondary  conformations,  such  as  hairpins  and  pseudoknots,  
which  fold  into  a  stable  tertiary  structure  to  bind  to  a  complementary  surface  on  their  
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target  (157).    Theoretically,  a  molecule  that  binds  to  and  alters  the  tertiary  structure  of  an  
aptamer  should  disrupt  the  ability  of  an  aptamer  to  bind  to  its  target  protein.    Because  
oligonucleotides  inherently  bind  to  each  other  through  simple  Watson-­‐‑Crick  base  
pairing,  a  short,  complementary  “antisense”  oligonucleotide  disrupts  the  structural  
elements  essential  for  binding  and  abolishes  aptamer  activity  (164).    
Although  matched  oligonucleotide  antidotes  can  successfully  modulate  the  
function  of  aptamer  anticoagulants,  there  are  a  few  drawbacks  of  this  strategy.    First,  this  
method  of  antidote  design  is  labor  intensive  and  costly,  because  custom  antidotes  must  
be  designed  and  tested  for  each  new  aptamer.    Moreover,  it  can  be  challenging  to  
develop  oligonucleotide  antidotes  to  highly  structured  aptamers  (unpublished  data).    
Finally,  because  aptamer-­‐‑oligonucleotide  antidote  complexes  are  double-­‐‑stranded  RNA,  
they  may  trigger  an  innate  immune  response  through  activation  of  toll-­‐‑like  receptors,  
although  there  has  been  no  direct  evidence  of  this  to  date.    
Because  of  these  potential  limitations  of  oligonucleotide  antidotes,  a  universal  
antidote  strategy  was  developed.    In  theory,  a  universal  antidote  is  a  molecule  that  can  
bind  to  and  control  the  activity  of  any  aptamer,  regardless  of  sequence  or  
conformational  shape.    In  healthy  individuals,  no  endogenous  oligonucleotides  circulate  
in  the  blood;  therefore,  an  antidote  that  can  recognize  and  bind  to  any  oligonucleotides  
will  be  able  to  neutralize  the  administered  aptamers,  regardless  of  sequence.  Because  all  
aptamers  are  oligonucleotides  and  thus  negatively  charged,  the  most  obvious  choice  for  
     61  
a  universal  antidote  is  a  positively  charged  molecule  that  can  bind  an  aptamer  through  
electrostatic  interactions.    Several  compounds  were  shown  to  be  successful  universal  
antidotes,  including  protamine  and  a  number  of  nucleic  acid  binding  polymers,  both  in  
vitro  and  in  vivo.    In  contrast  to  the  specific  base  pairing  mechanism  required  for  
oligonucleotide  antidotes,  binding  of  a  universal  antidote  to  the  oligonucleotide  
backbone  is  thought  to  envelope  the  aptamer,  thus  providing  a  barrier  around  the  
folded  aptamer  to  prevent  binding  to  the  therapeutic  target.    In  essence,  a  universal  
antidote  functions  like  a  “molecular  sponge”  by  binding  and  sequestering  any  
systemically  administered  oligonucleotides.    
Both  types  of  antidotes  have  several  benefits  that  led  themselves  well  to  
therapeutic  administration.    Because  of  their  specificity  and  ability  to  modulate  aptamer  
functionality,  matched  oligonucleotide  antidotes  can  allow  clinicians  to  fine-­‐‑tune  
therapy  to  the  degree  required,  rather  than  turn  it  on  or  off.    This  level  of  drug  control  
can  allow  clinicians  to  respond  immediately  to  urgent  clinical  needs  and  is  a  valuable  
advance  in  drug  therapy.    In  addition,  if  two  aptamers  are  administered  simultaneously,  
one  could  use  an  oligonucleotide  antidote  to  specifically  turn  off  a  single  aptamer,  thus  
reinstating  the  functionality  of  a  single  pathway  while  leaving  the  other  pathway(s)  
inhibited.    However,  the  clear  advantage  of  a  universal  antidote  lies  in  it  its  simplicity  
and  cost-­‐‑effectiveness  -­‐‑  one  antidote  compound  can  be  used  for  any  aptamer  
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therapeutic.    Additionally,  a  universal  antidote  could  simultaneously  reverse  the  activity  
of  any  aptamer  combinations.  
The  high  binding  affinity  and  specificity  of  aptamers  allow  for  isolation  of  an  
artificial  ligand  for  theoretically  any  therapeutic  target  of  interest.    Chemical  
manipulations  of  aptamers  also  allow  for  fine-­‐‑tuning  of  their  bioavailability,  and  
antidote  control  greatly  expands  their  clinical  use.    Thus  the  aptamer  platform  offers  a  
promising  therapeutic.  
1.4.3 Current aptamer therapeutics  
The  concept  of  using  nucleic  acids  to  modify  protein  function  originated  from  the  
study  of  viruses,  where  short,  structured  RNAs  encoded  by  the  virus  bound  to  proteins  
to  either  assist  with  virus  replication  or  inhibit  antiviral  responses.    In  the  first  study  
testing  the  idea  of  a  therapeutic  aptamer,  Sullenger  et  al.  demonstrated  that  the  single  
stranded  RNA  TAR  aptamer  could  successfully  inhibit  HIV  virus  replication  by  binding  
to  the  natural  nucleic  acid  binding  site  of  the  viral  protein  Tat,  and  thus  act  as  a  decoy  to  
block  normal  Tat  function  (166,  167).  Coupled  with  the  emergence  of  SELEX,  it  was  
recognized  that  this  process  could  be  used  to  rapidly  generate  oligonucleotide  designer  
ligands  to  essentially  any  therapeutic  target,  including  soluble  proteins  and  enzymes,  
prions  (pathogenic  misfolded  proteins),  cellular  surface  receptors,  and  transcription  
factors  (168).      
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While  a  number  of  therapeutic  aptamers  have  been  developed,  only  one  aptamer  
has  gained  FDA  approval:  an  anti-­‐‑VEGF  aptamer,  Macugen,  for  treatment  of  age-­‐‑related  
macular  degeneration  (169).    Since  its  approval  in  2004,  a  number  of  novel  aptamers  
have  been  introduced  into  clinical  trials,  as  summarized  in  Table  3.    
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Table  3.  Aptamers  in  clinical  trials    
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While  aptamers  function  well  as  antagonists  due  to  their  propensity  to  inhibit  
protein-­‐‑protein  interactions,  they  can  also  be  used  to  stimulate  protein  function.    A  
multimerized  aptamer  targeting  the  immune  surface  costimulatory  receptor  4-­‐‑1BB  was  
generated  that  mimicked  natural  ligand  binding  to  active  4-­‐‑1BB  and  promoted  T-­‐‑cell  
proliferation,  survival,  and  expansion  in  vitro  and  led  to  tumor  rejection  when  
administered  in  vivo  (170).    
In  addition  to  functioning  as  antagonists  or  agonists,  it  was  quickly  realized  that  
the  ability  to  easily  manipulate  aptamers  offers  a  platform  for  targeted  delivery.      
Aptamers  can  be  made  as  chimeras,  with  a  small  molecule,  nanoparticle,  toxin,  splice-­‐‑
switching  oligonucleotide,  or  siRNA,  to  name  a  few,  appended  to  the  end  of  the  aptamer  
sequence,  to  act  as  a  delivery  molecule  for  targeted  therapy  (171).    While  the  aptamer  
targets  a  certain  protein  and  offers  specificity,  the  cargo  attached  to  the  end  of  the  
aptamer  imparts  a  function.    While  there  are  several  examples  in  the  literature  of  this,  
one  of  the  first  displaying  this  concept  was  for  targeting  prostate-­‐‑specific  membrane  
antigen  (PSMA)  positive  prostate  cancer  cells  in  vitro  (172).    An  aptamer  targeting  PSMA  
was  hybridized  with  an  anti-­‐‑PLK1  or  anti-­‐‑BCL2  siRNA  and  the  complex  was  shown  to  
specifically  bind  to  PSMA  receptor  on  the  surface  of  the  cancer,  be  internalized,  and  
silence  PLK1  or  BCL2  function,  resulting  in  apoptosis  and  decreased  cell  proliferation.    
This  technology  has  wide  application  in  the  cancer  field,  offering  a  tumor-­‐‑specific  
targeting  device  for  other  therapeutic  agents,  hopefully  leading  to  targeted  cancer  
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therapy.    While  there  are  many  aptamers  targeting  tumor  markers  available,  each  
aptamer  has  to  be  validated  individually,  as  internalization  rates  and  methods  differ  
from  receptor  to  receptor.    Identifying  a  single  aptamer  that  can  internalize  into  many  
cancerous  cell  types  would  be  advantageous  in  further  developing  this  therapeutic  (173).    
Aside  from  direct  applications  as  therapeutics,  aptamers  have  been  designed  to  
have  clinical  diagnostic  functions  ranging  from  the  detection  of  tumor  cells  or  cancerous  
secretomes  to  uses  in  imaging,  flow  cytometry,  and  microarray  detection.    The  multiple  
functions  of  therapeutic  aptamers  have  been  extensively  reviewed  (168,  171,  174)  
1.4.4 Aptamers as antithrombotics  
While  the  use  of  antithrombotics  will  only  increase  as  more  of  the  population  is  
expected  to  have  a  cardiovascular  disease,  the  field  itself  has  been  hampered  by  
nonselective  agents  with  narrow  therapeutic  windows  and  no  dosing  flexibility  or  
reversal  agent.    As  a  therapeutic,  aptamers  lend  themselves  well  as  anticoagulants,  as  
aptamers  targeting  coagulation  factors  can  be  systemically  delivered  with  rapid  onset  in  
a  highly  reproducible  and  readily  measurable  manner,  as  well  as  be  rapidly  modulated  
or  completely  reversed  within  minutes  after  the  administration  of  an  antidote.  Thus,  
aptamers  targeting  several  members  of  the  coagulation  pathway  have  been  developed,  
and  a  few  of  those  compounds  have  progressed  into  clinical  trials.    
1.4.4.1  Inhibiting  the  common  pathway  
Prothrombin/Thrombin  
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   Thrombin  is  the  final  step  in  the  blood  coagulation  pathway,  and  mediates  many  
important  features  of  blood  coagulation,  from  cleaving  fibrinogen  into  fibrin  to  
activating  platelets.    Thrombin  has  three  main  binding  sites:  the  catalytic  active  site,  and  
two  anionic  bindings  sites:  exosite  I  and  II,  which  are  located  on  opposite  sides  of  the  
protein.    Exosite  I  is  present  on  both  prothrombin  and  thrombin,  and  binds  to  
fibrinogen,  FV,  FVIII,  thrombomodulin,  and  platelet  PAR  receptors.    In  this  way,  exosite  
I  mediates  fibrinogen  cleavage,  feedback  activation  of  clotting  cofactors,  and  platelet  
activation.    The  other  anion  binding  site,  exosite  II,  binds  to  heparin  and  also  to  a  platelet  
surface  receptor.  Therefore,  exosite  II  mediates  platelet  activation,  as  well  as  inhibition  
by  heparin.    Thus,  inhibitors  targeting  different  sites  on  thrombin  have  different  modes  
of  action,  and  combining  inhibitors  to  both  exosites  can  result  in  a  very  potent  inhibition  
of  thrombin  function  (175).    
Because  of  thrombin’s  central  role  in  coagulation,  this  well-­‐‑characterized  protein  
has  been  the  target  for  some  of  the  first  in  vitro  aptamer  selections.  The  first  aptamer  to  
be  isolated  to  a  non-­‐‑nucleic  acid  binding  protein  was  termed  HD1,  or  is  also  known  as  
ARC183.    This  aptamer  is  a  unmodified  15  nucleotide  single-­‐‑stranded  DNA  aptamer  
that  forms  a  stable  G-­‐‑quadraplex  and  binds  to  exosite  I,  thus  inhibiting  exosite  I  
functions,  including  fibrinogen  cleavage  (176,  177).    Due  to  its  anticoagulant  activity,  this  
aptamer  was  explored  in  several  animal  models  as  a  cardiopulmonary  bypass  agent.    In  
cynomolgous  monkeys,  HD1  has  a  very  short  half-­‐‑life  (108  seconds)  and  rapid  clearance  
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by  the  body  (2-­‐‑4  minutes);  therefore,  a  continuous  infusion  was  needed  to  achieve  
efficacious  anticoagulation  (178).    Once  administration  was  halted,  coagulation  values  
returned  to  baseline  in  approximately  10  minutes,  abolishing  the  need  for  a  reversal  
antidote.    While  preliminary  human  studies  were  commenced,  the  large  quantities  of  
aptamer  required  for  continual  administration  for  anticoagulation  resulted  in  
suboptimal  dosing  profile  (179).   
HD22  is  another  unmodified  DNA  aptamer,  29  nucleotides  long,  that  also  forms  
a  G-­‐‑quadraplex.    This  aptamer,  however,  binds  to  exosite  II  on  thrombin  to  inhibit  
thrombin-­‐‑mediated  activation  of  platelets,  but  has  minimal  effects  on  fibrinogen  
cleavage  (180).    A  very  potent  DNA  aptamer  was  made  by  designing  a  hybrid  aptamer  
joining  both  HD1  and  HD22  with  a  linker.    HD1-­‐‑22  thus  binds  to  both  exosites,  
effectively  shutting  down  thrombin  function  (70).    A  third  DNA  aptamer,  Nu172,  is  a  
26nt  single  stranded  unmodified  DNA  aptamer,  which  produced  a  dose  dependent  
increase  of  clinical  coagulation  assays  during  phase  I  testing  in  healthy  male  volunteers.    
Since  this  aptamer  has  a  short  half-­‐‑life,  after  terminating  infusion  of  Nu172,  coagulation  
values  returned  to  baseline.    This  aptamer  is  currently  being  evaluated  in  phase  II  
clinical  trials  for  acute  cardiovascular  surgical  procedures  (NCT00808964).    
While  many  of  the  first  thrombin  aptamers  were  DNA,  several  RNA  aptamers  
targeting  thrombin  have  since  been  developed.    Whereas  unmodified  DNA  has  a  very  
short  half-­‐‑life  in  the  body,  RNA  can  be  modified  to  be  resistant  to  endonuclease  
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cleavage,  thus  greatly  increasing  an  aptamer’s  plasma  stability.    A  25nt  2’F  pyrimidine  
RNA  aptamer,  Tog25,  was  selected  against  thrombin  using  a  “toggle”  SELEX  method  to  
promote  species  cross-­‐‑reactivity.    In  order  to  isolate  an  aptamer  that  was  efficacious  in  
both  human  and  porcine,  the  selection  was  toggled  back  and  forth  each  round  with  
human  and  porcine  thrombin  (151).  Tog25  binds  to  exosite  II  of  thrombin,  thus  
inhibiting  platelet  activation  but  having  a  minimal  effect  on  fibrinogen  cleavage  (158).    
In  contrast  to  the  G-­‐‑quadruplex  architecture  of  the  DNA  aptamers,  Tog25  has  a  
traditional  stem-­‐‑loop  structure  with  an  internal  bulge.    A  crystal  structure  of  Tog25  in  
complex  with  human  thrombin  shows  that  the  RNA  forms  an  elaborate  three-­‐‑
dimensional  structure  to  present  an  extended  molecular  surface  complementary  to  the  
protein.    A  number  of  key  interactions,  including  an  “A-­‐‑Arg  zipper”,  which  involves  a  
number  of  adenine-­‐‑arginine  stacking  interactions,  as  well  as  hydrogen  bonds  and  van  
der  Walls  interactions,  contribute  to  the  intricate  folding  that  allows  Tog25  to  tightly  
interact  with  thrombin  (Figure  6)  (157).  While  Tog25  is  not  itself  a  potent  anticoagulant,  
dual  administration  with  the  exosite  I  binding  DNA  aptamer,  HD-­‐‑1,  results  in  
synergistic  anticoagulation,  similar  to  the  bivalent  DNA  aptamer  described  above  (175).  
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Figure  6.  Crystal  structure  of  the  RNA  aptamer  Tog25  to  thrombin  
Adapted  from  Long,  et  al.,  RNA,  2008  (157).  
  
Recently,  another  2’F  pyrimidine  modified  RNA  aptamer  was  described.  R9d14t  
is  58  nucleotides  and  binds  to  both  prothrombin  and  thrombin  at  exosite  I,  thus  
inhibiting  fibrin  clot  formation,  FV  feedback  activity,  and  platelet  activation  mediated  by  
the  PAR  receptors.  In  addition,  because  the  aptamer  binds  to  the  pro-­‐‑exosite  I  on  
prothrombin,  it  inhibits  thrombin  generation  by  the  extrinsic  tenase  complex.    This  
aptamer  is  a  potent  inhibitor  of  clinical  clotting  assays.    In  addition,  an  oligonucleotide  
antidote  was  generated  towards  R9d14t  that  can  rapidly  and  stably  reverse  
anticoagulation.    While  this  aptamer  binds  to  the  same  exosite  as  the  DNA  aptamer  HD-­‐‑
1,  R9d14t  is  a  more  potent  inhibitor  of  thrombin  due  to  its  increased  stability  and  higher  
binding  affinity  (181).    Aside  from  NU172,  the  other  thrombin  aptamers  described  above  
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have  not  advanced  clinically  due  to  limited  anticoagulant  ability,  rapid  clearance,  or  
chemical  instability.    R9d14t  is  a  promising  thrombin  aptamer  therapeutic  with  an  
elegant  reversal  strategy;  however,  prothrombin  is  present  at  a  high  concentration  of  
approximately  1.4µμM  and  will  therefore  require  large  amounts  of  compound  to  fully  
saturate  the  target.    Further  optimization  of  Rd914t  will  be  warranted  before  pre-­‐‑clinical  
studies  can  proceed.    
FX  
   FX  combines  with  its  cofactor,  FVa,  on  the  surface  of  a  platelet  to  cleave  
prothrombin  to  thrombin.    While  FX  has  some  protease  activity  itself,  the  formation  of  
the  prothrombinase  complex  yields  a  ~105  fold  increase  in  thrombin  generation.    Since  
prothrombinase  cleavage  of  thrombin  is  the  only  reaction  not  duplicated  in  the  
coagulation  pathway,  inhibition  of  this  complex  would  yield  a  potent  anticoagulant.    An  
aptamer,  11F7t,  was  isolated  that  binds  to  FX  and  FXa.    This  aptamer  works  as  a  potent  
anticoagulant  in  clinical  coagulation  assays  by  blocking  the  assembly  of  the  
prothrombinase  complex  (182).    Biochemically,  11F7t  binds  to  FX  and  competes  for  
binding  with  FVa.    Therefore,  in  the  presence  of  aptamer,  the  prothrombinase  complex  
cannot  form,  resulting  in  a  decreased  amount  of  thrombin  able  to  be  formed.    
Interestingly,  the  aptamer  does  not  affect  membrane  binding,  catalytic  site  activity,  or  
influence  substrate  binding.    In  addition,  11F7t  blocks  the  ability  of  FXa  to  activate  FVIII  
in  a  feedback  loop,  as  well  as  blocking  TFPI  from  inhibiting  FXa  (182).    As  a  potent  
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anticoagulant,  this  aptamer  unfortunately  does  not  exhibit  a  high  amount  of  cross-­‐‑
reactivity  to  other  species  (unpublished  data).    Optimization  of  the  aptamer,  or  the  
isolation  of  a  separate  FX  aptamer,  would  be  needed  in  order  continue  developing  this  
aptamer  as  a  therapeutic.  
1.4.4.2  Inhibiting  the  extrinsic  pathway  
FVII  
   The  principle  activator  of  the  extrinsic  pathway,  and  also  the  major  activator  in  
vivo,  is  the  TF/FVIIa  complex.    Upon  TF  exposure,  FVIIa  binds  to  TF,  allowing  FVIIa  to  
then  cleave  FIX  and  FX  to  their  active  proteases,  and  thus  initiate  thrombin  generation  at  
the  site  of  injury.    An  inhibitor  against  FVIIa  would  therefore  shut  down  the  initiation  of  
thrombin  generation.    A  2’aminopyrimidine  RNA  aptamer,  termed  16.3,  was  generated  
that  binds  to  FVIIa  and  potently  inhibits  a  prothrombin  time  clotting  assay.    This  
aptamer  inhibits  the  TF/FVIIa  mediated  activation  of  FX,  at  least  in  part  by  preventing  
this  complex  to  form,  to  function  as  an  anticoagulant  (183).    Unfortunately,  the  folding  of  
this  aptamer  is  temperature  sensitive,  and  at  37oC,  has  decreased  binding  affinity  for  
FVIIa.    Therefore,  this  aptamer  was  not  further  developed.      
1.4.4.3  Inhibiting  the  intrinsic  pathway    
FIX  aptamer  
The  serine  protease  FIX  is  a  critical  component  in  coagulation,  where  it  plays  a  
fundamental  role  in  both  the  initiation  and  propagation  phases  leading  to  thrombin  
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generation  and  stable  fibrin  clot  formation.    Although  a  member  of  the  intrinsic  
pathway,  FIX  can  be  activated  by  both  FXI  and  the  TF/FVIIa  complex.    It  then  forms  a  
complex  with  its  cofactor,  FVIIIa,  to  activate  a  large  amount  of  FX  on  the  platelet  surface.    
Inhibiting  FIX  is  thought  to  be  a  “safer”  target,  since  current  FIX-­‐‑targeting  agents  show  
reduced  bleeding  risks  at  their  effective  doses.    However,  at  higher  doses,  these  agents  
still  have  bleeding  risks,  making  an  antidote  strategy  attractive.    
A  35  nucleotide,  2’F  pyrimidine  modified  RNA  aptamer  was  isolated  that  
inhibits  FIXa  activity  and  prolongs  plasma  clotting  in  a  dose-­‐‑dependent  manner.    
Optimal  doses  of  this  aptamer  induce  a  transient,  Hemophilia  A-­‐‑like  state  where  >99%  
FIXa  activity  is  inhibited.    This  aptamer  can  also  be  rapidly  reversed  by  a  number  of  
short  2’OMe  RNA  antidote  oligonucleotides  (164).    Biochemical  studies  indicate  that  this  
aptamer  blocks  an  extended  substrate  binding  site  so  as  to  inhibit  FIX-­‐‑mediated  
activation  of  FX,  but  it  does  not  inhibit  FVIII  binding  to  FIX  (184).    
This  FIXa  aptamer-­‐‑antidote  pair  was  next  tested  in  a  porcine  cardiopulmonary  
bypass  surgery  model,  and  it  was  found  that  this  strategy  could  limit  thrombin  
generation  and  inflammation  more  effectively  than  heparin  while  exhibiting  none  of  the  
dehabilitating  side  effects,  such  as  reduced  cardiac  function,  that  are  associated  with  
protamine  administration  (185).      Because  of  its  low  immunogenicity,  this  regimen  could  
lend  itself  well  to  applications  in  patients  who  cannot  tolerate  heparin/protamine  (HIT,  
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HITT,  or  sensitization  to  protamine)  and  currently  have  no  other  option  for  reversible  
anticoagulation.    
Because  of  the  success  in  the  preclinical  development  of  establishing  the  FIX  
aptamer-­‐‑antidote  pair  as  a  nontoxic,  predictable,  and  reversible  system  in  animals,  the  
aptamer-­‐‑antidote  pair  was  next  optimized  for  use  in  humans  and  moved  into  clinical  
development  as  the  REG1  Anticoagulation  System  (Regado  Biosciences,  Durham,  NC).    
The  REG1  system  consists  of  two  compounds:  RB006  is  the  FIXa  aptamer  further  
modified  with  active  2’F  and  2’OMe  nucleotides  and  a  3’  inverted  deoxythymidine  cap  
conjugated  to  a  40kDa  PEG  carrier  to  increase  its  half  life  and  RB007  is  a  2’OMe  
modified  15  nucleotide  RNA  oligonucleotide  antidote  complementary  to  a  portion  of  
RB006  (162)  (Figure  7).  
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Figure  7.  The  REG1  anticoagulation  system  
Adapted  from  Povsic,  et  al.,  Euro  Hrt  Jrl.,  2012  (163)  
  
Three  phase  one  clinical  studies  were  performed  to  determine  if  the  REG1  
Anticoagulation  System  would  be  well  tolerated  in  healthy  subjects  and  patients  with  
stable  CAD  currently  on  antiplatelet  agents,  as  well  as  to  determine  the  relationship  
between  drug  dose  and  clinical  monitoring  tests  (161,  186).    Overall,  The  RB006/RB007  
complex  was  found  to  be  both  stable  and  biologically  inactive,  with  irreversible  binding  
of  aptamer  to  antidote,  thus  exhibiting  no  rebound  anticoagulation  effect  due  to  
dissociation  of  aptamer  and  antidote.    Anticoagulation,  either  bolus  or  weight-­‐‑adjusted,  
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was  rapid  and  stable  for  several  hours,  whereas  antidote  administration  rapidly  
reversed  the  aptamer’s  activity  within  minutes  (161).    While  clearance  of  free  RB006  
involves  mainly  intravascular  and  some  renal  mechanisms,  clearance  of  RB007  and  the  
RB006/RB007  complex  is  believed  to  occur  rapidly  through  endogenous  endonuclease  
degradation,  allowing  for  the  re-­‐‑administration  of  aptamer  with  immediate  restoration  
of  anticoagulant  effects  (162,  186).  The  REG1  system  was  also  shown  to  be  well  tolerated  
and  predictable  in  patients  with  stable  CAD  that  commonly  undergo  procedures  
requiring  anticoagulation.    These  patients  tend  to  be  older  with  reduced  drug  clearance  
and  are  currently  on  other  medications,  such  as  oral  antiplatelets,  that  affect  hemostatic  
factors  and  can  increase  the  patient’s  propensity  for  bleeding  (186).    The  success  of  these  
studies  highlight  the  versatility  of  the  aptamer-­‐‑antidote  platform  for  use  in  a  wide  
number  of  clinical  indications,  as  the  pair  can  be  repeatedly  administered  with  highly  
predictive  results  and  no  evidence  of  toxicity,  immunogenicity,  or  adverse  bleeding  
events.    Importantly,  drug  reversal  can  be  closely  controlled  by  titrating  in  antidote  as  
needed  to  neutralize  the  anticoagulant  effects  of  the  aptamer  to  the  necessary  degree  
(187).  
Reversal-­‐‑PCI  (NCT00113997)  was  a  phase  2a  pilot  study  that  was  undertaken  to  
assess  the  REG1  system  as  the  sole  anticoagulant  for  use  in  elective  PCI  in  low  risk  
patients  with  stable  CAD.    This  study  represented  the  first  clinical  use  of  the  REG1  
system  and  exhibited  partial  or  complete  reversal  of  REG1  to  allow  for  a  safe  sheath  
     77  
removal.    Overall,  the  REG1  system  exhibited  low  inter-­‐‑patient  variability,  with  a  rapid  
onset  and  stable  anticoagulation  throughout  the  procedure.    RB006  was  either  fully  or  
partially  reversed  upon  administration  of  the  appropriate  dose  of  RB007  in  a  predictable  
manner.    This  ability  to  slowly  and  partially  reverse  is  useful  in  clinical  settings  where  
incomplete  or  slow  reversal  of  anticoagulation  is  desired,  such  as  PCI,  where  
anticoagulation  can  be  slowly  reversed  in  conjunction  with  sheath  removal.    This  study  
proved  that  REG1  could  replace  heparin/protamine  in  PCI  with  stable  and  predictable  
anticoagulation,  and  laid  the  groundwork  for  a  larger  clinical  trial  in  higher  risk  patients  
undergoing  PCI  (188).    
A  Phase  2b  study  termed  RADAR  (A  Randomized,  Partially  Blinded,  
Multicenter,  Active-­‐‑Controlled,  Dose-­‐‑Ranging  Study  Assessing  the  Safety,  Efficacy,  and  
Pharmacodynamics  of  the  REG1  Anticoagulation  System  in  Patients  with  ACS)  
(NCT00932100),  was  designed  to  asses  the  degree  of  reversal  required  for  early  sheath  
removal  and  mitigate  bleeding  following  cardiac  catheterization  (163).  A  total  of  640  
non-­‐‑ST  elevated  ACS  patients  from  multiple  international  centers  were  randomly  
assigned  to  one  of  four  REG1  treatment  arms,  all  receiving  a  weight  adjusted  dose  of  
RB006  (now  termed  pegnivacogin)  with  four  different  RB007  (now  termed  anivamersen)  
reversal  strategies.    Overall,  it  was  determined  that  at  least  50%  reversal  of  pegnivacogin  
is  required  for  safe  sheath  removal.  In  addition,  full  FIX  inhibition  with  pegnivacogin,  
followed  by  full  reversal  with  anivamersen,  did  not  increase  bleeding  or  subsequent  
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thrombotic  events  despite  early  sheath  removal,  suggesting  that  this  strategy  is  
efficacious  for  ACS  patients  undergoing  invasive  surgery.    While  the  incidence  of  
bleeding  rates  and  adverse  events  were  similar  with  REG1  and  heparin,  enrollment  in  
RADAR  was  halted  after  three  allergic  events  thought  to  be  due  to  exposure  to  PEG  and  
not  the  aptamer  itself.    In  addition,  all  three  patients  had  a  history  of  allergic  reactions  
(163).    Overall,  the  study  goals  were  met,  and  larger  clinical  trials  determining  the  
efficacy  of  the  REG1  system  compared  to  other  anticoagulation  strategies  are  warranted.  
While  the  REG1  system  was  administered  intravenously  in  these  previous  
studies  for  rapid  onset  anticoagulation,  a  subcutaneous  route  of  injection  could  be  
valuable  in  settings  that  require  chronic  anticoagulation,  such  as  VTE.    In  a  phase  1a  
clinical  trial  in  healthy  volunteers,  subcutaneous  administration  of  pegnivacogin  
resulted  in  anticoagulation  beginning  at  8-­‐‑12  hours  after  injection,  with  peak  
anticoagulation  at  ~48  hours.  This  effect  was  durable  with  a  half-­‐‑life  of  6  days.    
Anivamersin  administration  successfully  neutralized  RB006  plasma  activity,  but  did  not  
inhibit  further  absorption  of  RB006  in  the  bloodstream,  resulting  in  only  transient  
reversal  (189).  A  phase  2b  trial  with  multiple  dose  escalation  is  planned.    
Overall,  the  REG1  anticoagulation  system  is  the  first  aptamer-­‐‑antidote  pair  to  be  
tested  in  humans,  and  it  has  shown  to  be  safe  and  effective  in  the  clinical  setting  of  PCI  
with  a  number  of  advantages  over  the  standard  of  care  heparin/protamine.    Importantly,  
REG1  was  able  to  predictably  and  stably  anticoagulate  patients  and  was  easily  
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monitored  with  routine  point  of  care  assays.    Antidote  reversal  allowed  for  immediate  
restoration  of  FIX  function,  allowing  for  repeat  administration  with  stable  and  
predictable  anticoagulation.  The  hallmark  of  this  system  allows  for  unprecedented  
control  over  drug  titratability,  with  the  ability  to  fully  or  partially  neutralize  the  aptamer  
as  needed.  
1.4.4.4  Inhibiting  platelet  pathways  
VWF  Aptamer  
VWF  is  a  large,  multimeric  glycoprotein  (ranging  from  600  to  20,000  kDa)  
expressed  in  platelets  and  endothelial  cells  and  mediates  platelet  adhesion,  activation,  
and  aggregation.    Once  VWF  is  exposed  on  the  injured  vessel  wall,  it  can  then  interact  
with  collagen  near  the  site  of  injury,  as  well  as  adhesion  platelet  receptors  to  tether  
platelets  to  the  site  of  injury,  allowing  them  to  become  activated  and  aggregate,  thus  
forming  a  plug  at  the  site  of  injury.  Inhibiting  the  interaction  of  platelets  with  VWF,  
especially  in  a  high  flow  environment,  could  severely  impair  coagulation  by  not  
allowing  platelets  to  adhere  to  the  site  of  injury.    This  defect  is  evident  in  von  
Willebrand’s  disease,  where  patients  with  deficiencies  of  VWF  have  moderate  to  severe  
bleeding  phenotypes.    
A  mixed  modified  DNA/RNA  aptamer  against  VWF  was  isolated  that  binds  to  
the  A1  domain  of  VWF.    This  domain  is  responsible  for  platelet  binding  to  the  
glycoprotein.    As  such,  this  aptamer,  termed  ARC1779,  blocks  the  ability  of  VWF  to  
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interact  with  platelet  receptors,  thus  interrupting  VWF-­‐‑mediated  aggregation  and  
activation  of  platelets  in  clinical  platelet  aggregation  assays.    Given  as  a  continuous  
infusion,  this  aptamer  was  efficacious  in  preventing  occlusive  thrombi  from  forming  in  a  
cynomolgous  monkey  arterial  thrombosis  model  (190).    A  PEGylated  version  of  
ARC1779  was  subsequently  administered  in  healthy  volunteers  in  a  Phase  I  clinical  trial  
sponsored  by  Archemix  Corporation.    While  the  drug  was  well  tolerated  in  this  study,  
with  high  specificity  and  no  reports  of  excess  bleeding  or  toxicity,  further  clinical  studies  
with  this  aptamer  were  either  terminated  or  halted  (190).    
   A  2’F  pyrimidine  RNA  VWF  aptamer  was  isolated  using  a  convergent  SELEX  
approach  by  first  selecting  against  the  entire  plasma  proteome.    Then,  using  this  focused  
library,  several  rounds  of  purified  protein  selection  against  VWF  were  performed.    The  
lead  candidate,  R9.14,  was  shown  to  bind  within  the  A1  domain  that  mediates  platelet  
binding  to  VWF,  and  therefore,  this  aptamer  was  able  to  inhibit  platelet  aggregation  and  
activation  in  a  clinical  platelet  aggregation  assay.  An  antidote  was  also  generated  that  
could  potently  reverse  the  aptamer’s  action  within  two  minutes  (191).    
   A  truncated,  cholesterol-­‐‑modified  version  of  R9.14  was  next  tested  in  animal  
models.    These  modifications  allow  for  more  cost  effective  synthesis,  and  increase  the  
half-­‐‑life  of  the  aptamer  in  an  animal.  In  a  mouse  ferric-­‐‑chloride  arterial  thrombosis  
model,  administration  of  R9.14  kept  the  vessel  patent  and  free  of  thrombi  for  up  to  one  
hour  (192).    While  there  was  no  spontaneous  bleeding  in  these  mice,  the  aptamer  dose-­‐‑
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dependently  increased  bleeding  as  measured  by  a  tail  transection.  However,  
administration  of  either  a  matched  oligonucleotide  antidote  or  a  universal  antidote  
completely  reversed  the  bleeding  phenotype  (192).    As  use  of  antiplatelets  has  been  
limited  due  to  the  high  risk  of  hemorrhage,  especially  from  coupling  these  agents  with  
other  anticoagulants,  an  aptamer-­‐‑antidote  pair  could  be  rapidly  controlled  by  physicians  
in  response  to  adverse  bleeding  events  in  a  clinical  setting,  while  still  protecting  the  
patient  from  thrombotic  complications.    Thus,  the  VWF  aptamer-­‐‑antidote  system  is  
currently  undergoing  further  optimization  and  subsequent  pre-­‐‑clinical  trials.    
GPVI  
   The  platelet  receptor  Glycoprotein  VI  (GPVI)  binds  collagen  to  activate  platelets,  
and  is  a  promising  target  for  a  thrombosis  therapeutic,  as  inhibition  of  GPVI  impairs  
stable  platelet  aggregation  without  a  bleeding  phenotype.    Regado  Biosciences  has  
developed  a  GPVI  aptamer-­‐‑antidote  pair  that  can  inhibit  collagen-­‐‑induced  platelet  
aggregation  and  activation.    While  this  aptamer  is  still  in  preclinical  trials,  it  is  expected  
to  enter  safety  trials  in  2013.    In  addition,  a  2’F  pyrimidine  RNA  aptamer  was  isolated  
against  GPVI  by  the  Sullenger  lab  (unpublished  data).    While  this  aptamer  exhibited  
high  affinity  binding  towards  the  receptor,  the  aptamer  exhibited  agonistic  effects  by  
rapidly  activating  platelets  and  stimulating  aggregation  (unpublished  data).    It  is  
thought  that  at  high  concentrations,  the  aptamer  multimerizes  and  thus  mimics  other  
GPVI  agonists  to  activate  platelets.    
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2. Characterization of an anticoagulant aptamer against 
FXII 
Chapter  2  was  modified  from  a  manuscript  entitled  “Inhibiting  the  intrinsic  pathway  of  
coagulation  with  a  FXII-­‐‑targeting  RNA  Aptamer“  published  in  the  Journal  of  Thrombosis  and  
Haemostasis  in  May  2013  (epub  ahead  of  print).    The  authors  were  Rebecca  Woodruff,  Yiming  
Xu,  Juliana  Layzer,  Weizhen  Wu,  Martin  Ogletree,  and  Bruce  Sullenger.    
2.1 Introduction 
The  hemostatic  system  maintains  the  integrity  of  the  vasculature  by  sequentially  
activating  a  series  of  proteases,  culminating  in  thrombin  production  and  fibrin  clot  
formation.    Activation  of  coagulation  can  occur  by  either  exposure  of  TF  on  the  vessel  
wall  at  the  site  of  injury  (extrinsic  pathway)  or  by  activation  of  blood-­‐‑borne  components  
(factor  XII)  in  the  vasculature  (intrinsic,  or  contact  activation,  pathway)  (10).    While  the  
extrinsic  pathway  is  thought  to  initiate  thrombin  formation  at  the  site  of  injury,  the  
intrinsic  pathway  is  thought  to  mediate  continued  thrombin  generation  to  stabilize  a  
thrombus  (39).  Deficiency  of  FXII  in  animals  is  associated  with  protection  from  occlusive  
thrombus  formation  after  arterial  injury  and  stroke  models  (40,  41,  96).    While  thrombi  
can  still  form  in  these  models,  they  are  unstable  and  fail  to  occlude  the  vessel.    
Importantly,  while  offering  a  protective  thrombotic  effect,  deficiency  of  FXII  did  not  
interrupt  normal  hemostatic  events  (40).    Thus,  pharmacologic  inhibition  of  FXII  is  an  
attractive  alternative  in  providing  protection  from  pathologic  thrombus  formation  while  
minimizing  hemorrhagic  risk.  
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Human  FXII  is  an  80kDa  glycoprotein  consisting  of  an  enzymatic  light  chain  and  
a  heavy  chain  comprised  of  several  conserved  domains  that  mediate  binding  to  anionic  
surfaces  and  other  proteins  (15,  20).    Binding  of  the  FXII  heavy  chain  to  an  anionic  
surface  induces  a  conformational  change  and  results  in  a  small  amount  of  activated  FXII  
(FXIIa)  formed  (21).  While  a  number  of  negatively  charged  substances  have  been  shown  
to  autoactivate  FXII,  several  compounds  thought  to  be  involved  in  or  associated  with  
thrombosis  or  inflammation,  such  as  polyphosphates  (45),  nucleic  acids  (27,  89),  
activated  platelets  (43),  protein  aggregates  (44),  collagen  (25),  and  mast  cell  heparin  (28)  
have  been  identified  as  potential  autoactivators  of  FXII  in  vivo.    Once  activated,  FXIIa  can  
then  activate  FXI  and  the  intrinsic  pathway  of  coagulation  to  generate  thrombin,  leading  
to  fibrin  clot  formation  and  stabilization  and  platelet  and  cellular  activation  via  protease  
activated  receptors.    Additionally,  FXIIa  can  activate  plasma  kallikrein  (PK)  to  cleave  the  
inflammatory  mediator  bradykinin  (BK)  from  high-­‐‑molecular  weight  kininogen  (HK)  to  
facilitate  inflammatory  responses  (193).    
Aptamers  are  single  stranded,  highly  structured  oligonucleotides  that  act  as  
protein  antagonists  by  binding  to  large  surface  areas  on  their  target  protein  to  directly  
inhibit  protein-­‐‑protein  interactions.  A  number  of  aptamers  have  been  developed  as  
specific  and  high  affinity  inhibitors  of  coagulation  proteins  (FIX,  FVII,  VWF,  FX,  FII)  that  
function  as  potent  anticoagulants  by  interrupting  specific  complex  macromolecular  
interactions  on  their  target  protease  (164,  181-­‐‑183,  191).  The  aptamer  platform  offers  a  
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level  of  control,  as  each  aptamer  can  be  specifically  and  effectively  reversed  by  either  a  
sequence  specific  antidote  that  recognizes  and  binds  to  the  primary  sequence  of  the  
aptamer  to  disrupt  aptamer-­‐‑protein  binding  (160)  or  a  universal  antidote  that  can  
reverse  the  action  of  any  aptamer  independent  of  its  sequence  (165).    While  aptamer  
technology  has  been  successfully  applied  to  downstream  coagulation  factors,  an  
aptamer  inhibitor  of  the  upstream  contact  pathway  has  not  yet  been  reported.  Herein,  
we  describe  the  isolation  and  characterization  of  a  modified  RNA  aptamer  targeting  
FXII/FXIIa.    This  aptamer  functions  as  a  potent  anticoagulant  in  a  number  of  clinical  
coagulation  assays,  and  mediates  its  anticoagulant  effects  by  inhibiting  not  only  the  
autoactivation  of  FXII,  but  also  FXI-­‐‑mediated  intrinsic  pathway  activation.    However,  
this  aptamer  does  not  affect  FXIIa-­‐‑mediated  PK  activation,  demonstrating  that  aptamers  
can  selectively  interfere  with  specific  protein-­‐‑protein  interactions  without  inhibiting  the  
active  site  of  enzymes.  
2.2 Materials and Methods  
Materials:  
The  SELEX  DNA  template  sequence  was  5′-­‐‑
TCTCGGATCCTCAGCGAGTCGTCTG-­‐‑N40-­‐‑CCGCATCGTCCTCCCTA-­‐‑3′  and  was  
purchased  from  Oligos,  etc.  (Wilsonville,  OR).    The  5’  and  3’  SELEX  primer  sequence  are  
5’-­‐‑GGGGGAATTCTAATACGACTCACTATAGGGAGGACGATGCGG  and  5’-­‐‑
TCTCGGATCCTCAGCGAGTCGTC-­‐‑3’,  respectively,  and  were  purchased  from  
     85  
Integrated  DNA  Technologies  (IDT,  Coralville,  IA).    The  2’Flouro  modified  cytidine  and  
uridine  were  purchased  from  Trilink  BioTechnology    (San  Diego,  CA).    
Kallikrein,  prekallikrein,  α-­‐‑FXIIa,  and  β-­‐‑fXIIa,  were  purchased  from  Enzyme  Research  
Laboratories  (South  Bend,  IN),  and  FXII,  Corn  Trypsin  Inhibitor  (CTI),  and  all  other  
coagulation  proteins  were  purchased  from  Haematologic  Technologies  (Essex  Junction,  
VT).    Human  normal  pooled  plasma  was  purchased  from  George  King  Biomedical,  Inc.  
(Overland  Park,  Kansas).    Bovine  serum  albumin  (BSA)  was  purchased  from  EMD  
Chemicals  (Gibbstown,  NJ),  PEG-­‐‑8000  was  purchased  from  Fluka  Biochemika  (Buchs,  
Switzerland),  dextran  sulfate  was  purchased  from  Pharmacia  Biotech  (Piscataway,  NJ),  
and  kaolin  was  purchased  from  Sigma-­‐‑Aldrich  (St.  Louis,  MO).  AMV-­‐‑RT  enzyme  was  
purchased  from  Roche  Applied  Science  (Indianapolis,  IN).  Pacific  Hemostasis  APTT-­‐‑XL  
Reagent  (Ellagic  Acid)  was  purchased  from  Thermo  Scientific  (Waltham,  MA),  and  
TriniCLOT  aPTT  S  (micronized  silica)  was  purchased  from  Trinity  BioTech  (Bray,  Co  
Wicklow,  Ireland).  All  kinetic  assays  were  performed  in  96-­‐‑well  flat  bottom  microtiter  
plates  (Corning  Incorporated,  Corning,  NY),  the  absorbance  was  read  at  405nm  on  a  
Power  Wave  XS2  kinetic  microplate  spectrophotometer  (Biotek,  Winooski,  VT),  and  the  
data  were  analyzed  using  the  Graphpad  Prism  Software  (GraphPad  Prism,  GraphPad  
Software,  Inc.,  San  Diego,  CA).  
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Convergent  SELEX:  
Convergent  aptamer  selection  was  performed  as  described  previously  (191).  The  
sequence  of  the  starting  RNA  library  was  5'ʹ-­‐‑  
GGGAGGACGAUGCGG-­‐‑N40-­‐‑CAGACGACUCGCUGAGGAUCC-­‐‑3'ʹ,  where  N40  is  a  40  
nucleotide  randomized  region,  and  D  and  U  represent  2’F  modified  ribonucleotides,  
respectively.    Complex  selection  rounds  were  performed  by  incubating  the  modified  
starting  library  with  diluted  normal  human  plasma  in  a  low  salt,  Hepes-­‐‑based  binding  
buffer  (20mM  Hepes,  50mM  NaCl,  2mM  CaCl2,  and  .01%BSA).    To  inhibit  non-­‐‑specific  
binding  of  the  RNA  library  to  the  plasma  proteome,  yeast  tRNA  was  incorporated  into  
the  binding  mixture.    Bound  RNA  was  separated  from  unbound  RNA  by  passing  the  
mixture  through  a  25-­‐‑mm  0.45µμm  nitrocellulose  filter  membrane  (Protran  BA  85,  
Whatman,  Inc.,  Piscataway,  NJ).    The  bound  RNA  was  extracted  and  RT-­‐‑PCRed  to  
amplify  the  bound  RNA  species  as  previously  described  (152).    After  five  rounds  of  
selection  against  unfractionated  normal  human  pooled  plasma  (George  King  
Biomedical,  Inc.,  Overland  Park,  KA),  four  rounds  of  selection  were  performed  against  
purified  FXII  in  Hepes-­‐‑based  buffer  (20mM  Hepes,  150mM  NaCl,  2mM  CaCl2,  and  
.01%BSA).  Binding  of  each  round  to  FXII  was  monitored  by  a  nitrocellulose  filter-­‐‑
binding  assay.    The  final  round  was  cloned  and  sequenced  as  previously  described  to  
distinguish  individual  aptamer  sequences  (152).  
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RNA  Aptamers  
For  all  aptamer  sequences,  “C”  and  “U”  represent  2’fluorocytosine  and  2’fluorouracil.  
The  80-­‐‑nucleotide  full  length  R4cXII-­‐‑1  sequence  is  5’  -­‐‑
GGGAGGACGAUGCGGCCAAAUCUCGGCUGCCAGCAGGUCACGAGUCGCAAGAUAAC
AGACGACUCGCUGAGGAUCCGAGA-­‐‑3’.  The  51  nucleotide  truncated  R4cXII-­‐‑1t  sequence  is  
5’-­‐‑  GGCUCGGCUGCCAGCAGGUCACGAGUCGCAGCGACUCGCUGAGGAUCCGAG-­‐‑3’.    
The  51-­‐‑nucleotide  scrambled  control  RNA  sequence  is  
5’GGGGCAGCCGUGGACCGACUGCCGCAUGCCAUUGACAGUCCGAUGCCAGGC-­‐‑3’.      
The  sequence  for  the  point  mutant  control  R4cXII-­‐‑1T22M  is  
GGCUCGGCUGAACGCAGGUCACGAGUCGCAGCGACUCGCUGAGGAUCCGAG.    All  
aptamers  were  transcribed  in  vitro  as  previously  described  using  a  modified  polymerase  (152,  
194).    Before  use,  all  aptamer  preparations  were  diluted  into  a  Hepes-­‐‑based  buffer  with  or  
without  BSA  (20mM  Hepes,  150mM  NaCl,  2mM  CaCl2,  and  with  or  without  0.01%BSA)  as  
indicated.    Diluted  aptamers  were  refolded  by  heating  to  65oC  for  5  minutes,  and  then  cooled  
for  3  minutes  at  ambient  room  temperature.  
  
Nitrocellulose  filter  binding  assay:  
A  double-­‐‑filter  nitrocellulose  binding  assay  was  employed  to  determine  the  
apparent  binding  affinity  constants  (Kd  values)  of  aptamer  to  protein  (152).  The  5’  end  of  
the  RNA  was  dephosphorylated  using  bacterial  alkaline  phosphatase  (Gibco  BRL,  
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Gaithersburg,  MD),  and  subsequently  end-­‐‑labeled  with  [γ32P]  ATP  (Perkin  Elmer,  
Waltham,  MA)  using  T4  polynucleotide  kinase  (New  England  Biolabs,  Beverly,  MA).    
Varying  concentrations  of  purified  protein  were  incubated  with    [γ32P]  RNA  in  Hepes  
binding  buffer  with  BSA  (20mM  Hepes,  150mM  NaCl,  2mM  CaCl2,  and  .01%BSA)  at  
37oC  for  5  minutes.    The  RNA-­‐‑protein  complexes  were  then  separated  from  the  unbound  
RNA  by  passing  the  mixture  through  a  nitrocellulose  filter  (Protran  BA  85,  Whatman  
Inc.,  Florham  Park,  NJ).    The  levels  of  bound  RNA  were  quantified  using  a  Storm  825  
phosphoimager  (GE  Healthcare,  Piscataway,  NJ).    Non-­‐‑specific  binding  of  the  
radiolabeled  RNA  to  the  nitrocellulose  filter  was  subtracted,  and  the  data  were  fitted  
using  nonlinear  regression  to  determine  the  apparent  binding  affinity  for  the  RNA  
aptamer-­‐‑protein  interaction  (GraphPad  Prism,  GraphPad  Software,  Inc.,  San  Diego,  CA).  
  
Clotting  Assays  
Activated  partial  thromboplastin  time  (aPTT)  and  prothrombin  time  (PT)  assays  
were  carried  out  using  a  model  ST4  coagulometer  (Diagnostica  Stago,  Parsippany,  NJ).    
Aptamer  was  diluted  in  Hepes  buffer  without  BSA  (20mM  Hepes,  150mM  NaCl,  2mM  
CaCl2),  refolded  by  heating  for  5  minutes  at  65°C  and  then  cooled  to  ambient  
temperature  for  3  minutes.  For  the  aPTT,  aptamer  (5µμL)  was  then  added  to  50µL  normal  
human  pooled  plasma  (George  King  Biomedical,  Inc.,  Overland  Park,  KA)  and  
incubated  for  5  minutes  at  37°C.  50µL  APTT-­‐‑XL  reagent  was  then  added  to  activate  
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plasma  and  incubated  for  5  minutes  at  37°C.    Clotting  was  initiated  by  adding  50µL  of  
25mM  CaCl2  and  the  time  to  clot  formation  was  recorded.  Aptamer  concentrations  
represent  the  final  concentration  in  the  entire  reaction.  
For  the  PT,  refolded  aptamer  (5µμL)  was  added  to  50µL  plasma  and  incubated  for  
5  minutes  at  37°C.    TriniClot  PT  Excel  (Trinity  BioTech,  Bray,  Co  Wicklow,  Ireland)  was  
added  to  initiate  clotting.    
For  FXIIa  and  FXIa  clotting  times,  refolded  aptamer  (5µμL)  was  added  to  45µμL  of  
either  40nM  FXIa  or  250nM  FXIIa  and  incubated  for  5  minutes  at  37°C.    Aptamer  and  
protein  were  added  to  either  FXII  or  FXI-­‐‑deficient  human  plasma  (Haematologic  
Technologies,  Essex  Junction,  VT)  supplemented  with  3µM  phospholipid  (15%  
phosphatidylserine,  41%  phosphatidylcholine,  44%  phosphatidylethanolamine  (Avanti  
Polar  Lipids  (Alabaster,  AL))  and  incubated  for  30  seconds  at  37°C.  Clotting  was  
initiated  by  adding  50µL  of  25mM  CaCl2  and  the  time  to  clot  formation  was  recorded.  
Aptamer  concentrations  represent  the  final  concentration  in  the  entire  reaction.  
  
Thrombin  Generation  Assay  
In  an  Immulon  2HB  clear  U-­‐‑bottom  96  well  plate  (Thermo  Labsystems,  Franklin,  
MA),  CTI-­‐‑  treated  (50µμg/mL),  pooled  normal  human  platelet  poor  plasma  from  healthy,  
consented  volunteers  (60µμL)  was  mixed  with  aptamers  (3µμL)  diluted  in  Hepes-­‐‑based  
buffer  without  BSA  and  incubated  for  5  min  at  37oC.  Ellagic  acid  reagent  (final  
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concentration  0.1µμM,  diluted  1:200  with  4µμM  phospholipid  vesicles  (20%  
phosphatidylserine,  60%  phosphatidylcholine,  20%  phosphatidylethanolamine)  in  
Hepes-­‐‑based  buffered  saline)(15µμL)  was  added  to  the  plasma-­‐‑aptamer  mixture,  and  
incubated  for  5  minutes  at  37oC.  Flu-­‐‑Ca  (Diagnostica  Stago)(15µμL)  was  added  to  start  the  
assay  and  thrombin  generation  was  measured  using  a  Fluroskan  Ascent  Reader  
(Thermo  Scientific,  Waltham,  MA).    A  thrombin  calibrator  reagent  (Diagnostica  Stago,  
Parsippany,  NJ)  was  used  to  quantify  the  amount  of  thrombin  generated  in  the  samples.    
Data  analysis  was  performed  using  Thrombinoscope  software  (Thrombinoscope  BV,  the  
Netherlands).  Aptamer  concentrations  represent  the  final  concentration  in  the  entire  
reaction.  The  amount  of  ellagic  acid  used  was  standardized  to  produce  a  similar  curve  to  
a  TF-­‐‑activated  TGA.    In  addition,  the  amount  of  CTI  present  was  standardized  to  inhibit  
contact  activation  of  the  plasma  sample,  while  still  allowing  for  robust  FXII-­‐‑dependent  
activation  upon  administration  of  ellagic  acid.    
  
FXIIa  small  peptide  substrate  cleavage  
FXIIa  (final  concentration  10nM)  was  incubated  with  varying  concentrations  of  
either  aptamer  or  CTI  for  10min  at  37oC  in  a  Hepes-­‐‑based  reaction  buffer  (20mM  Hepes  
pH  7.4,  150mM  NaCl,  2mM  CaCl2,  .01%  BSA).  The  chromogenic  substrate  Spectrozyme  
FXIIa  (American  Diagnostica  Inc.  –  now  Sekisui  Diagnostics,  Stamford,  CT)  was  added  
to  a  total  volume  of  100µμL.    Substrate  cleavage  was  monitored  at  an  absorbance  of  
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405nm  using  a  kinetic  microplate  spectrophotometer  at  37oC,  and  rates  of  substrate  
cleavage  were  determined  using  linear  regression  analysis.  
  
FXII  autoactivation  assays  
FXII  (final  concentration  0.2µμM)  was  incubated  with  varying  concentrations  of  
aptamer,  dextran  sulfate,  or  buffer  for  1  hour  at  37oC  in  a  Hepes-­‐‑based  buffer  with  BSA  
and  with  or  without  0.1%  PEG.  To  determine  if  the  aptamer  could  block  autoactivation  
of  FXII,  1µμM  aptamer  or  buffer  was  pre-­‐‑incubated  with  FXII  for  5  minutes  prior  to  the  
addition  of  an  autoactivator,  and  the  mixture  was  incubated  for  1  hour  at  37oC.    The  final  
concentrations  of  the  autoactivators  were:  dextran  sulfate  (1µμg/mL),  kaolin  (100µμg/mL),  
micronized  silica  (30x-­‐‑diluted),  and  ellagic  acid  (30x-­‐‑diluted).    In  both  experiments,  the  
FXIIa  chromogenic  substrate  Spectrozyme  FXIIa  (American  Diagnostica  Inc.  –  now  
Sekisui  Diagnostics,  Stamford,  CT)  was  added  to  a  total  volume  of  100µμL  (final  
concentration  0.2mM).    Substrate  cleavage  was  monitored  at  an  absorbance  of  405nm  
using  a  kinetic  microplate  spectrophotometer  at  37oC,  and  rates  of  substrate  cleavage  
were  determined  using  linear  regression  analysis.  
  
FXIIa-­‐‑mediated  FXI  activation:  
Conversion  of  zymogen  FXI  to  activated  FXIa  by  FXIIa  was  measured  in  a  two  
stage  chromogenic  assay  performed  at  37oC  in  a  Hepes-­‐‑based  buffer  with  BSA.  Aptamer  
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or  buffer  was  incubated  with  FXIIa  (final  concentration  5nM)  for  5  minutes  at  37oC,  and  
reactions  were  initiated  with  the  addition  of  FXI  (final  concentration  25nM).    At  timed  
intervals  after  the  initiation  of  the  reaction,  samples  of  the  reaction  mixture  were  
removed,  FXIIa  activity  was  quenched  by  addition  of  1µμM  CTI,  and  FXIa  activity  was  
assayed  by  the  addition  of  1mM  Pefachrome  FXIa  (Centerchem,  Inc.,  Norwalk,  CT).    The  
rate  of  substrate  hydrolysis  was  recorded  at  405nM  using  a  kinetic  microplate  
spectrophotometer  at  37oC.  FXIa  cleavage  rates  of  substrate  were  then  used  to  determine  
the  amount  of  FXIa  formed  by  extrapolating  from  a  standard  curve  prepared  using  
purified  FXIa.      
To  determine  the  inhibition  constant  (Ki),  FXI  activation  reactions  were  
performed  as  described  above  in  the  presence  of  varying  concentrations  of  aptamer.    The  
initial  rate  of  FXI  activation  by  FXIIa  was  determined  by  linear  regression  of  the  amount  
of  FXIa  formed  versus  time  for  the  first  10  minutes  of  the  reaction.    Fractional  activity  
(V1/V)  was  calculated  by  dividing  the  initial  rate  of  FXI  activation  in  the  presence  of  
aptamer  by  the  initial  rate  of  FXI  activation  in  the  absence  of  aptamer.    The  Ki  was  
determined  using  nonlinear  regression  analysis.  
  
FXIIa-­‐‑mediated  Prekallikrein  activation  
Conversion  of  prekallikrein  to  kallikrein  by  FXIIa  was  measured  in  a  two  stage  
chromogenic  assay  performed  at  37oC  in  a  Hepes-­‐‑based  buffer  with  BSA  and  0.1%  PEG.    
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Aptamer  or  buffer  was  incubated  with  FXIIa  (final  concentration  4nM)  for  5  minutes  at  
37oC  and  reactions  were  initiated  with  the  addition  of  prekallikrein  (final  concentration  
20nM).    At  timed  intervals  after  the  initiation  of  the  reaction,  samples  of  the  reaction  
mixture  were  removed  and  FXIIa  activity  was  quenched  by  addition  of  1µμM  CTI.    
Kallikrein  activity  was  assayed  by  the  addition  of  0.25mM  Pefachrome  PK  (Centerchem,  
Inc.,  Norwalk,  CT),  and  the  rate  of  substrate  hydrolysis  was  recorded  at  405nM  using  a  
kinetic  microplate  spectrophotometer  at  37oC.    Kallikrein  cleavage  rates  of  substrate  
were  then  used  to  determine  the  amount  of  kallikrein  formed  by  extrapolating  from  a  
standard  curve  prepared  using  purified  kallikrein.  
  
2.3 Results 
 2.3.1 SELEX Pool Analysis and Lead Clone Selection 
High  affinity  aptamers  targeting  human  FXII  were  isolated  from  a  convergent  
selection  approach,  whereby  a  nucleic-­‐‑acid-­‐‑based  combinatorial  library  containing  
approximately  1014    RNA  species  was  first  enriched  for  binding  against  the  entire  human  
plasma  proteome,  and  then  further  enriched  for  binding  against  purified  FXII.    To  confer  
greater  stability  in  human  plasma,  the  library  contained  2’F  pyrimidines  (159).  Five  
rounds  of  complex  selection  were  performed  against  unfractionated  human  plasma  to  
obtain  a  focused  library  containing  aptamers  that  theoretically  bind  to  all  plasma  
components.    Using  this  focused  library,  four  rounds  of  selection  to  purified  FXII  
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yielded  further  enrichment  for  a  pool  of  aptamers  targeting  FXII  as  determined  by  a  
nitrocellulose  filter-­‐‑binding  assay  (Figure  8).  
  
  
Figure  8.  Binding  affinity  of  SELEX  rounds  against  purified  FXII  
Nitrocellulose  filter  binding  assay  of  the  plasma  proteome  enriched  starting  library  
(black  circles),  round  2  of  selection  against  purified  FXII  (black  squares),  and  round  4  of  
selection  against  purified  FXII  (red  diamonds).      Data  courtesy  of  Juliana  Layzer.  
  
  
The  selection  process  was  ended  by  cloning  and  sequencing  the  individual  RNA  
sequences  present  in  the  round  4  pool,  and  these  sequences  were  then  organized  into  
families  based  upon  their  primary  sequences  (Table  4).  
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Table  4.  RNA  aptamer  sequences  from  FXII  convergent  SELEX  
Clone  
ID  
Variable  Region  Sequence   Frequency  
R4cXII-­‐‑
12  
ACTCCGCCATGGACCATGCATCTTCACAGCTAACCCCGCA   26.1%  
R4cXII-­‐‑
15  
TCAAAACTCAACGAGCTCACAT-­‐‑CTAGCATTGACGGT   17.4%  
R4cXII-­‐‑
1  
CCAAATCTCGGCTGCCAGCAGGTCACGAGTCGCAAGATAA   13.0%  
R4cXII-­‐‑
7  
CCCTCCGCACAACCTCGGCTGCCAGCAGAACACGAGTTAC   13.0%  
R4cXII-­‐‑
8  
CATGAGCTGTCTTCTCGCGGCTGCCAGCAGGAATACGAGT   8.7%  
R4cXII-­‐‑
16  
TTCGATCCCCTCCGGCTACCAACAGAGTTTCCGAGTCTT   8.7%  
R4cXII-­‐‑
11  
TCGCTGACGAATAGACGTTCATCCAGGTGATCACATCTAG   4.3%  
R4cXII-­‐‑
21  
ACNCCGACACGAGATTACNNATTTAGTCACCACNAGAGTGTNGA   4.3%  
  
In  order  to  determine  the  binding  affinity  of  each  family  of  isolated  clones,  a  
nitrocellulose  filter-­‐‑binding  assay  was  performed  with  a  representative  clone  from  each  
family.  A  number  of  aptamers  bound  to  FXII  with  affinities  (measured  by  their  
dissociation  constants,  or  Kd’s)  in  the  low  nanomolar  range.    Binding  to  αFXIIa  was  also  
tested,  and  each  clone  bound  with  approximately  10-­‐‑fold  increased  affinity  to  the  
activated  form  (Table  5).    The  Bmax,  or  the  percentage  of  RNA  present  that  is  folded  
correctly  in  order  to  bind  to  the  target  protein,  was  also  determined  for  each  individual  
aptamer.    
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Table  5.  RNA  aptamer  binding  to  soluble  FXII  and  FXIIa  as  determined  by  a  
nitrocellulose  filter-­‐‑binding  assay    
   FXII   FXIIa  
Aptamer   Kd  approx  (nM)   Bmax  approx  (%)   Kd  approx  (nM)   Bmax  approx  (%)  
R4cXII-­‐‑1   8.9   75   0.31   58  
R4cXII-­‐‑7   2.8   53   0.22   28  
R4cXII-­‐‑8   17.9   47   0.52   20  
R4cXII-­‐‑11   20   58   0.24   24  
R4cXII-­‐‑12   9.3   47   0.13   46  
R4cXII-­‐‑15   463   46   0.08   4  
R4cXII-­‐‑16   29   44   0.25   21  
R4cXII-­‐‑21   5.9   45   0.05   8  
  
Although  several  clones  bound  with  high  affinity  to  FXII  and  FXIIa,  the  
nitrocellulose  filter-­‐‑binding  assay  does  not  examine  the  functionality  of  these  aptamers  
as  anticoagulants.  Therefore,  we  next  tested  each  aptamer  for  anticoagulant  activity  in  a  
common  clinical  coagulation  test,  the  activated  partial  thromboplastin  time  (aPTT).    This  
assay  measures  the  time  it  takes  for  a  fibrin  clot  to  occur  in  plasma,  and  is  sensitive  to  
deficiencies  or  inhibition  of  the  intrinsic  and  common  pathways  of  coagulation.    This  
assay  uses  a  negatively  charged  substance,  such  as  kaolin  or  ellagic  acid,  to  activate  FXII  
and  prime  the  cascade,  and,  upon  addition  of  Ca2+  to  initiate  clotting,  records  the  time  
for  a  fibrin  clot  to  form.    Because  initial  tests  using  normal  human  plasma  and  a  
micronized  silica  activator  did  not  show  any  affect  of  the  FXII  aptamers  over  control  
RNA  at  the  concentration  used  on  altering  the  clotting  time,  the  assay  was  performed  in  
99%  FXII  deficient  plasma  and  1%  normal  plasma,  affectively  lowering  the  amount  of  
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FXII  present  and  allowing  for  a  lower  concentration  of  aptamer  to  show  an  effect  (Figure  
9).      
  
Figure  9.  Screen  of  FXII  aptamers  in  a  functional  clotting  assay,  the  aPTT  
Selected  aptamers  (0.5µμM)  were  screened  for  prolongation  of  clotting  time  in  1%  
Normal/99%  FXII  deficient  human  plasma.  Aptamer  clotting  times  were  compared  
against  a  buffer  control  (WBF),  library  RNA  (Sel2),  100%  FXII  deficient  plasma  (XII-­‐‑/-­‐‑  +  
WBF)  and  100%  normal  human  plasma  (Normal  +  WBF).    The  dotted  line  represents  the  
clotting  time  of  library  RNA  and  serves  as  a  baseline  clotting  time  to  compare  to  
aptamer  clotting  time.  
  
The  clone  R4cXII-­‐‑1  was  chosen  as  the  lead  aptamer  due  to  its  greater  effect  in  the  
aPTT  assay,  as  well  as  its  superior  binding  profile  compared  to  all  other  aptamers.    
While  R4cXII-­‐‑1  did  not  necessarily  have  the  lowest  Kd,  it  did  have  the  highest  Bmax,  
meaning  a  larger  proportion  of  the  RNA  is  in  a  folded  state  that  is  able  to  bind  to  FXII  or  
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FXIIa  compared  to  the  other  aptamers.    This  is  reflected  in  the  functional  clotting  assay,  
where  R4cXII-­‐‑1  outperformed  all  other  aptamers.    
2.3.2 Lead aptamer binding affinity and specificity 
The  full  length,  80  nucleotide,  2’F  pyrimidine  modified  RNA  R4cXII-­‐‑1  was  
chosen  as  the  lead  aptamer  out  of  the  convergent  selection  against  FXII  (Figure  10).      
  
  
Figure  10.  The  M-­‐‑fold  predicted  secondary  structure  of  the  full-­‐‑length  aptamer  
R4cXII-­‐‑1  
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In  depth  binding  of  R4cXII-­‐‑1  was  analyzed  by  a  nitrocellulose  filter-­‐‑binding  
assay  and  the  aptamer  was  found  to  bind  to  both  the  zymogen  and  active  form  of  FXII.    
R4cXII-­‐‑1  bound  to  FXII  with  a  Kd  of  8.9  ±  1.0nM  and  a  Bmax  of  74.8  ±  4.7%and  to  αFXIIa  
with  a  Kd  of  0.5  ±  0.2nM  and  a  Bmax  of  58  ±  3.2%  to  αFXIIa  (Figure  11).  
  
Figure  11.    Aptamer  R4cXII-­‐‑1  binds  with  high  affinity  to  FXII  and  FXIIa    
Nitrocellulose  filter  binding  assays  of  aptamer  to  A)  FXII  (n)  and  FXIIa  (p)  and  B)  
indicated  proteins.    C)  Linear  sequence  and  dissociation  constants  of  full  length  R4cXII-­‐‑1  
and  truncated  R4cXII-­‐‑1  (R4cXII-­‐‑1t).  In  A,  the  data  represent  the  mean  ±  SEM  of  triplicate  
measures  and  in  B,  the  data  are  representative  of  at  least  two  independent  experiments.  
  
  
This  high  affinity  binding  of  R4cXII-­‐‑1  to  FXII  and  FXIIa  was  also  found  to  be  
specific,  as  R4cXII-­‐‑1  binding  to  a  number  of  other  structurally  and  functionally  related  
coagulation  factors,  including  thrombin,  FXIa,  FIXa,  FXa,  FVIIa,  urokinase  plasminogen  
activator,  and  tissue  plasminogen  activator,  was  shown  to  be  non-­‐‑existent  or  very  weak,  
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with  dissociation  constants  greater  than  1000nM  and  no  different  from  a  random  RNA  
library  (data  not  shown).    In  addition,  R4cXII-­‐‑1  exhibited  greatly  reduced  binding  to  β-­‐‑
fXIIa  (dissociation  constant  Kd  of  51.4  ±  9.0nM  and  a  Bmax  of  34.7  ±  2.3%),  a  cleaved  form  
of  FXIIa  which  is  missing  part  of  the  heavy  chain  (Figure  12).  
  
Figure  12.    Aptamer  R4cXII-­‐‑1  binds  with  reduced  affinity  to  β-­‐‑fXIIa  
Nitrocellulose  filter  binding  assay  of  aptamer  to  β-­‐‑fXIIa.  The  data  represent  the  mean  ±  
SEM  of  triplicate  measures.  
  
2.3.3 Biochemical Characterization of aptamer inhibition 
Assessment  of  aptamer  activity  on  FXII  active  site  function  
A  number  of  purified  protein  assays  were  performed  to  characterize  the  
mechanism  of  aptamer  binding  and  inhibition.    First,  we  studied  the  impact  of  aptamer  
binding  on  active  site  function  of  αFXIIa  by  monitoring  the  cleavage  of  a  small  peptide  
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chromogenic  substrate  in  the  presence  of  a  range  of  concentrations  of  aptamer,  size  
matched  scrambled  control  RNA,  and  a  known  FXIIa  active  site  inhibitor,  corn  trypsin  
inhibitor  (CTI).    While  CTI  potently  and  dose  dependently  inhibited  the  ability  of  FXIIa  
to  cleave  the  small  peptide  chromogenic  substrate,  both  the  control  RNA  and  R4cXII-­‐‑1  
did  not  affect  small-­‐‑substrate  cleavage  (Figure  13).    These  data  indicate  that  the  
anticoagulant  effect  of  the  aptamer  is  not  due  to  the  inhibition  of  the  active  site  on  FXIIa.    
Because  aptamers  tend  to  impede  protein-­‐‑protein  interactions  without  affecting  the  
active  site  (157),  the  ability  of  the  aptamer  to  inhibit  FXII/XIIa-­‐‑mediated  macromolecular  
interactions  was  next  evaluated.  
  
Figure  13.  Aptamer  R4cXII-­‐‑1  does  not  inhibit  FXIIa  cleavage  of  a  small  peptide  
substrate  
αFXIIa  (10nM)  was  incubated  with  varying  amounts  of  R4cXII-­‐‑1  (n),  size  matched  
scrambled  control  RNA  (p),  and  CTI  (q),  and  active  site  activity  was  measured  by  an  
αFXIIa-­‐‑specific  chromogenic  substrate.  The  data  were  normalized  to  the  rate  in  the  
absence  of  compound  and  represent  the  mean  ±  SEM  of  duplicate  measures.  
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Assessment  of  aptamer  activity  on  FXII  autoactivation  
Since  a  range  of  anionic  compounds,  including  unmodified  nucleic  acids  (27,  89),  
have  been  found  to  autoactivate  FXII,  aptamer  and  size  matched  scrambled  control  RNA  
were  tested  to  determine  if  relatively  short  2’F  pyrimidine  modified  RNAs  could  also  
autoactivate  FXII.    While  a  known  FXII  autoactivator,  dextran  sulfate,  was  able  to  
convert  FXII  to  FXIIa  with  the  characteristic  bell-­‐‑shaped  concentration  curve  of  a  
template-­‐‑related  mechanism  (195),  neither  the  control  RNA  nor  R4cXII-­‐‑1  could  
autoactivate  FXII  over  a  wide  range  of  concentrations  (Figure  14A).      
Next,  the  ability  of  R4cXII-­‐‑1  to  block  the  autoactivation  of  FXII  by  various  known  
activators  was  tested.    Dextran  sulfate,  as  well  as  purified  kaolin,  and  standardized  aPTT  
reagents  including  micronized  silica  (TriniClot  S)  and  ellagic  acid  (APTT-­‐‑XL)  were  all  
tested  and  found  to  activate  FXII  at  widely  different  rates  (data  not  shown).    The  final  
concentration  of  each  activator  that  yielded  an  optimal  rate  of  autoactivation  of  FXII  was  
used  for  further  studies.    R4cXII-­‐‑1  (1µμM)  was  able  to  greatly  inhibit  the  ability  of  dextran  
sulfate  (1µμg/mL)  and  micronized  silica  (30x)  to  autoactivate  FXII,  and  partially  inhibit  
the  ability  of  kaolin  (100µμg/mL)  and  ellagic  acid  (30x-­‐‑diluted)  to  autoactivate  FXII  
(Figure  14B).    In  contrast,  a  size  matched  scrambled  control  RNA  was  not  able  to  inhibit  
autoactivation  by  any  activator.    Autoactivation  assays  conducted  with  physiologic  
activators,  such  as  polyphosphates,  were  hampered  by  the  necessity  for  the  aptamer  
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buffer  to  contain  divalent  ions,  which  assist  in  proper  aptamer  folding  but  inhibit  the  
ability  of  these  physiologic  activators  to  measurably  autoactivate  FXII  with  a  cofactor  
present  (data  not  shown).  
  
Figure  14.  Aptamer  R4cXII-­‐‑1  does  not  induce  autoactivation  of  FXII  but  blocks  
the  activities  of  several  autoactivators  of  FXII  
A)  FXII  (200nM)  was  incubated  for  1  hour  with  varying  amounts  of  dextran  sulfate  (n),  
R4cXII-­‐‑1  (p),  or  size  matched  scrambled  control  RNA  (q),  and  assayed  for  the  amount  
of  FXIIa  formed  by  an  FXIIa-­‐‑specific  chromogenic  substrate.    The  data  represent  the  
mean  ±  SEM  of  triplicate  measures.    B)  FXII  (200nM)  was  incubated  for  5  min  with  
R4cXII-­‐‑1  (black  bars)  or  size  matched  scrambled  control  RNA  (grey  bars)  prior  to  the  
addition  of  autoactivators,  and  the  amount  of  FXIIa  formed  after  1  hour  was  assayed.  
The  data  were  normalized  to  the  rate  in  the  absence  of  any  RNA  and  represent  the  mean  
±  SEM  of  triplicate  measures.  
  
Assessment  of  aptamer  activity  on  FXIIa-­‐‑mediated  activation  of  biologic  substrates  
Once  activated,  FXIIa  can  subsequently  activate  FXI  to  propagate  the  intrinsic  
pathway  of  coagulation.  The  ability  of  R4cXII-­‐‑1  to  inhibit  FXIIa-­‐‑mediated  FXI  activation  
was  assessed  by  monitoring  the  amount  of  FXIa  formed  in  a  purified  system  containing  
FXIIa  as  an  activator  in  the  absence  of  aptamer,  or  in  the  presence  of  R4cXII-­‐‑1  or  control  
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RNA.  R4cXII-­‐‑1  reduced  the  initial  rate  of  FXI  activation  by  greater  than  ~90%,  while  the  
presence  of  size  matched  scrambled  control  RNA  did  not  (Figure  15A).    To  determine  
the  potency  of  inhibition,  the  initial  rate  of  FXI  activation  by  FXIIa  was  measured  in  the  
presence  of  varying  concentrations  of  R4cXII-­‐‑1.    As  shown  in  Figure  15B,  R4cXII-­‐‑1  
concentration-­‐‑dependently  decreased  the  amount  of  FXIa  formed.  An  apparent  
equilibrium  inhibition  constant  (Ki)  of  3.0nM  ±  0.3nM  was  obtained  by  plotting  the  
fractional  rates  of  FXI  activation  versus  the  concentration  of  R4cXII-­‐‑1  used  (Figure  15C).    
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Figure  15.  Aptamer  R4cXII-­‐‑1  dose  dependently  inhibits  FXIIa-­‐‑catalyzed  
activation  of  FXI  
FXI  (25nM)  was  activated  by  FXIIa  (5nM),  the  reaction  was  quenched  at  various  time-­‐‑
points  by  the  addition  of  1  µμM  CTI,  and  the  amount  of  FXIa  was  quantified  using  a  
chromogenic  substrate.  A)  The  amount  of  FXIa  formed  at  various  time  points  was  
determined  in  the  presence  of  1µμM  R4cXII-­‐‑1  (n),  1µμM  size  matched  scrambled  control  
aptamer  (q),  or  buffer  (p).    Lines  represent  linear  regression  fits  of  the  data.    The  data  
represent  the  mean  ±  SEM  of  triplicate  measures.  B)  Dose  dependent  response  on  FXIa  
generation  with  increasing  concentrations  of  R4cXII-­‐‑1.  The  amount  of  FXIa  formed  was  
determined  in  the  presence  of  R4cXII-­‐‑1  at  final  concentrations  of  0nM(p),  1nM  (n),  3nM  
(l),  6nM  (u),  10nM  (q),  20nM  (o),  and  50nM  (m).  Lines  represent  linear  regression  fits  
of  the  data.    The  data  are  representative  of  three  independent  measures.  C)  Fractional  
activity  of  R4cXII-­‐‑1  versus  the  ratio  of  R4cXII-­‐‑1  to  FXII  present  in  the  reaction.    
Fractional  activity  of  R4cXII-­‐‑1  was  calculated  by  dividing  the  initial  rate  of  FXI  activation  
in  the  presence  of  R4cXII-­‐‑1  by  the  initial  rate  of  FXI  activation  in  the  absence  of  aptamer.  
The  Ki  was  calculated  by  nonlinear  regression  analysis.  The  data  represent  the  mean  ±  
SEM  of  triplicate  measures.  
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Aside  from  activating  the  intrinsic  pathway  through  FXI  activation,  FXIIa  can  
also  activate  plasma  kallikrein  (PK),  which  in  turn  reciprocally  activates  more  FXII  in  a  
feedback  loop  that  amplifies  the  activation  of  the  contact  pathway  (23).    PK  is  involved  
in  the  initiation  of  the  kallikrein-­‐‑kinin  system  by  cleaving  the  small  peptide  bradykinin  
(BK)  from  high  molecular  weight  kininogen  (HK),  leading  to  activation  of  various  
inflammatory  processes,  including  vasodilation  and  vascular  permeability  (115).    The  
ability  of  R4cXII-­‐‑1  to  inhibit  prekallikrein  activation  by  FXIIa  was  examined  by  
monitoring  the  amount  of  kallikrein  formed  in  a  purified  system  using  FXIIa  as  an  
activator.    In  contrast  to  the  ability  of  R4cXII-­‐‑1  to  inhibit  the  generation  of  activated  FXI  
(Figure  15),  the  aptamer  did  not  affect  prekallikrein  activation  by  FXIIa  compared  to  
buffer  or  size  matched  scrambled  control  RNA  (Figure  16).    This  indicates  that  R4cXII-­‐‑1  
does  not  bind  to  FXIIa  in  a  manner  that  inhibits  FXIIa-­‐‑PK  interactions,  while  it  does  
inhibit  FXIIa-­‐‑FXI  interactions.  Collectively,  these  data  suggest  that  R4cXII-­‐‑1  is  a  potent  
inhibitor  of  both  the  autoactivation  of  FXII  and  FXIIa-­‐‑mediated  activation  of  FXI,  while  
having  no  effect  on  prekallikrein  activation.    
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Figure  16.  Aptamer  R4cXII-­‐‑1  does  not  inhibit  the  ability  of  FXII  to  activate  
prekallikrein  
Prekallikrein  (20nM)  was  activated  by  FXIIa  (4nM),  the  reaction  was  quenched  at  
various  time  points  by  the  addition  of  1µμM  CTI,  and  the  amount  of  kallikrein  was  
quantified  using  a  chromogenic  substrate.  The  amount  of  kallikrein  formed  was  
determined  in  the  presence  of  1µμM  R4cXII-­‐‑1  (q),  1µμM  size  matched  scrambled  control  
aptamer  (p),  or  buffer  (n).    Lines  represent  linear  regression  fits  of  the  data.    The  data  
represent  the  mean  ±  SEM  of  triplicate  measures.  
  
2.3.4 Truncation of aptamer 
In  order  to  facilitate  optimal  transcription  yields  and  reduce  background  noise  
due  to  RNA  length,  R4cXII-­‐‑1  was  truncated  by  systematic  nucleotide  deletion.    Three  to  
five  constructs  were  tested  at  a  time,  with  deletions  beginning  on  each  end  of  the  
aptamer,  and  then  internally  to  shorten  stems  and  loops  as  much  as  possible  without  
losing  binding  affinity  or  functionality.    Table  6  depicts  the  truncation  strategy,  where  
each  possible  truncate  was  tested  for  binding  affinity  and  functionality.        
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Table  6.  Truncation  strategy  for  R4cXII-­‐‑1  
Kd’s  and  Bmax’s  were  determined  using  a  nitrocellulose  filter-­‐‑binding  assay.    FXIa  
generation  inhibition  was  determined  using  a  chromogenic  assay.  
Aptamer  
Name  






R4cXII-­‐‑1   80   4.0   85   Yes  
T1   67   8.9   86   Yes  
T2   58   109.5   106   Yes  
T4   60   5.5   55   Yes  
T6   63   9.9   57   Yes  
T7   65   120   84   No  
T8   60   308   67   No  
T9   50   203   70   No  
T10   59   38.5   88   Yes  
T11   59   60.2   98   Yes  
T12   57   4.2   74   Yes  
T13   56   28.2   80   Yes  
T14   52   5.8   73   Yes  
T15   55   277   113   No  
T16   55   289   106   No  
T17   55   350   123   No  
T18   51   50   65   Yes  
T19   54   279   104   Yes  
T20   50   20.5   72   Yes  
T21   48   116   88   No  
T22   51   13.2   80   Yes  
T23   51   71   101   No  
  
When  a  truncation  lost  binding  (generally  a  Kd  of  over  100nM)  and/or  
functionality,  those  deleted  portions/nucleotides  were  considered  to  be  essential  in  
either  facilitating  the  proper  folding  and  final  structure  of  the  aptamer  or  directly  
involved  in  binding  to  the  target  protein.    The  most  optimal  truncation  that  retained  
binding  affinity  to  both  FXII  (apparent  Kd  of  12.9  ±  2.06nM)  and  FXIIa  (apparent  Kd  of  0.4  
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±  0.02  nM),  as  well  as  the  ability  to  block  FXIIa-­‐‑mediated  FXIa  generation,  was  the  51-­‐‑
nucleotide  truncate  22  (R4cXII-­‐‑1T22).    The  predicted  secondary  structure  of  the  aptamer  
features  an  “L”  shaped  aptamer,  with  several  bulge  regions  and  two  lengthy  stems  
(Figure  17).  
  
Figure  17.  The  M-­‐‑fold  predicted  secondary  structure  of  the  truncated  aptamer  
R4cXII-­‐‑1T22  
  
For  ongoing  functional  studies,  a  51  nucleotide  scrambled  RNA  that  had  no  
binding  or  functional  activity  against  FXII  was  also  employed  as  an  aptamer  control.  
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2.3.5 Functional Characterization of aptamer inhibition 
   Biochemical  characterization  of  R4cXII-­‐‑1  suggests  that  the  aptamer  acts  as  an  
anticoagulant  by  specifically  inhibiting  FXII  activation  and  FXIIa-­‐‑mediated  FXI  
activation.    However,  the  functionality  of  this  aptamer  as  an  anticoagulant  in  a  plasma  
setting  is  not  certain,  as  several  redundant  pathways,  including  a  feedback  loop  
whereby  thrombin  can  directly  activate  FXI,  can  contribute  to  thrombin  activation  with  
minimal  or  no  FXII  involvement.    
We  next  tested  aptamer  R4cXII-­‐‑1  for  anticoagulant  activity  in  two  common  
coagulation  tests,  the  activated  partial  thromboplastin  time  (aPTT)  and  the  thrombin  
generation  assay  (TGA).  The  aPTT  assay  uses  a  negatively  charged  substance,  such  as  
kaolin  or  ellagic  acid,  to  strongly  activate  FXII  and  thus  initiate  clotting  through  the  
intrinsic  pathway.    Therefore,  this  test  is  highly  sensitive  to  deficiencies  or  inhibition  of  
the  intrinsic  pathway  of  coagulation.  A  51-­‐‑nucleotide  truncated  version  of  R4cXII-­‐‑1  
(R4cXII-­‐‑1t)  that  retained  binding  affinity  to  both  FXII  (apparent  Kd  of  12.9  ±  2.06nM)  and  
FXIIa  (apparent  Kd  of  0.4  ±  0.02  nM)  dose  dependently  anticoagulated  human  plasma  in  
an  aPTT  activated  with  ellagic  acid.    This  inhibition  was  specific  to  the  intrinsic  
pathway,  as  the  aptamer  had  no  effect  on  PT,  which  measures  the  function  of  the  
extrinsic  pathway  of  coagulation  (Figure  18).    A  size  matched  scrambled  control  RNA  
that  does  not  retain  binding  to  FXII/FXIIa  had  minimal  impact  on  clotting  time  (Figure  
18).  R4cXII-­‐‑1t  also  dose-­‐‑dependently  increased  clotting  time  when  a  micronized  silica  
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based  reagent  was  utilized,  indicating  that  inhibition  of  the  intrinsic  pathway  of  




Figure  18.  Aptamer  R4cXII-­‐‑1t  dose  dependently  anticoagulates  human  plasma  
in  an  aPTT,  but  not  a  PT  clotting  assay  
Effect  of  the  51-­‐‑nucleotide  R4cXII-­‐‑1t  (n)  and  size  matched  scrambled  mutant  control  (p)  
in  an  aPTT  clotting  assay  activated  with  ellagic  acid,  and  R4cXII-­‐‑1t  (q)  in  a  PT  clotting  
assay  activated  with  tissue  factor.    The  data  were  normalized  to  the  baseline  clot  time  
without  aptamer  present  and  represent  the  mean  ±  SEM  of  duplicate  measures.  
  
In  addition,  this  prolongation  was  specific  to  FXII/FXIIa  inhibition,  as  the  
aptamer  dose-­‐‑dependently  prolonged  FXIIa  clotting  times,  with  no  effect  on  the  FXIa  
clotting  time  (Figure  19).  
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Figure  19.  Aptamer  R4cXII-­‐‑1t  dose  dependently  inhibits  FXIIa  clotting  times,  
but  not  FXIa  clotting  times  
Effect  of  the  51-­‐‑nucleotide  R4cXII-­‐‑1t  in  a  clotting  assay  activated  with  250nM  FXIIa  (n)  
or  40nM  FXIa  (p).    The  data  were  normalized  to  the  baseline  clotting  time  of  a  size-­‐‑
matched  control  RNA  and  represent  the  mean  ±  SEM  of  duplicate  measures.  
  
The  TGA  is  a  coagulation  assay  that  measures  the  amount  of  thrombin  generated  
in  human  plasma  in  real-­‐‑time  by  monitoring  cleavage  of  a  thrombin-­‐‑specific  fluorogenic  
substrate  (196).    Using  a  TGA  allows  for  several  more  parameters  to  be  analyzed  in  
addition  to  the  lag  time  (the  time  when  thrombin  begins  to  appear),  including  the  peak  
(maximal  amount  of  thrombin  formed),  the  endogenous  thrombin  potential  (ETP,  the  
total  amount  of  thrombin  formed),  and  the  rate  of  thrombin  generation  (the  slope  of  the  
line  from  no  thrombin  generation  to  peak  thrombin  generation).    While  a  standard  TGA  
is  initiated  using  various  concentrations  of  TF  to  activate  the  extrinsic  pathway,  an  assay  
using  ellagic  acid  as  an  activator  was  developed  with  our  colleagues  at  Merck  Research  
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Labs  to  study  effects  on  thrombin  generation  during  inhibition  of  the  intrinsic  pathway.  
Similar  to  its  activity  in  an  aPTT,  R4cXII-­‐‑1t  dose-­‐‑dependently  increased  the  lag  time,  as  
well  as  decreased  peak  thrombin  generation,  ETP,  and  the  rate  of  thrombin  generation  
in  a  TGA  initiated  with  ellagic  acid  (Figure  20).      Overall  thrombin  generation  was  
decreased  to  background  levels,  with  a  clear  saturation  point  of  aptamer  inhibition  
(3.75µμM),  while  the  peak  amount  of  thrombin  generated  and  the  rate  of  thrombin  
generation  were  robustly  inhibited.      In  contrast,  a  size  matched  scrambled  control  RNA  
did  not  inhibit  thrombin  generation  (Figure  20).    These  data  suggest  that  R4cXII-­‐‑1  acts  as  
an  anticoagulant  by  specifically  inhibiting  FXII  function  to  effectively  shut  down  
intrinsic  pathway  activation  and  thus  impair  thrombin  generation  triggered  by  ellagic  
acid.      
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Figure  20.  Aptamer  R4cXII-­‐‑1t  dose  dependently  impairs  thrombin  generation  in  a  
TGA  assay  initiated  with  ellagic  acid  
Thrombograms  of  normal  pooled  plasma  activated  with  200x-­‐‑diluted  ellagic  acid  with  
various  concentrations  of  A)  R4cXII-­‐‑1t  and  B)  a  size  matched  scrambled  RNA.  C)  Lag  
time,  D)  Peak  thrombin  generation,  E)  Endogenous  thrombin  potential,  and  F)  Rate  of  
thrombin  generation  of  R4cXII-­‐‑1t  (n)  and  a  size  matched  scrambled  RNA  (p).      Data  are  
representative  of  three  independent  experiments.  
  
   While  the  FXII  aptamer  was  isolated  solely  against  the  human  form  of  the  
coagulation  factor,  analysis  for  cross  reactivity  in  animal  plasma  is  a  must  before  
proceeding  into  in  vivo  models  of  thrombosis.    In  general,  aptamers  have  exhibited  some  
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efficacy  in  a  variety  of  species;  with  the  FIX  aptamer  cross-­‐‑reacting  in  every  species  
tested  except  for  rabbit  (data  not  shown).    However,  other  aptamers  exhibit  limited  
cross-­‐‑reactivity.    R4cXII-­‐‑1  was  tested  in  a  number  of  animal  plasmas  in  an  aPTT  assay,  as  
well  as  with  different  activating  reagents.    Activation  with  ellagic  acid  gave  the  most  
reproducible  data,  with  less  background  control  aptamer  activity.    Aside  from  human  
plasma,  R4cXII-­‐‑1t  did  not  exhibit  robust  anticoagulation  above  control  aptamer  in  any  of  
the  plasma’s  tested  at  a  fixed  concentration  (Figure  21).    However,  there  was  slight  
anticoagulant  activity  over  control  aptamer  in  canine,  bovine,  rat,  rabbit,  and  baboon.    
Importantly,  the  plasma  samples  used  here  were  not  treated  with  CTI,  thus  contact  
activation  of  the  plasma  sample  may  already  be  present.    
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Figure  21.    Analysis  of  R4cXII-­‐‑1t  cross-­‐‑reactivity  utilizing  the  aPTT  across  
select  animal  species  
Effect  of  buffer,  R4cXII-­‐‑1t,  a  point  mutant,  and  a  size  matched  scrambled  mutant  control  
in  an  aPTT  clotting  assay  activated  with  ellagic  acid.    None  of  the  plasmas  were  treated  
with  CTI  to  inhibit  contact  activation  during  the  blood  drawing  process.  The  data  
represent  the  mean  ±  SEM  of  duplicate  measures.  
2.4 Discussion 
Herein,  we  describe  the  isolation  and  characterization  of  a  novel  FXII/FXIIa  
inhibitor  (Figure  22).    A  nuclease  resistant,  2’F  pyrimidine  modified  RNA  aptamer  was  
isolated  using  in  vitro  iterative  selection  methods.    This  aptamer  binds  with  high  affinity  
to  both  FXII  and  FXIIa  and  is  a  potent  anticoagulant  in  common  clinical  coagulation  
assays.  Although  the  aptamer  does  not  inhibit  the  active  site  of  FXIIa,  it  functions  as  an  
anticoagulant  by  both  inhibiting  the  autoactivation  of  FXII  and  inhibiting  FXIIa-­‐‑
mediated  activation  of  FXI.  Additionally,  the  aptamer  does  not  impede  the  ability  of  
FXIIa  to  activate  PK.    
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Figure  22.    A  schematic  depicting  the  role  of  the  FXII  aptamer,  R4cXII-­‐‑1,  in  
inhibiting  FXII/FXIIa  function  
The  aptamer  R4cXII-­‐‑1  inhibits  FXII  autoactivation  by  negatively  charged  surfaces  as  well  
as  FXIIa-­‐‑mediated  FXI  activation  to  effectively  shut  down  thrombin  generation  in  a  
plasma  setting.    However,  the  aptamer  does  not  affect  the  ability  of  FXIIa  to  activate  the  
inflammatory  mediator  prekallikrein.    Predicted  secondary  structure  of  aptamer  
adapted  from  M-­‐‑fold.  
  
Taken  together,  the  data  indicate  that  the  aptamer  binds  to  a  region  on  FXII/FXIIa  
implicated  in  anionic  and  FXI  binding,  which  is  spatially  separate  from  where  PK  binds  
to  FXII.    Although  a  crystal  structure  of  FXII  is  not  available,  domain  mapping  has  
suggested  a  closely  located  binding  site  for  FXI  and  anionic  surfaces  in  the  N-­‐‑terminus  
fibronectin  type  II  domain  (197-­‐‑199).  Studies  on  thrombin  aptamers  have  determined  
that  an  aptamer  binds  by  presenting  an  extended  surface  complementary  to  the  protein  
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binding  site  (157)  and  subsequently  sterically  interferes  with  macromolecular  
interactions  formed  between  the  aptamer  binding  region  and  large  protein  substrates.    
While  aptamer  binding  can  thus  disrupt  a  specific  exosite’s  function,  it  can  still  allow  
other  distant  exosites  and  active  sites  to  function  (181).    Interestingly,  other  putative  
binding  sites  on  FXII  for  anionic  molecules  exist  in  separate  domains  (200).    As  distinct  
anionic  compounds  bind  discretely  to  FXII  and  autoactivate  FXII  at  different  rates,  this  
binding  to  different,  and  possibly  partially  overlapping,  domains  could  explain  why  the  
aptamer  was  not  able  to  inhibit  the  autoactivation  of  FXII  by  various  autoactivators  to  
the  same  degree.  Continued  studies  into  aptamer  binding  and  function  using  FXII  
mutant  proteins  could  help  to  further  delineate  the  regions  involved  in  macromolecular  
substrate  interaction  (197),  especially  the  differential  binding  of  anionic  molecules  to  
FXII.  
The  ability  to  inhibit  the  intrinsic  pathway  of  coagulation  while  leaving  the  
kallikrein-­‐‑kinin  system  intact  will  be  beneficial  in  parsing  out  the  importance  of  FXIIa  
functions  in  vivo.    While  all  members  of  the  contact  pathway  (FXII,  FXI,  PK,  HK,  BK)  
have  been  implicated  in  thrombosis  through  studying  various  knockdown  or  knockout  
animal  models,  it  is  not  entirely  clear  which  FXIIa-­‐‑mediated  process,  inflammation  or  
coagulation,  plays  the  primary  part  in  contributing  to  thrombosis  (40,  41,  72,  91,  94,  95,  
201).  Targeted  inhibition  or  animal  knockout  models  have  suggested  that  FXIIa-­‐‑
mediated  FXI  activation  is  responsible  for  thrombotic  protection  in  injury  models  due  to  
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the  similar  thrombotic  protection  profiles  of  FXI  and  FXII  deficient  animals  (40,  78,  201).    
Currently,  studies  using  FXIIa  inhibitors  to  assess  thrombosis  have  employed  active  site  
inhibitors,  which  thus  inhibit  all  amidolytic  functions  of  FXIIa,  including  PK  activation  
(41,  202).      Utilizing  a  specific  inhibitor  of  the  intrinsic  pathway,  while  leaving  the  
kallikrein-­‐‑kinin  system  intact,  would  be  valuable  in  parsing  out  the  various  functions  of  
FXIIa  in  thrombosis.    
The  development  of  a  TGA  assay  triggered  by  contact  activation  is  instrumental  
for  studying  the  functions  of  contact  pathway  and  intrinsic  cascade  proteins  in  plasma  
thrombin  generation.  While  autoactivation  of  FXII  serves  as  the  mechanism  to  initiate  
the  aPTT,  and  is  oftentimes  the  diagnostic  test  used  to  detect  FXII  deficiencies  in  the  
clinic  during  routine  preoperative  screening,  the  TGA  is  commonly  triggered  by  the  
extrinsic  pathway  activator  TF,  and  is  thus  not  sensitive  to  deficiencies  or  inhibitors  of  
FXII  (203).  Both  the  aPTT  and  TGA  assays  showed  a  dose-­‐‑dependent  increase  in  the  time  
it  takes  for  thrombin  or  a  clot  to  form  with  aptamer  R4cXII-­‐‑1  present.    However,  the  
TGA  also  showed  the  ability  of  the  aptamer  to  decrease  the  total  amount  of  thrombin  
formed,  the  peak  amount  of  thrombin  generation,  and  the  overall  rate  of  thrombin  
generation.    Importantly,  the  rate  of  thrombin  generation  has  previously  been  shown  to  
be  a  key  contributor  in  influencing  clot  stability,  with  a  slower  rate  of  thrombin  
generation  associated  with  less  stable  clots  (64,  204).    The  finding  that  FXII  inhibition  
decidedly  decreases  the  rate  of  thrombin  generation  in  this  assay  is  consistent  with  
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observations  that  FXII  inhibition  or  deficiency  is  antithrombotic,  potentially  due  to  
formation  of  unstable  clots  that  can  easily  break  up  in  thrombosis  models  under  flow(39,  
41).    
In  addition  to  its  role  in  thrombosis,  activation  of  the  contact  pathway  through  
FXII  occurs  upon  exposure  to  foreign  substances,  such  as  on  the  surface  of  a  catheter  in  
invasive  surgery  or  even  during  the  process  of  drawing  blood  into  a  collection  tube  (205,  
206).    In  these  situations,  the  irreversible  FXIIa  inhibitor  CTI  has  been  effective  in  
inhibiting  contact  activation  (207);  however,  inhibition  of  the  autoactivation  of  FXII  
might  result  in  a  better  antithrombotic  profile.    In  addition,  the  ability  to  fully  reverse  
aptamer  activity  by  addition  of  a  matched  oligonucleotide  antidote  (164)  or  a  universal  
antidote  (165)  may  be  beneficial  in  these  and  other  settings,  especially  for  allowing  
further  studies  into  the  contact  pathway  after  drawing  blood.  
Through  in  vitro  and  animal  studies,  FXII  has  been  well  established  as  an  
important  mediator  of  thrombotic  effects  while  not  affecting  normal  hemostatic  
function.    In  thrombosis,  it  is  hypothesized  that  aggregated  proteins,  activated  platelets,  
and  polyphosphate,  among  other  compounds  present  at  a  developing  thrombus,  can  
contribute  to  the  continued  activation  of  FXII  and  the  intrinsic  pathway,  leading  to  
excessive  thrombin  generation  to  exacerbate  the  growth  of  the  thrombus  (101).    
Inhibition  of  the  autoactivation  of  FXII,  as  well  as  a  significant  decrease  in  the  rate  of  
thrombin  generated  at  the  site  of  a  growing  thrombus  through  targeted  inhibition  of  the  
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intrinsic  pathway  of  coagulation,  could  be  a  viable  antithrombotic  strategy  in  a  number  
of  clinical  settings.    While  clinical  studies  have  not  always  mirrored  the  results  seen  in  
FXII  deficient  animal  models,  further  analysis  into  the  utility  of  targeted  inhibition  of  the  
intrinsic  pathway  of  coagulation  is  warranted.  Currently,  an  aptamer  generated  against  
FIXa  and  its  matched  oligonucleotide  antidote  is  making  their  way  through  clinical  
development  (163,  164).  We  anxiously  await  the  clinical  evaluation  of  other  aptamers  
targeting  upstream  coagulation  factors,  such  as  FXII,  that  may  not  require  antidotes  to  
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3. Characterization of an anticoagulant aptamer 
targeting FXI 
3.1 Introduction 
There  is  a  large  unmet  need  for  antithrombotics  that  are  efficacious  enough  to  
treat  both  arterial  and  venous  thrombotic  disorders  while  safe  enough  to  not  induce  
severe  bleeding.    While  currently  approved  antithrombotics  target  mainly  the  common  
pathway  of  coagulation,  whose  action  is  imperative  for  hemostasis  to  occur,  human  and  
animal  data  have  suggested  that  inhibition  of  the  upstream  intrinsic  pathway  proteins,  
FXI  and  FXII,  have  a  role  in  pathological  thrombus  formation  but  not  hemostasis.    This  is  
supported  by  the  fact  that  humans  deficient  in  FXII  and  FXI  have  either  no  bleeding  
phenotype  or  a  mild  bleeding  phenotype,  respectively.    In  addition,  genetic  mouse  
knockouts  of  FXII  and  FXI  do  not  exhibit  prolonged  bleeding  times,  but  these  mice  are  
protected  in  several  models  of  thromboembolism  (40,  41,  72,  91).    Because  FXII  also  has  
an  initiating  role  not  only  in  coagulation,  but  also  in  the  inflammatory  kallikrein-­‐‑kinin  
system,  FXI  might  be  a  safer  target  to  managing  thrombosis  without  a  risk  of  undesired  
side  effects.        
Human  FXI  is  a  160-­‐‑kDa  serine  protease  glycoprotein  that  circulates  as  a  
disulfide  linked  dimer  of  two  identical  subunits.    Each  subunit  consists  of  a  35-­‐‑kDa  C-­‐‑
terminal  light  chain  containing  the  catalytic  domain,  and  an  N-­‐‑terminal  45-­‐‑kDa  heavy  
chain  with  four  ~90  amino  acid  tandem  repeats  termed  apple  domains  (82).    The  four  
apple  domains  confer  binding  to  other  proteins:  A1  contains  binding  sites  to  thrombin  
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(208),  A2  to  HK  (209),  A3  to  FIX  (51),  the  platelet  receptor  GP1bα  (52),  and  heparin  (210),  
and  A4  to  FXIIa  (211).    Dimerization  occurs  at  the  interface  between  the  two  A4  domains  
(54).    The  four  apple  domains  form  a  disk-­‐‑like  structure  that  supports  the  catalytic  
domain  (54).    In  plasma,  FXI  can  be  activated  by  XIIa  (49),  thrombin  and  thrombin  
intermediates  (88,  212),  as  well  as  autoactivated  by  FXIa  (88).    Platelet  polyphosphates  
can  potently  accelerate  the  activation  of  FXI  by  thrombin,  thrombin  intermediates,  and  
FXIa,  and  are  thus  thought  to  amplify  thrombin  generation  in  a  FXI-­‐‑mediated  fashion  
after  extrinsic  pathway  activation  in  the  hemostatic  process  (111,  203).  In  contrast,  FXII-­‐‑
mediated  FXI  activation  is  not  thought  to  be  relevant  for  hemostasis,  but  can  enhance  
thrombin  generation  at  the  site  of  a  thrombus,  thus  contributing  to  pathological  
thrombosis  (96).  
All  activators  of  FXI  cleave  the  zymogen  at  the  same  activation  loop  site  in  the  
catalytic  domain.    Activation  proceeds  through  an  intermediate  structure,  1/2FXIa,  with  
one  activated  subunit,  and  is  thought  to  possibly  be  the  primary  form  of  activated  FXIa  
in  plasma  (56).    Dimerization  seems  to  be  required  for  FXI  activation,  as  it  is  thought  that  
the  proteases  bind  to  one  subunit  while  activating  the  other  (60).    In  addition,  
dimerization  might  be  important  in  tethering  FXI  to  the  site  of  injury,  as  the  zymogen  
subunit  can  bind  to  the  platelet  receptor  GP1bα,  and  leave  the  active  subunit  free  to  bind  
to  and  activate  FIX.    Zymogen  FXI  binds  to  platelets  better  than  FXIa,  with  
approximately  1500  binding  sites  per  platelet  (61).    Whereas  optimal  binding  requires  
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HK,  zinc  ions,  residues  in  the  apple  3  domain  of  FXI,  and  the  N-­‐‑terminal  domain  of  
GP1bα,  recent  data  has  suggested  that  FXI  binds  to  the  platelet  receptor  ApoER2,  which  
colocalizes  with  GP1bα  (55).    FXIa  also  binds  to  platelets,  but  with  a  much  lower  
frequency  of  250  binding  sites  per  platelet  (62).    FXI  and  FXIa  bind  to  platelets  through  a  
separate  binding  site  and  mechanism,  as  FXIa  binding  to  platelets  seemingly  requires  
the  catalytic  domain,  but  not  the  apple  3  domain  as  does  FXI  (55).    
FXI  deficiency  was  first  described  as  hemophilia  C  in  1953,  and  is  a  rare  bleeding  
disorder  that  affects  approximately  one  in  10,000  people  worldwide,  but  is  more  
common  in  distinct  populations,  such  as  Ashkenazi  Jews  (65).    While  hemophilia  C  does  
not  normally  result  in  spontaneous  bleeding,  it  is  a  mild  to  moderate  bleeding  disorder  
with  increased  bleeding  tendencies  in  tissues  with  high  fibrinolytic  activity.  Historically,  
it  has  been  difficult  to  predict  bleeding  tendency  in  FXI  deficient  patients  as  there  has  
been  a  poor  correlation  between  bleeding  phenotype  and  plasma  FXI  levels.    For  
example,  some  patients  with  severely  low  levels  of  FXI  will  not  bleed  after  surgery,  
while  patients  with  normal  levels  of  FXI  do  bleed,  suggesting  that  bleeding  risk  may  be  
modified  by  the  levels  of  other  coagulation  factors  (213).      With  over  190  reported  
mutations  in  the  F11  gene  (www.factorxi.com),  there  are  two  main  types  of  mutation:  
CRM-­‐‑  (Type  I)  are  mutations  causing  low  FXI  plasma  levels  while  CRM+  (Type  II)  are  
mostly  functional  mutations  correlating  with  normal  FXI  levels  but  reduced  coagulant  
activity.  Treatment  is  usually  not  necessary  for  patients  undergoing  mild  procedures,  
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but  antifibrinolytic  agents,  as  well  as  fresh  frozen  plasma  or  human  FXI  concentrate  is  
effective  in  reducing  bleeding  events.    
While  the  function  of  FXI  in  hemostasis  may  depend  on  the  setting,  the  potential  
uncoupling  of  FXI’s  role  in  thrombosis  and  hemostasis  is  supported  by  observations  
from  thrombosis  models  in  FXI-­‐‑  deficient  mice.    Several  studies  using  a  ferric  chloride  
model  of  arterial  injury  demonstrated  that  FXI  deficiency  protected  mice  from  thrombus  
occlusion  at  a  level  comparable  to  FIX  deficiency  or  high  concentrations  of  
unfractionated  heparin  (40,  72,  73).  Attenuation  of  thrombus  development  was  also  
observed  following  arterial  injury  from  mechanical  damage  to  the  vessel  or  ligation  (40).    
This  protection  was  not  limited  to  arterial  thrombosis  models,  as  FXI  deficiency  also  
conferred  a  thromboprotective  effect  in  a  transient  middle  cerebral  artery  stroke  model  
(tMCAO),  with  a  lower  volume  of  infarcted  brain  tissue  and  less  fibrin  deposition  in  
distal  microvessels  compared  to  wild  type  mice  without  any  detectable  hemorrhage  (41).    
The  potential  antithrombotic  effect  of  FXI  depletion  or  inhibition  has  also  been  observed  
in  species  other  than  mice.    Antibody-­‐‑mediated  FXI  inhibition  in  rabbits  increased  clot  
lysis  in  jugular  veins  and  reduced  thrombus  propagation  on  injured  neointima  of  the  
iliac  artery  (74,  75),  while  infusion  of  FXI  antibodies  in  baboons  prevented  growth  of  
occlusive  thrombi  in  arterio-­‐‑venous  shunt  and  vascular  graft  occlusion  models  (76,  77).    
Administration  of  a  FXI  specific  antisense  oligonucleotide  in  mice  reduced  levels  of  FXI  
while  conferring  an  antithrombotic  effect  similar  to  warfarin  without  abnormal  bleeding  
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times  (78).    The  same  technology  has  been  applied  to  non-­‐‑human  primates,  as  antisense  
mediated  depletion  of  FXI  in  cynomolgus  moneys  results  in  a  prolongation  of  clotting  
times  (214).    Overall,  the  in  vivo  evidence  strongly  suggests  that  FXI  contributes  to  fibrin  
formation  and  platelet  activation,  stabilizing  occlusive  thrombi  under  high  flow  
conditions.    This  differs  from  its  participation  in  hemostasis,  where  FXI-­‐‑driven  fibrin  
formation  is  not  needed  to  prevent  blood  loss  following  vascular  injury  in  most  tissues  
(215).  The  effect  appears  to  be  mediated  primarily  through  FXII’s  activation  of  FXI  and  
not  via  thrombin  activation,  as  FXII  deficiency  shows  similar  protective  effects  in  
thrombosis  models.  
A  number  of  anticoagulant  aptamers  have  been  isolated  targeting  various  
proteases  of  the  coagulation  cascade.    Aptamers  are  short,  single-­‐‑stranded  
oligonucleotides  that  bind  over  large  surface  areas  on  the  target  protein  and  tend  to  act  
as  anticoagulant  by  blocking  specific  macromolecular  interactions.    Herein,  we  describe  
the  isolation  and  characterization  of  aptamers  targeting  FXI.    These  aptamers  can  
partially  inhibit  FXIa  active  site  cleavage,  as  well  as  greatly  reduce  the  ability  of  FXIa  to  
activate  FIX.    In  addition,  one  of  these  aptamers  acts  as  an  anticoagulant  to  decrease  
thrombin  generation  in  a  modified  thrombin  generation  assay  activated  through  the  
intrinsic  pathway.    
3.2 Materials and Methods 
Materials  
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The  SELEX  DNA  template  sequence  was  5′-­‐‑TCGGGCGAGTCGTCTG-­‐‑N40-­‐‑
CCGCATCGTCCTCCCTA-­‐‑3′  and  was  purchased  from  Oligos,  etc.  (Wilsonville,  OR).    
The  5’  and  3’  SELEX  primer  sequence  are  5′-­‐‑
GGGGGAATTCTAATACGACTCACTATAGGGAGGACGATGCGG-­‐‑3′  and  5′-­‐‑
TCGGGCGAGTCGTCTG-­‐‑3′,  respectively,  and  were  purchased  from  Integrated  DNA  
Technologies  (IDT,  Coralville,  IA).    The  2’Flouro  modified  cytidine  and  uridine  were  
purchased  from  Trilink  BioTechnology    (San  Diego,  CA).    FXIIa  and  prekallikrein  were  
purchased  from  Enzyme  Research  Laboratories  (South  Bend,  IN).    FXI,  FXIa,  and  all  
other  coagulation  proteins  were  purchased  from  Haematologic  Technologies  (Essex  
Junction,  VT).    Human  normal  pooled  plasma  was  purchased  from  George  King  
Biomedical,  Inc.  (Overland  Park,  Kansas).  AMV-­‐‑RT  enzyme  was  purchased  from  Roche  
Applied  Science  (Indianapolis,  IN).    Bovine  serum  albumin  (BSA)  was  purchased  from  
EMD  Chemicals  (Gibbstown,  NJ),  ethylene  glycol  was  purchased  from  Sigma-­‐‑Aldrich  
(St.  Louis,  MO)  and  lima  bean  trypsin  inhibitor  was  purchased  from  USB  Corporation  
(Cleveland,  OH).    The  Ellagic  Acid-­‐‑based  Pacific  Hemostasis  APTT-­‐‑XL  Reagent  was  
purchased  from  Thermo  Scientific  (Waltham,  MA),  and  micronized  silica-­‐‑based  
TriniCLOT  aPTT  S  was  purchased  from  Trinity  BioTech  (Bray,  Co  Wicklow,  Ireland).    
All  kinetic  assays  were  performed  in  96-­‐‑well  flat  bottom  microtiter  plates  (Corning  
Incorporated,  Corning,  NY),  the  absorbance  was  read  at  405nm  on  a  Power  Wave  XS2  
kinetic  microplate  spectrophotometer  (Biotek,  Winooski,  VT),  and  the  data  were  
     128  
analyzed  using  the  Graphpad  Prism  Software  (GraphPad  Prism,  GraphPad  Software,  
Inc.,  San  Diego,  CA).  
  
SELEX  
Solution  based  SELEX  was  performed  as  previously  described  (164).    The  
sequence  of  the  starting  RNA  library  was  5'ʹ-­‐‑  
GGGAGGACGAUGCGG-­‐‑N40-­‐‑CAGACGACUCGCCCGA-­‐‑3'ʹ,  where  N40  is  a  40  
nucleotide  randomized  region,  and  C  and  U  represent  2’F  modified  ribonucleotides,  
respectively.  A  modified  RNA  library  was  transcribed  in  vitro  using  a  modified  
polymerase  that  can  incorporate  2’F  cytidine  triphosphates  and  2’F  uridine  
triphosphates  (194).    Selection  rounds  were  performed  by  incubating  the  modified  
starting  library  with  FXIa  and  passing  the  mixture  through  a  25-­‐‑mm  0.45µμm  
nitrocellulose  filter  membrane  (Protran  BA  85,  Whatman,  Inc.,  Piscataway,  NJ)  to  
separate  the  bound  RNA  from  the  unbound  RNA.    The  bound  RNA  was  extracted  and  
RT-­‐‑PCRed  to  amplify  the  bound  RNA  species.    For  rounds  1-­‐‑6,  1  nmol  RNA  was  
incubated  with  FXIa  in  a  low  salt  Hepes  buffer  E/F  (20mM  Hepes,  100mM  NaCl,  2mM  
CaCl2,  and  0.01%BSA).  For  rounds  6-­‐‑14,  1  nmol  RNA  was  incubated  with  FXIa  in  a  
physiologic  salt-­‐‑Hepes  buffer  (20mM  Hepes,  150mM  NaCl,  2mM  CaCl2,  and  0.01%BSA).  
Rounds  11,  12  and  14  were  cloned  and  sequenced  as  previously  described  to  distinguish  
individual  aptamer  sequences  (152).    
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RNA  Aptamers  
For  all  aptamer  sequences,  “C”  and  “U”  represent  2’fluorocytosine  and  
2’fluorouracil.    The  70  nucleotide  Xla7  (11.7)  aptamer  sequence  is  5’ –
GGGAGGACGATGCGGCTCGCTACTATTCCGGATCAGCAGATCACCCCCTCCCCC
CAGACGACTCGCCCGA-­‐‑3’  and  the  71  nucleotide  sequence  for  Xla9  (12.7)  is  5’-­‐‑ 
GGGAGGACGATGCGGTAACGCCACGCTCGACAACGCGTCGAGTGTCCTCCGCC
CCCAGACGACTCGCCCGA-­‐‑3’.  All  aptamers  were  transcribed  in  vitro  as  previously  
described  using  a  modified  polymerase  that  can  incorporate  2’F  cytidine  triphosphates  
and  2’F  uridine  triphosphates  (194).    Before  use,  all  aptamer  preparations  were  diluted  
into  a  Hepes-­‐‑based  buffer  with  or  without  BSA  (20mM  Hepes,  150mM  NaCl,  2mM  
CaCl2,  and  with  or  without  .01%BSA)  as  indicated.    Diluted  aptamers  were  refolded  by  
heating  to  65oC  for  5  minutes,  and  then  cooled  for  3  minutes  at  ambient  room  
temperature. 
  
FXIa  small  peptide  substrate  cleavage  
FXIa  (final  concentration  25nM)  was  incubated  with  500nM  aptamer,  library,  or  
buffer  for  5min  at  37oC  in  a  Hepes-­‐‑based  reaction  buffer  (20mM  Hepes  pH  7.4,  150mM  
NaCl,  2mM  CaCl2,  .01%  BSA).  The  chromogenic  substrate  Pefachrome  FXIa  
(Centerchem,  Inc.,  Norwalk,  CT)  (final  concentration  1mM)  was  added  to  a  total  volume  
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of  100µμL.    Substrate  cleavage  was  monitored  at  an  absorbance  of  405nm  using  a  kinetic  
microplate  spectrophotometer  at  37oC,  and  rates  of  substrate  cleavage  were  determined  
using  linear  regression  analysis.  
  
Restriction  Fragment  Length  Polymorphism  
   Library  and  SELEX  round  DNA  (50pmoles)  were  end-­‐‑labeled  with  [y32P]  ATP  
(Perkin  Elmer,  Waltham,  MA)  using  T4  polynucleotide  kinase  (New  England  Biolabs,  
Beverly,  MA).    [y32P]  DNA  was  digested  with  AluI,  HhaI,  and  HaeIII  (New  England  
Biolabs,  Beverly,  MA)  for  3  hours  at  37oC.    Digested  radiolabeled  DNA  was  then  
separated  on  an  acrylamide  gel  and  visualized  using  a  Storm  825  phosphoimager  (GE  
Healthcare,  Piscataway,  NJ).  
  
Nitrocellulose  filter  binding  assay  
A  double-­‐‑filter  nitrocellulose  binding  assay  was  employed  to  determine  the  
apparent  binding  affinity  constants  (Kd  values)  of  aptamer  to  protein  (152).  The  5’  end  of  
the  RNA  was  dephosphorylated  using  bacterial  alkaline  phosphatase  (Gibco  BRL,  
Gaithersburg,  MD),  and  subsequently  end-­‐‑labeled  with  [y32P]  ATP  (Perkin  Elmer,  
Waltham,  MA)  using  T4  polynucleotide  kinase  (New  England  Biolabs,  Beverly,  MA).    
Varying  concentrations  of  purified  protein  were  incubated  with    [y32P]  RNA  in  Hepes  
binding  buffer  with  BSA  at  37oC  for  5  minutes.    The  RNA-­‐‑protein  complexes  were  then  
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separated  from  the  unbound  RNA  by  passing  the  mixture  through  a  nitrocellulose  filter  
(Protran  BA  85,  Whatman  Inc.,  Florham  Park,  NJ).    The  levels  of  bound  RNA  were  
quantified  using  a  Storm  825  phosphoimager  (GE  Healthcare,  Piscataway,  NJ).    Non-­‐‑
specific  binding  of  the  radiolabeled  RNA  to  the  nitrocellulose  filter  was  subtracted,  and  
the  data  were  fitted  using  nonlinear  regression  to  determine  the  apparent  binding  
affinity  for  the  RNA  aptamer-­‐‑protein  interaction  (GraphPad  Prism,  GraphPad  Software,  
Inc.,  San  Diego,  CA).  
  
FXIa-­‐‑mediated  FIX  activation  
Conversion  of  zymogen  FIX  to  activated  FIXa  by  FXIa  was  measured  in  a  two  
stage  chromogenic  assay  performed  at  37oC  in  a  Hepes-­‐‑based  reaction  buffer  (20mM  
Hepes  pH  7.4,  150mM  NaCl,  2mM  CaCl2,  .01%  BBF).    Aptamer  or  buffer  was  incubated  
with  FXIa  (final  concentration  5nM)  for  5  minutes  at  37oC,  and  reactions  were  initiated  
with  the  addition  of  FIX  (final  concentration  1µμM).    At  timed  intervals  after  the  initiation  
of  the  reaction,  samples  of  the  reaction  mixture  were  removed  and  FXIa  activity  was  
quenched  by  addition  of  lima  bean  trypsin  inhibitor  (final  concentration  1mg/mL)  
suspended  in  EDTA  (final  concentration  2.1mM).    FIXa  activity  was  assayed  by  the  
addition  of  1mM  Pefachrome  FIXa  3107  (Centerchem,  Inc.,  Norwalk,  CT)  suspended  in  
Hepes-­‐‑based  reaction  buffer  supplemented  with  ethylene  glycol  (20mM  Hepes  pH  7.4,  
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150mM  NaCl,  2mM  CaCl2,  .01%  BBF,  30%  ethylene  glycol).    The  rate  of  substrate  
hydrolysis  was  recorded  at  405nM  using  a  kinetic  microplate  spectrophotometer  at  37oC.    
To  determine  the  inhibition  constant  (Ki),  FIX  activation  reactions  were  
performed  as  described  above  in  the  presence  of  varying  concentrations  of  aptamer.    The  
initial  rate  of  FIX  activation  by  FXIa  was  determined  by  linear  regression  of  the  rate  of  
FIXa  formed  versus  time  for  the  first  10  minutes  of  the  reaction.    Fractional  activity  
(V1/V)  was  calculated  by  dividing  the  initial  rate  of  FXI  activation  in  the  presence  of  
aptamer  by  the  initial  rate  of  FXI  activation  in  the  absence  of  aptamer.    The  Ki  was  
determined  using  nonlinear  regression  analysis.  
  
Cell-­‐‑based  model  of  thrombin  generation  
   The  cell-­‐‑based  model  system  has  been  described  in  detail  (64).    Briefly,  human  
monocytes  from  one  individual  were  isolated  and  cultured  overnight  in  a  96-­‐‑well  
microtiter  plate  in  500ng/mL  lipopolysaccharide-­‐‑containing  macrophage  serum  free  
media  (Gibco,  Invitrogen  Life  Technologies,  Grand  Island,  NY)  to  induce  TF  expression.    
Platelets  were  obtained  and  purified  from  a  normal  healthy  individual,  and  diluted  to  a  
final  concentration  of  ~150x109  L-­‐‑1.  TF  expression  on  cultured  monocytes  were  checked,  
and  determined  to  be  on  the  order  of  1pM.    Final  concentrations  of  proteins  were  
approximately  at  normal  plasma  levels:  antithrombin  (3.0µμM),  TFPI  (3nM),  FII  (1.4µμM),  
FIX  (70nM),  FX  (135nM),  FVIIa  (0.2nM),  FXI  (25nM),  FV  (20nM),  and  FVIII  (0.3nM).    
     133  
Aptamers  were  incubated  with  FXI  for  5  minutes  at  room  temperature.    This  mixture  
was  added  to  the  culture  monocytes,  as  well  as  platelets,  the  purified  coagulation  
proteins,  and  3mM  calcium  chloride.  At  timepoints,  10µμL  of  the  reaction  mixture  was  
added  to  1mM  FIIa  Chromozyme  (Aniara,  West  Chester,  Ohio)  in  1mM  EDTA.    After  10  
minutes,  50%  acetic  acid  was  added  to  stop  the  reaction,  and  the  rate  of  substrate  
hydrolysis  was  recorded  at  405nM  using  a  kinetic  microplate  spectrophotometer  at  37oC.      
  
Clotting  Assays  
Activated  partial  thromboplastin  time  (aPTT)  and  prothrombin  time  (PT)  assays  
were  carried  out  using  a  model  ST4  coagulometer  (Diagnostica  Stago,  Parsippany,  NJ).    
Aptamer  diluted  in  Hepes  buffer  without  BSA  (20mM  Hepes,  150mM  NaCl,  2mM  
CaCl2)  was  refolded  by  heating  for  5  minutes  at  65°C  and  then  cooled  to  ambient  
temperature  for  3  minutes.    Pooled  normal  human  platelet  poor  plasma  was  prepared  by  
drawing  blood  into  sodium  citrate  tubes.  For  the  aPTT,  aptamer  (5µμL)  was  then  added  
to  50µL  pooled  normal  human  platelet  poor  plasma  and  incubated  for  5  minutes  at  37°C.    
50µL  APTT-­‐‑XL  Reagent  was  then  added  to  activate  plasma  and  incubated  for  5  minutes  
at  37°C.    Clotting  was  initiated  by  adding  50µL  of  25mM  CaCl2  and  the  time  to  clot  
formation  was  recorded.    Aptamer  concentrations  represent  the  final  concentration  in  
the  entire  reaction.  
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   For  the  PT,  refolded  aptamer  (5µμL)  was  added  to  50  µL  pooled  normal  human  
platelet  poor  plasma  and  incubated  for  5  minutes  at  37°C.      TriniClot  PT  Excel  (Trinity  
BioTech,  Bray,  Co  Wicklow,  Ireland)  was  added  to  initiate  clotting.    
  
Thrombin  Generation  Assay  
In  an  Immulon  2HB  clear  U-­‐‑bottom  96  well  plate  (Thermo  Labsystems,  Franklin,  
MA),  CTI-­‐‑  treated  (50µμg/mL),  pooled  normal  human  platelet  poor  plasma  from  healthy,  
consented  volunteers  (60µμL)  was  mixed  with  aptamers  (3µμL)  diluted  in  Hepes-­‐‑based  
buffer  without  BSA  and  incubated  for  5  min  at  37oC.  Ellagic  acid  reagent  (final  
concentration  0.1µμM,  diluted  1:200  with  4µμM  phospholipid  vesicles  (20%  
phosphatidylserine,  60%  phosphatidylcholine,  20%  phosphatidylethanolamine)  in  
Hepes-­‐‑based  buffered  saline)(15µμL)  was  added  to  the  plasma-­‐‑aptamer  mixture,  and  
incubated  for  5  minutes  at  37oC.  Flu-­‐‑Ca  (Diagnostica  Stago)(15µμL)  was  added  to  start  the  
assay  and  thrombin  generation  was  measured  using  a  Fluroskan  Ascent  Reader  
(Thermo  Scientific,  Waltham,  MA).    A  thrombin  calibrator  reagent  (Diagnostica  Stago,  
Parsippany,  NJ)  was  used  to  quantify  the  amount  of  thrombin  generated  in  the  samples.    
Data  analysis  was  performed  using  Thrombinoscope  software  (Thrombinoscope  BV,  the  
Netherlands).  Aptamer  concentrations  represent  the  final  concentration  in  the  entire  
reaction.  The  amount  of  ellagic  acid  used  was  standardized  to  produce  a  similar  curve  to  
a  TF-­‐‑activated  TGA.    In  addition,  the  amount  of  CTI  present  was  standardized  to  inhibit  
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contact  activation  of  the  plasma  sample,  while  still  allowing  for  robust  FXII-­‐‑dependent  
activation  upon  administration  of  ellagic  acid.    
  
Thromboelastogram  
   Blood  was  drawn  from  healthy,  consented  volunteers  under  a  Duke  University  
Institutional  Review  Board  Protocol  into  tubes  with  3.2%  sodium  citrate.    Whole  blood  
(320µμL)  was  mixed  with  aptamer  (10µμL)  and  incubated  at  room  temperature  for  5  
minutes.    Kaolin  (10µμL)(Haemonetics,  Niles,  IL)  was  added,  and  the  entire  reaction  
(340µμL)  was  added  to  20µμL  CaCl2  in  a  disposable,  plain  TEG  cup  (Haemonetics).    Clot  
formation  was  measured  at  37oC  with  a  Thromboelastograph  Analyzer  (Haemonetics)  
until  a  stable  clot  was  formed.  Parameters  were  automatically  calculated  using  the  
TEG®  Analytical  Software  version  4.2.3  (Haemonetics).    
  
3.3 Results 
 3.3.1 SELEX Pool Analysis and Lead Clone Selection 
To  isolate  aptamers  targeting  FXIa,  we  utilized  a  traditional  solution  based  
SELEX  against  purified  FXIa.    A  library  of  approximately  1014    2’Fpyrimidine  modified  
RNA  sequences  were  incubated  with  FXIa  and  screened  for  high  affinity  binding  and  
active  site  inhibition.    Because  binding  of  the  pool  RNA  was  initially  weak,  the  selection  
was  begun  in  a  binding  buffer  with  a  lower  salt  concentration  (100mM  NaCl),  and  
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subsequently  increased  to  physiologic  salt  concentration  (150mM  NaCl)  once  higher  
binding  affinity  was  established.    After  6  rounds  of  selection  in  a  lower  salt  buffer,  the  
binding  affinity  of  the  pool  RNA  began  to  increase  as  high  affinity  binding  sequences  
began  to  dominate  the  pool.    The  final  rounds  were  performed  at  physiological  salt  
conditions.      
Fourteen  total  rounds  of  SELEX  were  performed,  with  progression  monitored  in  
several  ways.    First  the  binding  affinity  of  each  round  was  determined  by  a  
nitrocellulose  filter-­‐‑binding  assay;  however,  this  assay  was  often  inconsistent,  perhaps  
because  of  the  dimer  formation  of  FXIa.    Thus,  the  evolution  of  the  selection  was  
additionally  assessed  for  functionality  and  diversity  (Figure  23).    The  functionality  of  the  
pool  RNA  was  monitored  by  its  ability  to  reduce  the  active  site  cleavage  rate  of  a  small  
substrate.    As  shown  in  Figure  23A,  the  pool  began  to  include  a  higher  number  of  
sequences  that  could  decrease  the  rate  of  active  site  cleavage  of  FXIa  as  early  as  round  4,  
and  these  sequences  were  maximally  present  in  rounds  11  and  12.    Later  rounds  began  
to  slightly  loose  this  functionality,  indicating  the  loss  of  functional  aptamers  as  
stringency  towards  tighter  binders  was  increased.    Lastly,  the  diversity  of  sequences  
present  in  the  pool  was  examined  using  a  restriction  fragment  length  polymorphism  
(RFLP)  assay  (Figure  23B).    In  this  assay,  the  oligonucleotide  pool  is  digested  with  a  set  
of  restriction  enzymes  and  separated  according  to  length  by  gel  electrophoresis.    The  
emergence  of  separate  bands  from  the  starting  library  RNA  was  apparent  from  the  
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earliest  round  tested,  round  8.    Rounds  13  and  14  exhibited  an  additional  band,  
suggesting  the  further  evolution  of  the  pool.    For  comparison  of  diversity,  and  to  isolate  
the  more  frequent  functional  sequences  present  in  the  earlier  pools,  rounds  11,  12  and  14  
were  chosen  to  clone  and  sequence.      
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Figure  23.  Analysis  of  FXIa  SELEX  rounds  active  site  functionality  and  
sequence  diversity  
A)  Chromogenic  assay  for  active  site  activity.  FXIa  (25nM)  was  incubated  with  SELEX  
RNA  rounds  (500nM),  and  active  site  activity  was  measured  by  a  FXIa  specific  
chromogenic  substrate.    The  data  were  normalized  to  the  rate  in  the  absence  of  
compound  and  represent  the  mean  ±  SEM  of  duplicate  measures.    B)  RFLP  analysis  of  
SELEX  rounds.    Radiolabeled  DNA  from  each  round  was  digested  with  the  same  set  of  
restriction  enzymes  and  separated  by  gel  electrophoresis.    The  labels  above  the  lanes  
indicate  the  round:  “R8”  means  round  8.  
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The  seventy  clones  selected  to  sequence  from  all  three  rounds  were  organized  
into  families  based  upon  their  primary  sequences  (Table  7).    There  was  considerable  
diversity  in  the  pool,  with  the  highest  frequency  clone  present  only  in  20%  of  the  pooled  
sequences.    While  many  of  the  conserved  sequences  were  found  in  two  or  all  three  of  the  
sequenced  pools,  there  were  many  “orphan”  sequences,  or  sequences  that  do  not  fit  into  
a  family,  but  are  present  at  a  low  frequency  in  the  final  pool.    The  functional  data  and  
progression  of  the  SELEX  rounds  indicate  that  there  is  some  loss  of  functional  binders,  
therefore,  several  of  the  orphan  sequences  from  rounds  11  and  12  were  analyzed,  and  
indicated  by  their  individual  clone  name.    
Table  7.  RNA  aptamer  sequences  from  FXIa  solution-­‐‑based  SELEX  
Clone  ID   Variable  Region  Sequence   Frequency  
Xla1   ACCGCATCCGTGAAGATCCCTCTTCTCCCCTCCCCCC   20.0%  
Xla8   GCCGTCCTGAGTCGTATGAATTCCGCATGGTCGTCGTGTG   12.9%  
Xla2   AATTACCCGCGTCTGTAGTACACATGCTATCCCCTCCCCC   8.6%  
Xla7   CAAACTAATTCGGGCCGCGCACTGGGTCCTTCCCCCCC   8.6%  
Xla4   ATCGTGCATTATTTCTGGCTACCAGCCAACGGTCCCCCCC   5.7%  
Xla5   ATGTCTGGTAATCACACCACACTGCTCCAGCCTTCCCCCC   5.7%  
Xla3   CACTACGAGGCGTCACTTGCCCGAACATCACCTCCCCCCC   2.9%  
Xla6   AGCACATAAACGCTGGTGTTTCCACCCACCTCCCCCCCC   2.9%  
  11.7   CTCGCTACTATTCCGGATCAGCAGATCACCCCCTCCCCC   2.9%  
  11.23   TATCAGCACGCGTCTGCACTCTAGAGTGTCCCCTCCCCCC   1.4%  
12.7   TAACGCCACGCTCGACAACGCGTCGAGTGTCCTCCGCCCC   1.4%  
  
Sequence  analysis  of  the  clones  indicated  a  conserved  region  near  the  end  of  the  
random  region,  found  in  most  families,  consisting  of  a  string  of  C’s.    Predicted  structural  
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analysis  indicated  that  this  region  bound  to  the  5’  constant  region,  resulting  in  a  similar  
structure  for  many  of  the  sequence  families  (Figure  24).    This  structure  is  hallmarked  by  
a  central  loop  with  two  stem  loops  emerging  from  it,  as  well  as  a  stem  and  the  un-­‐‑base-­‐‑
paired  3’  constant  region.  Outside  of  the  constant  regions  and  the  string  of  C’s,  no  
sequence  similarity  was  found  between  families.    
  
  
Figure  24.    Representative  secondary  structures  of  clone  families  
The  M-­‐‑fold  predicted  secondary  structures  of  A)  Xla1,  B)  Xla2,  C)  11.7  and  D)  12.7.  
  
In  order  to  select  a  lead  aptamer  for  further  analysis,  a  representative  clone  from  
each  of  family  was  screened  in  three  separate  assays:  binding  affinity  utilizing  the  
nitrocellulose  filter  binding  assay,  functionality  of  active  site  cleavage,  and  functionality  
of  FXIa-­‐‑mediated  FIXa  activation.    A  summary  of  these  results  is  found  in  Table  8.    
While  not  found  in  a  high  frequency  in  the  selection  pool,  two  of  the  most  potent  
aptamers,  11.7  and  12.7,  were  further  characterized.    
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Table  8.    FXI  aptamer  screening  results  
Aptamers  were  screened  in  a  binding  affinity  assay,  and  two  chromogenic  assays  to  
determine  the  rates  of  active  site  cleavage  of  FXIa  and  FXIa-­‐‑mediated  FIXa  generation.    
For  the  chromogenic  assays,  all  aptamers  were  tested  at  0.5µμM.    Data  represents  one  
independent  experiment.  
Aptamer   FXIa  Binding  
affinity  






Xla1   753.9   2.346   0.618  
Xla2   394.9   2.021   0.419  
Xla3   303.5   4.100   1.314  
Xla4   73.1   4.481   1.177  
Xla5   65.5   4.436   0.526  
Xla6   362.3   2.302   0.823  
Xla7   2,182.0   3.974   ND  
11.7   27.5   1.603   0.259  
11.23   75.6   2.235   1.312  
12.7   21.0   1.511   0.178  
Library   461.7   4.375   1.81  
Buffer   N/A   3.966   1.682  
  
  
3.3.2 Lead Aptamer Biochemical Characterization  
  While  several  of  the  aptamer  clones  did  not  affect  active  site  cleavage,  a  number  
of  aptamers  were  able  to  slow  the  rate  of  active  site  cleavage  of  FXIa  to  varying  degrees.    
For  all  FXI  biochemical  assays,  a  non-­‐‑binding,  size-­‐‑matched  control  RNA  was  used  to  
assess  the  non-­‐‑specific  effects  of  RNA  activity  on  FXI.    Clones  11.7  and  12.7  were  
maximally  able  to  slow  active  site  cleavage  rates  by  ~65%  compared  to  library  control  
RNA  or  non-­‐‑functional  aptamers  (Figure  25).    
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Figure  25.  Active  site  activity  assay  to  determine  lead  clone  candidates  
FXIa  (25nM)  was  incubated  with  FXIa  aptamer  clones  (500nM),  and  active  site  activity  
was  measured  by  a  FXIa  specific  chromogenic  substrate.    The  data  were  normalized  to  
the  rate  in  the  absence  of  compound  and  represent  the  mean  ±  SEM  of  at  least  duplicate  
measures.  
  
Both  of  these  clones  were  next  analyzed  using  nitrocellulose  filter  binding  assays  
to  determine  their  binding  affinity  to  both  zymogen  FXI  and  FXIa  (Figure  26).    Binding  
in  general  to  FXI  and  FXIa  was  quite  variable  and  inconsistent,  even  with  control  RNA,  
compared  with  binding  studies  on  other  proteins,  resulting  in  widely  changing  
disassociation  constants.    A  compilation  of  all  binding  studies  suggested  that  11.7  binds  
to  only  FXIa,  while  12.7  binds  to  both  zymogen  FXI  and  FXIa  (Table  9).    For  both  clones,  
the  Bmax,  or  the  percentage  of  RNA  present  that  is  folded  correctly  in  order  to  bind  to  the  
target  protein,  was  also  very  low,  suggesting  that  only  a  small  fraction  of  the  RNA  is  
able  to  bind  the  protein.    Additional  nitrocellulose  filter  binding  assays  to  other  proteins  
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were  employed  to  determine  specificity  of  aptamer  binding.    Both  aptamers  did  not  
exhibit  binding  toward  a  panel  of  coagulation  factors,  including  the  structurally  related  
prekallikrein  (data  not  shown).    However,  11.7  did  exhibit  weak  binding  to  the  
enzymatically  inactive  HK,  a  protein  that  circulates  in  complex  with  FXI  or  PK.    
  
  
Figure  26.  Aptamer  11.7  binds  preferentially  to  FXIa  while  aptamer  12.7  binds  
to  both  zymogen  FXI  and  FXIa  
Representative  nitrocellulose  filter  binding  assay  of  11.7  (n),  12.7  (q),  and  library  
control  RNA  (l)  to  A)  FXI  and  B)  FXIa.  
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Table  9.  RNA  aptamer  binding  to  soluble  FXI  and  FXIa  as  determined  by  a  
nitrocellulose  filter-­‐‑binding  assay  
Data  represent  at  least  duplicate  measures.      
   FXI   FXIa  
Aptamer   Kd  approx  (nM)   Bmax  approx  (%)   Kd  approx  (nM)   Bmax  approx  (%)  
11.7   671.6  ±  265.9   21.3  ±  4.3   52.0  ±  13.5   24.7  ±  2.0  
12.7   139.2  ±81.9   10.45  ±  1.7   84.9  ±  32.5   9.1  ±  2.5  
  
In  the  coagulation  cascade,  FXI  functions  to  activate  FIX  to  amplify  thrombin  
generation.    Thus,  the  ability  of  the  lead  aptamers  to  inhibit  this  reaction  was  next  
determined.  This  reaction  was  assessed  by  monitoring  the  amount  of  FIXa  formed  in  a  
purified  system  using  FXIa  as  an  activator  in  the  presence  or  absence  of  aptamer  or  
control  RNA.    The  presence  of  either  aptamer  in  this  reaction  impaired  the  initial  rate  of  
FIX  activation  by  greater  than  ~80%,  while  the  presence  of  control  RNA  did  not  (Figure  
27A).      To  determine  the  potency  of  inhibition,  the  initial  rate  of  FIX  activation  by  FXIa  
was  measured  in  the  presence  of  varying  concentrations  of  either  11.7  or  12.7,  and  was  
shown  to  dose  dependently  decrease  the  amount  of  FIXa  formed.  An  apparent  
equilibrium  inhibition  constant  (Ki)  of  82.4  ±  12.8nM  for  11.7  or  190.1  ±  27.3nM  for  12.7  
was  obtained  by  plotting  the  fractional  rates  of  FIX  activation  versus  the  concentration  of  
aptamer  used  (Figure  27B  and  C).    While  11.7  could  maximally  inhibit  90%  of  FIXa  
generation,  12.7  had  slightly  less  potency  while  able  to  inhibit  75%  of  FIXa  generation.    
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Figure  27.  Both  lead  aptamers  reduce  FXIa-­‐‑catalyzed  activation  of  FIX  
FIX  (1µμM)  was  activated  by  FXIa  (5nM),  the  reaction  was  quenched  at  various  
timepoints  by  the  addition  of  1mg/mL  LBTI,  and  the  amount  of  FIXa  was  quantified  
using  a  chromogenic  substrate.  A)  The  rate  of  FIXa  generation  at  various  timepoints  was  
determined  in  the  presence  of  500nM  11.7  (q),  12.7  (p),  control  library  RNA  (u),  or  
buffer  (n).    Lines  represent  nonlinear  regression  fits  of  the  data.    The  data  are  
representative  of  two  independent  measures.  Fractional  FXla  activity  of  B)  11.7  and  C)  
12.7.  Fractional  activity  was  calculated  by  dividing  the  initial  rate  of  FXI  activation  in  the  
presence  of  R4cXII-­‐‑1  by  the  initial  rate  of  FXI  activation  in  the  absence  of  aptamer.  The  Ki  
was  calculated  by  nonlinear  regression  analysis.  The  data  represent  the  mean  ±  SEM  of  
at  least  duplicate  measures  
  
Since  both  aptamers  can  reduce  FXla  active  site  cleavage  and  FIXa  generation,  
they  were  next  tested  to  see  if  they  could  reduce  thrombin  generation  in  a  reconstituted  
cell-­‐‑based  model  of  coagulation.    This  assay  was  developed  to  assess  thrombin  
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generation  using  cultured  monocytes  as  a  source  of  tissue  factor,  and  purified  platelets  
as  a  surface  for  physiologic  amounts  of  procoagulant  proteins  to  generate  thrombin  (64,  
216).    Preliminary  results  suggest  that  both  aptamers  are  potent  inhibitors  of  thrombin  
generation  in  this  assay  (Figure  28).    This  assay  does  not  include  FXII,  thus  any  FXI  
activity  is  thought  to  occur  from  the  thrombin  feedback  loop.      
  
  
Figure  28.  Both  aptamers  inhibit  thrombin  generation  in  a  reconstituted  cell-­‐‑
based  model  
Purified  platelets  and  physiologic  amounts  of  procoagulant  factors  are  added  to  human  
monocytes  induced  to  express  tissue  factor  and  thrombin  generation  is  determined  by  a  
chromogenic  substrate.  The  amount  of  thrombin  formed  with  pre-­‐‑incubation  of  FXI  with  
11.7(l),  and  12.7  (q)  with  control  library  RNA  (n)  was  determined.    The  data  are  
representative  of  two  independent  experiments.  
  
3.2.3 Lead Aptamer Functional Analysis 
While  both  aptamers  exhibit  biochemical  inhibition  of  FXIa  function  and  
downstream  thrombin  generation,  we  next  tested  each  aptamer  for  anticoagulant  
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activity  in  a  plasma-­‐‑based  common  clinical  coagulation  test,  the  activated  partial  
thromboplastin  time  (aPTT).    This  assay  measures  the  time  it  takes  for  a  fibrin  clot  to  
form  in  plasma,  and  is  sensitive  to  deficiencies  or  inhibition  of  the  intrinsic  and  common  
pathways  of  coagulation.    This  assay  uses  a  negatively  charged  substance,  such  as  kaolin  
or  ellagic  acid,  to  activate  FXII  and  prime  the  cascade,  and,  upon  addition  of  Ca2+  to  
initiate  clotting,  records  the  time  for  a  fibrin  clot  to  form.  Aptamer  12.7  shows  a  slight  
increase  of  clotting  time  over  control  RNA  in  an  aPTT  activated  with  ellagic  acid  (Figure  
29A),  although  this  increase  plateaus  once  aptamer  saturation  of  target  protein  is  
reached.    In  addition,  11.7  does  not  show  activity  in  this  assay.  As  a  control,  both  
aptamers  do  not  inhibit  clotting  time  in  a  PT,  which  measured  extrinsic  pathway  
inhibition  (Figure  29B).    Use  of  a  different  activator  (micronized  silica),  abolished  the  
ability  of  12.7  to  prolong  clotting  time  in  an  aPTT  (data  not  shown).    
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Figure  29.  Lead  aptamer  screening  in  functional  clotting  assays  
Dose  titration  of  11.7  (n)  and  12.7  (p)  in  A)  an  aPTT  clotting  assay  activated  with  ellagic  
acid  or  B)  a  PT  clotting  assay  activated  with  TF.    The  data  were  normalized  to  the  clot  
time  of  a  control  library  RNA.  
  
Because  of  the  minimal  prolongation  of  clot  time  seen  in  an  aPTT,  12.7  was  
examined  in  the  more  sensitive  thrombin  generation  assay  (TGA)  to  determine  
functionality  in  plasma.  This  is  a  coagulation  assay  similar  to  the  cell-­‐‑based  model  
system  that  measures  thrombin  generation  in  human  plasma  in  real-­‐‑time  by  monitoring  
cleavage  of  a  thrombin-­‐‑specific  chromogenic  substrate.    While  the  cell-­‐‑based  model  
system  used  cultured  macrophages  to  initiate  thrombin  generation  through  the  extrinsic  
pathway,  a  TGA  was  developed  with  our  colleagues  at  Merck  Research  Labs  using  
ellagic  acid  as  an  activator  to  study  thrombin  generation  during  inhibition  of  the  
intrinsic  pathway.    Using  a  TGA  allows  for  several  more  parameters  to  be  analyzed  in  
addition  to  the  lag  time  (the  time  when  thrombin  begins  to  appear),  including  the  peak  
(maximal  amount  of  thrombin  formed),  the  endogenous  thrombin  potential  (ETP,  the  
total  amount  of  thrombin  formed),  and  the  rate  of  thrombin  generation  (the  slope  of  the  
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line  from  the  lag  time  to  peak  thrombin  generation).  Contrary  to  the  aPTT  data,  12.7  
exhibited  potent  inhibition  of  thrombin  generation  in  this  assay,  including  prolongation  
of  the  lag  time  by  several  minutes  (Figure  30).    Importantly,  in  contrast  to  the  aPTT,  
which  uses  sodium  citrate  pooled  human  plasma,  this  assay  uses  human  plasma  that  has  
been  treated  with  corn  trypsin  inhibitor  (CTI),  a  FXIIa  inhibitor  that  is  added  during  the  
blood  drawing  process  to  inhibit  any  contact  activation  that  may  occur.  While  12.7  dose  
dependently  inhibited  thrombin  generation  and  all  analyzed  parameters,  including  the  
ETP,  the  peak  amount  of  thrombin  formed,  and  the  rate  of  thrombin  generation,  size  
matched  library  control  RNA  exhibited  agonist  activity  and  dose  dependently  increased  
the  rate  of  thrombin  generation  and  the  peak  amount  of  thrombin  formed.    While  the  
mechanism  of  this  is  undetermined,  other  control  RNA  with  no  inhibitory  characteristics  
also  exhibited  this  trend  (data  not  shown).    However,  control  RNA  had  no  effect  on  the  
ETP  of  the  sample,  indicating  that  the  same  amount  of  thrombin  was  generated  across  
doses.  In  contrast,  12.7  completely  abolished  ETP,  with  no  thrombin  formed  at  the  two  
highest  concentrations  tested  (Figure  30D).    
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Figure  30.  Aptamer  12.7  dose  dependently  impairs  thrombin  generation  in  a  
TGA  assay  initiated  with  ellagic  acid  
Thrombograms  of  normal  pooled  plasma  activated  with  ellagic  acid  with  various  
concentrations  of  A)  12.7  and  B)  size-­‐‑matched  library  control  RNA.    C)  Lag  time,  D)  
Endogenous  thrombin  potential  E)  Peak  thrombin  generation,  and  F)  rate  of  thrombin  
generation  of  12.7  (n)  and  library  control  RNA  (p).      Data  are  representative  of  one  
independent  experiment.  
 
While  the  aPTT  and  TGA  indirectly  measure  thrombin  generation  in  a  plasma-­‐‑
based  setting,  an  assay  that  uses  whole  blood,  and  thus  also  platelets,  was  utilized  to  
measure  clot  strength  kinetics.    This  assay,  the  thromboelastogram,  uses  kaolin  to  
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activate  citrated  blood,  and  measures  the  time  it  takes  for  a  clot  to  form  (lagtime),  the  
rate  of  clot  formation  (αangle)  and  the  strength  of  the  clot  (maximum  amplitude).    Both  
lead  aptamers  were  tested  in  this  assay,  and  both  11.7  and  12.7  could  prolong  the  time  it  
takes  for  a  clot  to  form  over  size-­‐‑matched  control  RNA  (Figure  31).    Aptamer  12.7  also  
significantly  decreased  the  angle,  or  the  rate  of  clot  formation.    
  
Figure  31.    FXI  aptamers  can  impair  clot  strength  parameters  in  a  
thromboelastogram  activated  with  kaolin  
Thromboelastogram  tracings  for  A)  12.7  (green)  and  size-­‐‑matched  control  scrambled  
RNA  (black)  and  B)  11.7  (green)  and  size-­‐‑matched  control  scrambled  RNA  (black).    The  
data  are  representative  of  two  independent  observations.  
  
While  the  FXI  aptamer  was  isolated  solely  against  the  human  form  of  the  
coagulation  factor,  analysis  for  cross  reactivity  in  animal  plasma  is  a  must  before  
proceeding  into  in  vivo  models  of  thrombosis.    In  general,  aptamers  have  exhibited  some  
efficacy  in  a  variety  of  species;  with  the  FIX  aptamer  retaining  binding  in  every  species  
tested  except  for  rabbit  (data  not  shown).    However,  other  aptamers  exhibit  limited  
cross-­‐‑reactivity.    Both  lead  FXI  aptamers  were  tested  in  a  number  of  animal  plasmas  in  
an  aPTT  assay,  as  well  as  with  different  activating  reagents.    Unfortunately,  no  
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anticoagulant  effect  was  seen  in  any  of  the  plasmas  tested  (data  not  shown).    
Importantly,  the  animal  plasma  samples  were  not  treated  with  CTI,  thus  contact  
activation  of  the  plasma  sample  may  already  be  present,  and  subsequent  aptamer  
inhibition  may  not  be  detected.    This  experiment  will  be  repeated  once  we  obtain  CTI-­‐‑
treated,  non-­‐‑contact  activated  plasma  from  each  animal  species.  
3.4 Discussion 
We  utilized  a  solution  based  SELEX  to  isolate  aptamers  that  bound  to  FXIa  and  
inhibited  coagulant  function.    A  number  of  aptamers  were  characterized  that  could  
reduce  the  rate  of  FXIa  active  site  cleavage  of  a  small  chromogenic  substrate,  as  well  as  
inhibit  FXIa-­‐‑mediated  FIX  activation  (Figure  32).    All  of  these  functional  aptamers  
evolved  a  similar  predicted  secondary  structure,  however,  binding  affinities  varied  
widely,  and  were  generally  low  compared  to  other  aptamer  selections.    Two  lead  
aptamers  exhibited  a  robust  decrease  in  thrombin  generation  in  a  reconstituted  cell  
based  model  system.    Plasma  or  blood  based  assays  utilizing  the  FXIa  aptamers  did  not  
initially  have  a  robust  affect  on  thrombin  generation;  however,  contact  activation  during  
a  blood  draw  could  decrease  the  function  of  these  aptamers  in  plasma  or  blood  that  was  
not  treated  with  a  contact  pathway  inhibitor.    Addition  of  a  FXIa  aptamer  in  a  plasma  
assay  using  contact-­‐‑inhibited  plasma  during  the  blood  draw  showed  potent  inhibition  of  
thrombin  generation.    
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Figure  32.    A  schematic  depicting  the  role  of  the  FXI  aptamer,  12.7,  in  
inhibiting  FXI/FXIa  function  
The  aptamer  12.7  inhibits  FXIa  active  site  cleavage  as  well  as  FXIa-­‐‑mediated  FIX  
activation  to  effectively  shut  down  thrombin  generation  in  a  plasma  setting.  Predicted  
secondary  structure  of  aptamer  adapted  from  M-­‐‑fold.  
  
Initial  binding  of  the  starting  RNA  library  to  FXIa  was  low  at  physiologic  salt  
concentrations;  therefore,  SELEX  was  initially  started  in  a  lower  salt  containing  buffer  in  
which  the  library  RNA  exhibited  binding  (data  not  shown).    After  six  rounds,  the  pool  
had  evolved  with  a  higher  affinity  binding  than  the  starting  library  in  both  lower  salt  
and  physiologic  salt  buffers;  thus,  the  selection  was  then  continued  at  physiologic  salt  
concentrations.    Throughout  the  selection,  background  binding  varied  widely  in  
separate  experiments  and  in  separate  lots  of  FXIa.    While  each  lot  of  FXIa  was  believed  
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to  be  >95%  pure  by  the  company  it  was  purchased  from,  during  the  preparation  process,  
the  zymogen  protein  is  activated  by  FXIIa,  a  protein  that  can  bind  to  library  RNA  fairly  
easily.    While  there  are  not  any  of  the  original  lots  of  protein  available  to  subsequently  
test  for  purity,  contamination  of  a  high  nucleic  acid  binding  protein  could  have  been  
responsible  for  the  varied  background  binding.  Subsequent  lots  showed  much  reduced  
and  more  consistent  background  bindings,  suggesting  that  purification  methods  have  
been  optimized.    
Because  of  the  inconsistencies  with  the  nitrocellulose  filter-­‐‑binding  assay,  the  
SELEX  rounds  were  also  monitored  functionally  in  a  simple  chromogenic  assay  
determining  the  rate  of  FXIa  active  site  cleavage.    While  aptamers  do  not  normally  bind  
within  and  inhibit  the  active  site,  some  aptamers  have  been  found  to  reduce  this  activity  
(184).    It  is  thought  that  the  aptamer  either  binds  in  such  a  way  to  partially  occlude  or  
allosterically  affect  the  active  site,  thus  reducing  rates  of  substrate  cleavage.    Beginning  
with  Round  4,  the  selection  pool  contained  sequences  that  could  slightly  reduce  FXIa  
active  site  cleavage.    Further  evolution  of  the  pool  resulted  in  further  reduction  of  active  
site  cleavage.    However,  as  stringency  in  binding  was  increased  in  later  rounds,  the  pool  
began  to  loose  the  frequency  of  functional  binders.    Analysis  of  individual  clones  
identified  the  most  functional  aptamers  from  the  two  most  potent  rounds  in  this  assay.    
Cloning  and  sequencing  three  rounds  from  this  selection  led  to  identification  of  
numerous  aptamer  families  and  orphan  sequences.    While  some  selections  are  driven  
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nearly  to  completion,  with  the  identification  of  one  or  two  closely  related  sequences  that  
tend  to  dominate  the  pool  (152,  191),  this  selection  had  many  aptamer  families  present  to  
screen  for  functionality.    Testing  these  aptamers  in  a  panel  of  biochemical  assays  
identified  several  of  the  most  potent  aptamers,  and  several  aptamers  that  had  no  
functionality.    Interestingly,  all  of  the  functional  aptamers  contained  the  same  predicted  
structure,  while  the  non-­‐‑functional  aptamer  structures  varied.    In  analyzing  the  
sequences  of  the  aptamer  families,  most  sequences  evolved  a  string  of  C’s  near  the  end  
of  the  variable  region  that  bound  to  the  5’  constant  region.    The  library  used  for  this  
selection  was  shorter  than  previous  libraries  (71  nucleotides  versus  80  nucleotides).    
While  both  libraries  contained  40  nucleotide  random  regions,  the  shorter  library  
contained  a  truncated  3’  constant  region.    In  another  selection  using  this  library,  the  
same  string  of  C’s  near  the  end  of  the  variable  region  was  also  evolved.    This  suggests  
that  the  constant  regions  in  this  shorter  library  may  not  exhibit  stable  binding,  and  thus  
the  selection  had  to  evolve  stable  aptamer  structures  first  before  then  selecting  for  high  
affinity  binders.    Since  the  binding  affinity  was  so  low  in  this  selection,  and  this  was  the  
first  selection  using  this  library  to  isolate  aptamers  against  coagulation  factors,  the  initial  
library  may  not  have  been  able  to  exhibit  high  structural  diversity  due  to  low  stability  
binding  of  the  constant  regions,  especially  at  physiologic  salt  concentrations.  
Similar  to  the  selection  rounds,  binding  analysis  of  the  two  most  potent  
functional  clones  exhibited  lower  binding  affinities  (high  nanomolar  range)  and  Bmax  
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percentages  (10-­‐‑20%)  than  normally  seen  with  other  aptamers  to  coagulation  factors  
(152,  162).  As  most  coagulation  proteins  are  not  dimers,  the  nitrocellulose  filter-­‐‑binding  
assay  may  not  be  a  suitable  assay  to  determine  binding  with  a  dimerized  protein.    It  is  
possible  that  the  protein  could  fall  apart,  or  bound  RNAs  could  be  eluted  off  the  protein  
due  to  a  structural  change  upon  binding  to  the  nitrocellulose  filter.    Separate  binding  
assays  to  compare  aptamer  binding  to  FXIa  are  currently  planned,  as  well  as  binding  
assays  to  a  non-­‐‑dimeric  form  of  the  protein,  as  well  as  the  isolated  catalytic  domain.    In  
addition,  the  predicted  secondary  structure  of  the  RNA’s  present  a  large  un-­‐‑basepaired  
3’  region.    While  no  other  structures  are  predicted,  it  is  our  experience  that  un-­‐‑
basepaired  regions  are  not  very  stable.    A  native  gel  binding  assay  with  11.7  to  FXIa  
showed  three  aptamer  states,  where  only  one  of  those  states  were  able  to  bind  to  FXIa,  
corresponding  with  the  determined  Bmax  where  only  30%  of  the  aptamer  is  folded  
correctly  to  bind  to  FXIa.      Truncation  of  the  aptamers,  especially  eliminating  the  3’  un-­‐‑
basepaired  region,  could  lead  to  further  stabilization  of  the  aptamer  structure  capable  of  
binding  to  FXIa,  thus  increasing  the  Bmax  of  the  aptamer.    
The  crystal  structure  of  FXIa  has  been  solved,  along  with  the  locations  of  the  
binding  site  of  the  proteins  that  FXIa  interacts  with.  These  binding  sites  are  located  in  
four  apple  domains,  on  top  of  which  the  catalytic  site  sits.    The  decision  to  perform  
SELEX  on  FXIa  rather  than  FXI  preceded  from  the  observation  that  zymogen  FXI  does  
not  bind  FIX.    Cleavage  of  the  activation  loop  by  FXIIa  or  thrombin  in  the  catalytic  
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domain  results  in  significant  conformational  changes.  Specifically,  an  arginine  residue  
which  is  normally  buried  in  the  A3  domain  near  the  FIX  binding  site  is  subsequently  
exposed  upon  FXI  activation,  acting  as  a  switch  to  shift  the  position  of  the  apple  domain  
disk  relative  to  the  catalytic  domain,  thus  exposing  the  FIX  binding  site  (54).  As  both  
lead  aptamers  reduce  active  site  cleavage  and  block  FIX  activation,  they  most  likely  bind  
near  or  in  this  region,  as  aptamers  tend  to  home  in  on  sites  that  mediate  protein-­‐‑protein  
interactions  (157).  Interestingly,  11.7  binds  only  to  FXIa  and  is  a  more  potent  inhibitor  of  
FIX  activation  in  a  purified  protein  setting  than  12.7,  which  can  bind  to  both  FXI  and  
FXIa.    This  suggests  that  11.7  binds  more  directly  than  12.7  in  the  FIX  binding  site  that  is  
occluded  in  zymogen  form.    Other  proteins  bind  the  regions  surrounding  the  FIX  
binding  site,  such  as  GP1bα,  which  binds  in  the  same  apple  domain,  and  thrombin  and  
HK,  which  bind  in  separate  apple  domains.    As  aptamers  tend  to  bury  large  surface  
areas,  biochemical  analysis  to  determine  if  these  aptamers  block  the  function  of  these  
other  proteins  would  help  to  map  the  aptamer  binding  site,  as  well  as  further  elucidate  
the  mechanism  of  aptamer  inhibition.  
Functionally,  there  was  initially  a  discrepancy  between  the  lack  of  potency  in  
plasma-­‐‑based  assays  versus  the  potent  inhibition  of  FXI  function  in  biochemical  assays  
or  the  reconstituted  cell-­‐‑based  model  of  thrombin  generation.    This  could  be  due  to  prior  
contact  pathway  activation  in  the  plasma  samples.  The  process  of  drawing  blood  can  
activate  the  contact  pathway  through  the  exposure  and  subsequent  activation  of  FXII  to  
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foreign  surfaces.    Therefore,  FXIa  can  already  be  present  and  bound  to  FIX  in  a  plasma  
preparation  from  a  blood  draw  without  an  inhibitor  of  FXIIa  present,  and  subsequent  
inhibition  of  FXIa  in  these  samples  might  not  be  viable  or  as  potent  as  inhibition  in  CTI-­‐‑
treated  samples,  where  presumably  no  FXI  has  been  activated.    CTI  is  an  irreversible  
FXIIa  inhibitor,  and  inclusion  has  been  shown  to  inhibit  contact  pathway  activation  
during  the  blood  drawing  process.    This  discrepancy  can  be  seen  when  comparing  the  
results  from  the  aPTT  and  TGA  with  12.7.    While  12.7  has  minimal  activity  in  the  aPTT,  
which  uses  plasma  without  CTI,  there  is  robust  inhibition  of  thrombin  generation  in  the  
TGA,  including  the  lag  time,  using  plasma  prepared  with  CTI.    Further  analysis  to  
determine  if  CTI-­‐‑treated  plasma  would  have  a  great  aptamer  effect  in  the  aPTT  is  
warranted.    In  addition,  11.7  has  not  been  evaluated  in  a  CTI-­‐‑based  plasma  assay;  thus,  
its  functionality  in  plasma  is  unknown,  although  it  was  able  to  decrease  thrombin  
generation  in  the  cell-­‐‑based  model.    However,  11.7  could  also  be  less  potent  in  plasma  
than  12.7  because  it  only  binds  to  activated  FXI  while  12.7  binds  to  both  FXI  and  FXIa.  
Therefore,  12.7  would  already  be  bound  to  FXI  in  plasma  and  able  to  immediately  block  
FIX  activation.    In  addition,  several  aptamers  that  bind  to  the  zymogen  as  well  as  the  
activated  protein  have  been  shown  to  not  only  inhibit  downstream  function  of  their  
target  protein,  but  also  to  inhibit  their  protein’s  activation  (181,  184).    While  it  has  not  
been  directly  studied  if  these  aptamers  can  block  FXIIa-­‐‑mediated  FXI  activation,  the  
aptamer  would  presumably  be  more  potent  if  it  could  block  these  two  subsequent  
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stages.    In  addition,  the  aPTT  and  TGA  used  here  only  measures  FXI  as  a  function  of  the  
contact  activation  pathway,  and  does  not  incorporate  feedback  activation  by  thrombin  
or  interactions  with  platelets.    The  cell  based  model  system,  however,  does  not  include  
FXII,  thus  the  inhibition  of  thrombin  generation  seen  in  this  system  indicates  that  the  
aptamer  does  affect  either  or  both  of  these  functions.    Further  biochemical  assays,  as  well  
as  a  TGA  assay  run  with  platelet-­‐‑rich  plasma,  can  determine  the  extent  of  inhibition  of  
either  of  these  functions.    
     Overall,  we  have  isolated  an  aptamer  inhibitor  of  FXIa  that  is  a  potent  inhibitor  
of  thrombin  generation.  Additional  biochemical  assays  would  assist  in  mapping  the  
binding  site  of  the  aptamer,  as  well  as  give  additional  information  into  the  mechanism  of  
thrombin  inhibition.    As  the  conditions  for  plasma  preparation  are  continually  being  
determined  for  each  species,  further  assessment  of  aptamer  activity  in  plasma  and  blood  
based  assays,  as  well  as  assessment  of  cross-­‐‑reactivity  of  the  aptamer  in  animal  plasmas  
will  be  necessary  in  order  to  determine  if  this  aptamer  is  potent  enough  to  move  
forward  into  clinical  trials.    As  FXI  may  have  a  slightly  more  prominent  role  in  
coagulation  than  FXII,  as  evident  by  FXI  deficiency  being  accompanied  with  a  mild  
bleeding  disorder,  the  development  of  a  specific  FXIa  inhibitor  is  promising  step  in  
finding  a  therapeutic  to  inhibit  thrombosis.    An  aptamer  inhibitor  of  FXI  is  attractive,  as  
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antidote,  thus  increasing  the  safety  and  providing  an  effective  therapeutic  to  treat  
thromboembolism.    
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4. Comparing the sensitivity of coagulation assays for 
target validation  
The  results  in  this  chapter  were  performed  as  part  of  a  collaboration  with  the  scientists  at  
Merck  Research  Labs  in  Rahway,  NJ.    
4.1 Introduction 
Clinically,  a  number  of  hemostatic  tests  are  available  that  serve  as  a  simple  
indicator  of  the  clotting  function  of  blood  in  a  human  being  by  determining  the  time  that  
it  takes  for  a  plasma  sample  to  clot.    These  tests  are  used  to  identify  or  assess  bleeding  
risk  in  patients  with  genetic  clotting  factor  defects  or  those  under  anticoagulant  therapy.    
In  reality,  these  clotting  times,  while  commonly  used,  do  not  always  correlate  with  
bleeding  phenotypes  and  cannot  detect  the  use  of  all  anticoagulants  (196,  217).    
Thrombin  is  the  pivotal  step  in  the  coagulation  cascade;  thus,  any  alteration  in  any  of  the  
components  responsible  for  making  thrombin  can  greatly  affect  bleeding  rates.    Aside  
from  the  clotting  time,  the  rate  of  thrombin  generation  or  the  peak  amount  of  thrombin  
generated  can  have  a  profound  affect  on  the  stability  of  a  clot  (64).    Thus,  a  more  
comprehensive  view  of  thrombin  dynamics  could  more  predictably  predict  bleeding  
rates  in  patients  with  genetic  defects  or  under  anticoagulant  therapy.      
The  thrombin  generation  assay  (TGA)  offers  this  more  comprehensive  and  global  
assessment  of  thrombin  formation,  as  it  uses  a  small  chromogenic  substrate  to  detect  
thrombin  generation  in  a  plasma  sample.    While  the  analysis  of  thrombin  generation  has  
been  around  for  decades,  the  development  of  an  automated  system  has  been  hampered  
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by  the  difficulties  of  measuring  optical  density  (thrombin  formation)  during  a  change  in  
turbidity  of  the  plasma  sample  due  to  clot  formation  (196).    The  introduction  of  a  slow-­‐‑
reacting  thrombin-­‐‑specific  fluorogenic  substrate  circumvented  this  problem,  and  the  
fluorescence  signal  is  converted  to  the  amount  of  thrombin  generated  as  a  function  of  
time  by  comparing  thrombin  generation  in  a  calibrated  parallel  sample  (196).    In  this  
way,  several  thrombograms,  the  graph  that  measures  thrombin  generation  overtime,  can  
be  measured  simply  and  reliably  in  many  samples  at  the  same  time  with  minimal  
manpower,  thus  making  it  an  excellent  candidate  for  use  in  the  clinic.  
In  general,  a  thrombogram  in  normal  plasma  follows  the  same  trend:    after  
activation  of  the  plasma  sample,  there  is  a  lagtime  during  which  the  coagulation  cascade  
is  generating  undetectable  amounts  of  thrombin  and  priming  the  cascade  for  a  large  
burst  of  thrombin.    Once  detectable  amounts  of  thrombin  have  formed  and  the  burst  of  
thrombin  generation  has  begun,  the  lagtime  has  ended,  and  is  generally  correlated  with  
the  formation  of  a  fibrin  clot  or  the  clotting  times  that  are  measured  in  the  mechanical  
aPTT  and  PT  assays.    During  the  burst  of  thrombin  generation,  thrombin  is  formed  very  
quickly,  with  a  steep  rate  of  reaction,  culminating  in  a  peak  amount  of  thrombin  being  
formed.    After  the  peak  is  reached,  thrombin  generation  slowly  tails  off,  as  coagulation  
factors  in  the  sample  have  been  used  or  are  inactivated.  These  measurable  parameters  
(lagtime,  peak  thrombin  generated,  total  amount  of  thrombin  formed,  etc.)  are  
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dependent  upon  the  type  of  activator  used;  commonly,  low  amounts  of  TF  (1pmol)  are  
used  and  are  generally  thought  to  be  the  most  physiological  setting  for  activation  (196).    
While  the  TGA  has  been  slowly  making  its  way  into  the  clinic,  it  has  found  a  
home  in  research  settings,  as  it  can  easily  be  used  to  study  the  contribution  of  clotting  
factors  to  thrombin  generation.    In  addition,  this  assay  is  well  suited  for  in  vitro  drug  
development  to  identify  drugs  that  affect  thrombin  dynamics  for  antithrombotic  
therapy.    Analysis  of  current  anticoagulant  drugs  have  determined  that  inhibition  of  the  
ETP  to  approximately  20-­‐‑40%  of  normal  results  in  stable  anticoagulation  (218),  while  
inhibition  of  the  ETP  to  less  than  20%  of  normal  is  correlated  with  bleeding  phenotypes  
(217).    Therefore,  this  assay  has  been  used  to  determine  a  target  therapeutic  window  of  
20-­‐‑40%  ETP  for  efficacious  and  safe  antithrombotic  administration.      
While  the  above  studies  have  primarily  been  carried  out  with  deficiencies  or  
drugs  that  target  the  common  or  extrinsic  pathway  of  coagulation,  recent  insight  into  the  
actions  of  the  intrinsic  pathway,  primarily  FXIIa-­‐‑mediated  FXI  activation,  have  led  to  the  
hypothesis  that  these  factors  may  be  involved  in  pathological  thrombus  formation,  but  
not  hemostasis  (40).    While  the  common  TGA  is  activated  through  the  extrinsic  pathway  
without  the  contribution  of  FXII,  a  standardized  TGA  activated  through  the  intrinsic  
pathway  would  be  beneficial  to  determine  the  effects  on  thrombin  generation  during  
inhibition  of  these  factors,  as  well  as  identify  potential  therapeutics.    
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Here,  we  developed  a  standardized  modified  TGA  (mTGA)  assay  that  is  
activated  by  ellagic  acid.    We  use  a  panel  of  anticoagulant  RNA  aptamers  that  
specifically  target  five  clotting  factors  (FII,  FX,  FIX,  FXI,  and  FXII)  to  assess  inhibition  of  
the  intrinsic  and  common  pathways  of  coagulation  in  this  assay,  as  well  as  compare  
thrombin  inhibition  in  the  mTGA  to  the  standard,  TF-­‐‑activated  TGA.    Aptamers  are  
single  stranded,  highly  structured  oligonucleotides  that  act  as  protein  antagonists  by  
binding  to  large  surface  areas  on  their  target  protein  to  directly  inhibit  protein-­‐‑protein  
interactions  (157).    The  aptamer  platform  is  a  promising  tool  for  anticoagulant  therapy,  
as  aptamer  administration  can  be  rapidly  and  effectively  reversed  by  a  sequence  specific  
or  universal  aptamer  antidote  (160,  165).    Currently,  an  aptamer  generated  against  FIXa  
and  its  matched  oligonucleotide  antidote  are  making  their  way  through  clinical  
development  (163,  164).    Using  these  aptamers  as  specific  anticoagulant  tools,  it  was  
found  that  this  assay  can  detect  inhibitors  of  the  intrinsic  and  common  pathway,  and  
will  be  useful  in  target  validation  for  analysis  of  an  anticoagulant  in  human  as  well  as  
animal  plasmas.    
  
4.2 Materials and Methods 
Materials  
The  2’F  modified  cytidine  and  uridine  were  purchased  from  Trilink  
BioTechnology    (San  Diego,  CA).  CTI  collection  tubes  were  purchased  from  
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Haematologic  Technologies  (Essex  Junction,  VT).    Human  normal  pooled  plasma  was  
purchased  from  George  King  Biomedical,  Inc.  (Overland  Park,  Kansas).  The  ellagic  




For  all  aptamer  sequences,  “C”  and  “U”  represent  2’fluorocytosine  and  
2’fluorouracil.    The  FII  aptamer  sequence  (58nt)  is  5’-­‐‑
GGCGGUCGAUCACACAGUUCAAACGUAAUAAGCCAAUGUACGAGGCAGACG
ACUCGCC-­‐‑3’  (181),  the  FX  aptamer  sequence  (80nt)  is  5’-­‐‑  
GGGAGGACGATGCGGACATCTCCGCACTCAGTTTGAGCACCAAACCAACAGCT
CCCAGACGACTCGCTGAGGATCCGAGA-­‐‑3’,  the  FIX  aptamer  sequence  (80nt)  is  5’-­‐‑  
GGGAGGACGATGCGGACTTGTCGGATAGGCCCTGATCCTAGTACACAAGACCA
AGCAGACGACTCGCTGAGGATCCGAGA-­‐‑3’,  the  FXI  aptamer  sequence  (71nt)  is  5’-­‐‑  
GGGAGGACGATGCGGTAACGCCACGCTCGACAACGCGTCGAGTGTCCTCCGCC
CCCAGACGACTCGCCCGA-­‐‑3’  and  the  FXII  aptamer  sequence  (51nt)  is  5’-­‐‑  
GGCTCGGCTGCCAGCAGGTCACGAGTCGCAGCGACTCGCTGAGGATCCGAG-­‐‑3’.    
The  FII  and  FXII  control  aptamer  sequence  (51nt)  is  5’-­‐‑  
GGGGCAGCCGTGGACCGACTGCCGCATGCCATTGACAGTCCGATGCCAGGC-­‐‑3’,  the  FIX  
and  FX  control  aptamer  sequence  (80nt)  is  5’-­‐‑  GGGAGGACGAUGCGG-­‐‑N40-­‐‑
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CAGACGACUCGCUGAGGAUCCGAGA-­‐‑3’  and  the  FXI  control  aptamer  sequence  (71nt)  is  5’-­‐‑  
GGGAGGACGATGCGG-­‐‑N40-­‐‑CAGACGACTCGCCCGA-­‐‑3’.    
All  aptamers  were  transcribed  in  vitro  as  previously  described  using  a  modified  
polymerase  that  can  incorporate  2’F  cytidine  triphosphates  and  2’F  uridine  
triphosphates  (194).    Before  use,  all  aptamer  preparations  were  diluted  into  a  Hepes-­‐‑
based  buffer  (20mM  Hepes,  150mM  NaCl,  2mM  CaCl2).    Diluted  aptamers  were  refolded  




Activated  partial  thromboplastin  time  (aPTT)  and  prothrombin  time  (PT)  assays  
were  carried  out  using  a  model  ST4  coagulometer  (Diagnostica  Stago,  Parsippany,  NJ).    
Pooled  normal  human  platelet  poor  plasma  was  prepared  by  drawing  blood  into  
sodium  citrate  tubes.  For  the  aPTT,  aptamer  (5µμL)  was  then  added  to  50µL  pooled  
normal  human  platelet  poor  plasma  and  incubated  for  5  minutes  at  37°C.    50µL  APTT-­‐‑
XL  Reagent  was  then  added  to  activate  plasma  and  incubated  for  5  minutes  at  37°C.    
Clotting  was  initiated  by  adding  50µL  of  25mM  CaCl2  and  the  time  to  clot  formation  was  
recorded.    Aptamer  concentrations  represent  the  final  concentration  in  the  entire  
reaction.  
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   For  the  PT,  refolded  aptamer  (5µμL)  was  added  to  50  µL  pooled  normal  human  
platelet  poor  plasma  and  incubated  for  5  minutes  at  37°C.      TriniClot  PT  Excel  (Trinity  
BioTech,  Bray,  Co  Wicklow,  Ireland)  was  added  to  initiate  clotting.    
  
Thrombin  Generation  Assay  
In  an  Immulon  2HB  clear  U-­‐‑bottom  96  well  plate  (Thermo  Labsystems,  Franklin,  
MA),  CTI-­‐‑  treated  (50µμg/mL),  pooled  normal  human  platelet  poor  plasma  from  healthy,  
consented  volunteers  (60µμL)  was  mixed  with  aptamers  (3µμL)  diluted  in  Hepes-­‐‑based  
buffer  without  BSA  and  incubated  for  5  min  at  37oC.  Ellagic  acid  reagent  (final  
concentration  0.1µμM,  diluted  1:200  with  4µμM  phospholipid  vesicles  (20%  
phosphatidylserine,  60%  phosphatidylcholine,  20%  phosphatidylethanolamine)  in  
Hepes-­‐‑based  buffered  saline)(15µμL)  was  added  to  the  plasma-­‐‑aptamer  mixture,  and  
incubated  for  5  minutes  at  37oC.  Flu-­‐‑Ca  (Diagnostica  Stago)(15µμL)  was  added  to  start  the  
assay  and  thrombin  generation  was  measured  using  a  Fluroskan  Ascent  Reader  
(Thermo  Scientific,  Waltham,  MA).    A  thrombin  calibrator  reagent  (Diagnostica  Stago,  
Parsippany,  NJ)  was  used  to  quantify  the  amount  of  thrombin  generated  in  the  samples.    
Data  analysis  was  performed  using  Thrombinoscope  software  (Thrombinoscope  BV,  the  
Netherlands).  Aptamer  concentrations  represent  the  final  concentration  in  the  entire  
reaction.  The  amount  of  ellagic  acid  used  was  standardized  to  produce  a  similar  curve  to  
a  TF-­‐‑activated  TGA.    In  addition,  the  amount  of  CTI  present  was  standardized  to  inhibit  
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contact  activation  of  the  plasma  sample,  while  still  allowing  for  robust  FXII-­‐‑dependent  
activation  upon  administration  of  ellagic  acid.    
  
Thromboelastogram  
   Blood  was  drawn  from  healthy  volunteers  into  standard  sodium  citrate  tubes.    
Whole  blood  (320µμL)  was  mixed  with  aptamer  (10µμL)  and  incubated  at  room  
temperature  for  5  minutes.    Kaolin  (10µμL)(Haemonetics,  Niles,  IL)  was  added,  and  the  
entire  reaction  (340µμL)  was  added  to  20µμL  CaCl2  in  a  disposable,  plain  TEG  cup  
(Haemonetics).    Clot  formation  was  measured  at  37oC  with  a  Thromboelastograph  
Analyzer  (Haemonetics)  until  a  stable  clot  was  formed.  Parameters  were  automatically  
calculated  using  the  TEG®  Analytical  Software  version  4.2.3  (Haemonetics).    
  
4.3 Results 
4.3.1 Modified TGA assay validation 
In  order  to  evaluate  inhibition  of  the  intrinsic  pathway  of  coagulation,  as  well  as  
the  common  pathway  in  the  TGA,  the  standard  TF-­‐‑activated  TGA  was  modified  so  that  
plasma  samples  were  activated  with  diluted  ellagic  acid  aPTT  reagent,  thus  
autoactivating  FXII  to  stimulate  thrombin  generation  through  the  intrinsic  pathway.    
During  the  development  of  this  assay,  it  was  recognized  that  activation  of  the  plasma  
sample  occurs  relatively  easily  during  the  blood  drawing  or  plasma  preparation  process,  
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as  samples  with  only  added  phospholipids  and  calcium  were  able  to  generate  thrombin  
without  an  activator  present  (data  not  shown).    Activation  of  the  plasma  sample  is  
thought  to  occur  through  the  contact  pathway,  as  FXII  can  be  readily  autoactivated  upon  
exposure  to  foreign  surfaces,  resulting  in  activated  FXII  and  FXI  in  the  plasma  sample.  
While  this  does  not  pose  a  problem  in  the  standard  TF-­‐‑activated  assay,  as  calcium  is  
needed  for  extrinsic  pathway  reactions,  as  well  as  the  activation  of  FIX  by  FXI,  prior  
activation  of  the  intrinsic  pathway  in  the  plasma  sample  will  confound  results  in  an  
intrinsic  pathway  based  assay.    Therefore,  a  standardized  amount  of  corn  trypsin  
inhibitor  (CTI),  an  irreversible  FXIIa  inhibitor,  was  used  to  inhibit  any  FXIIa  that  may  
become  activated  during  the  blood  draw  or  plasma  preparation  process.    Importantly,  
only  enough  CTI  was  used  to  inhibit  activation  of  FXII  in  this  process,  and  not  further  
inhibit  FXII  during  activation  in  the  assay.    
To  assess  inhibition  in  the  mTGA  assay,  a  panel  of  RNA  aptamers  was  used  to  
determine  thrombin  generation  during  inhibition  of  each  coagulation  factor  in  the  
intrinsic  and  common  pathways.    Each  of  these  aptamers  have  slightly  different  binding  
properties  to  their  respective  target  (Table  10);  however,  each  is  specific  for  binding  to  
only  their  specific  protease.    Although  the  exact  mechanisms  of  all  of  these  aptamers  
have  not  been  evaluated,  aptamers  tend  to  bind  to  exosites  on  the  surface  of  their  
protein,  and  thus  inhibit  protein-­‐‑protein  interactions  that  are  essential  for  their  
coagulant  function  (157,  181).    
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Table  10.  Summary  of  aptamer  properties  
Aptamer  Target   Length  (nt)   Kd  Zymogen  (nM)   Kd  Protease  (nM)  
FII   58   10.0   1.0  
FX   80   136.0   39.0  
FIX   80   0.7   0.4  
FXI   71   139.2   84.9  
FXII   51   12.9   0.4  
  
Inhibition  of  each  coagulation  factor  in  the  common  (FII  and  FX)  and  intrinsic  
(FIX,  FXI,  FXII)  pathways  were  detected  in  the  modified  TGA  (mTGA)  upon  
administration  of  aptamers.    Dose  titrations  of  each  aptamer  exhibited  a  distinct  
inhibition  profile:  full  inhibition  of  FII,  FX,  and  FIX  completely  abolished  thrombin  
generation  while  inhibition  of  FXI  and  FXII  reduced,  but  did  not  completely  inhibit  
thrombin  generation  (Figure  33).  Further  analysis  and  comparison  of  individual  TGA  
parameters  during  aptamer  inhibition  is  discussed  below.  
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Figure  33.  Dose  titrations  of  the  panel  of  aptamers  in  the  mTGA  
Thrombograms  of  normal  pooled  plasma  activated  with  200x-­‐‑diluted  ellagic  acid  with  
indicated  concentrations  of  A)  FII  Aptamer,  B)  FX  Aptamer,  C)  FIX  aptamer,  D)  FXI  
Aptamer,  and  E)  FXII  Aptamer.  Preliminary  data  represent  one  assay.  
  
Comparison  of  the  mTGA  versus  the  standard  TF-­‐‑activated  TGA  was  analyzed  
by  comparing  parameters  of  both  assays  during  inhibition  of  either  FX  (common  
pathway)  or  FIX  (intrinsic  pathway).    As  a  common  pathway  coagulation  factor,  
inhibition  of  FX  in  both  assays  gave  comparable  results,  with  the  FX  aptamer  in  TF-­‐‑
activated  (Figures  34A,C,E)  and  ellagic  acid  activated  (Figure  34B,D,F)  exhibiting  similar  
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potency  in  thrombograms  (Figure  34A,B),  ETP  (Figure  34C,D)  and  the  peak  amount  of  
thrombin  generated  (Figure  34E,F).    Both  assays  were  able  to  detect  a  complete  
inhibition  of  thrombin  generation  at  saturating  concentrations  of  the  FX  aptamer,  with  a  
slightly  steeper  dose  response  curve  in  the  modified  TGA  versus  the  low  TF  activated  
TGA.    
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Figure  34.    Comparison  of  the  inhibition  of  the  common  pathway  with  the  FX  
aptamer  during  the  standard  TF-­‐‑activated  TGA  versus  the  modified  ellagic  acid-­‐‑
activated  TGA  
Normal  pooled  plasma  was  mixed  with  the  FX  aptamer  and  activated  with  either  low  
(1pM)  TF  (A,C,E)  or  200x-­‐‑diluted  ellagic  acid  (B,  D,  F).    A)  and  B)  represent  
thrombograms  of  the  FX  aptamer  at  indicated  concentrations.    C)  and  D)  are  the  ETP  
and  E)  and  F)  are  the  peak  thrombin  generated  of  the  FX  aptamer  (n)  and  a  library  size-­‐‑
matched  control  RNA  (p).  Preliminary  data  represent  one  assay.  
  
Comparison  of  the  standard  and  mTGA  assays  during  inhibition  of  the  lower  
intrinsic  pathway  of  coagulation  was  assessed  using  an  aptamer  targeting  FIX.    FIX  can  
be  activated  through  FXI  (intrinsic  pathway)  or  at  a  smaller  extent  through  the  TF/FVIIa  
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complex  (extrinsic  pathway).    Activating  the  TGA  with  ellagic  acid  forces  thrombin  
generation  to  proceed  mainly  through  the  intrinsic  pathway,  thus  analyzing  FXI  
activation  of  FIX,  while  activating  the  TGA  with  TF  allows  for  the  TF/FVIIa  to  activate  
FIX  as  well  as  activate  the  common  pathway  directly  through  FX.    The  mTGA  was  more  
sensitive  to  FIX  inhibition,  as  saturating  concentrations  of  the  aptamer  were  able  to  
completely  inhibit  thrombin  generation  (Figure  35B,D,F).    In  contrast,  high  amounts  of  
aptamer  were  not  able  to  fully  inhibit  thrombin  generation  in  the  TF-­‐‑activated  assay  
(Figure  35A,  C,  E).  
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Figure  35.  Comparison  of  the  inhibition  of  the  intrinsic  pathway  during  the  
standard  TF-­‐‑activated  TGA  versus  the  modified  ellagic  acid-­‐‑activated  TGA  
Normal  pooled  plasma  was  mixed  with  the  FIX  aptamer  and  activated  with  either  low  
(1pM)  TF  (A,C,E)  or  200x-­‐‑diluted  ellagic  acid  (B,  D,  F).    A)  and  B)  represent  
thrombograms  of  the  FX  aptamer  at  indicated  concentrations.    C)  and  D)  are  the  ETP  
and  E)  and  F)  are  the  peak  thrombin  generated  of  the  FIX  aptamer  (n)  and  a  library  size-­‐‑
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4.3.2 Modified TGA parameter analysis upon aptamer inhibition 
Analysis  of  thrombogram  parameters  can  further  validate  the  modified  TGA  
assay,  as  well  as  give  insight  into  the  mechanisms  of  inhibition  of  each  individual  
coagulation  factor  when  thrombin  generation  is  initiated  by  the  intrinsic  pathway.    First,  
the  ETP  for  each  aptamer  was  analyzed  (Figure  36).    The  ETP  represents  the  total  
amount  of  thrombin  generated  over  time,  and  is  determined  by  calculating  the  area  
under  the  thrombin  generation  curve.    Full  inhibition  of  the  common  pathway,  as  well  
as  FIX  and  FXI,  completely  inhibited  thrombin  generation  in  this  assay,  as  the  ETP  of  
each  sample  was  zero  or  a  negligible  amount.    Inhibition  of  FXII  with  the  RNA  aptamer,  
however,  only  decreased  the  ETP,  but  did  not  completely  shut  down  thrombin  
generation.  
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Figure  36.    Comparison  of  the  endogenous  thrombin  potential  (ETP)  during  
aptamer  inhibition  in  the  modified  ellagic  acid-­‐‑activated  TGA  
Normal  pooled  plasma  was  mixed  with  either  the  indicated  aptamer    (n)  or  a  size-­‐‑
matched  control  RNA  (p)  and  activated  with  200x-­‐‑diluted  ellagic  acid.    The  ETP  was  
calculated  using  the  Thrombinoscope  software.    A)  FII  Aptamer,  B)  FX  Aptamer,  C)  FIX  
Aptamer,  D)  FIX  Aptamer,  E)  FXII  Aptamer.    The  preliminary  data  represent  one  or  
more  assays.  
  
Next,  the  peak  amount  of  thrombin  formed  was  analyzed  during  aptamer  
administration.    The  peak  is  measured  by  calculating  the  maximum  amount  of  thrombin  
formed,  which  is  the  peak  of  the  thrombin  generation  curve.    Analysis  of  this  parameter  
in  the  mTGA  behaves  similarly  to  the  ETP  with  aptamer  inhibition  of  FIX,  FX,  and  FII  
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exhibiting  a  steep  dose  response  curve  (Figure  37A,B,C).    Inhibition  of  FXI  and  FXII  
more  slowly  reduced  the  peak,  with  maximal  inhibition  able  to  severely  diminish  the  
peak  without  completely  abolishing  thrombin  generation  (Figure  37D,E).    This  is  in  
contrast  to  the  ETP,  as  the  FXII  aptamer  was  able  to  greatly  reduce  the  peak  amount  of  
thrombin  formed  without  having  such  affect  on  the  ETP  (Figure  37E).    
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Figure  37.    Comparison  of  the  peak  amount  of  thrombin  formed  during  
aptamer  inhibition  in  the  modified  ellagic  acid-­‐‑activated  TGA  
Normal  pooled  plasma  was  mixed  with  either  the  indicated  aptamer    (n)  or  a  size-­‐‑
matched  control  RNA  (p)  and  activated  with  200x-­‐‑diluted  ellagic  acid.    The  peak  
amount  of  thrombin  generated  was  calculated  using  the  Thrombinoscope  software.    A)  
FII  Aptamer,  B)  FX  Aptamer,  C)  FIX  Aptamer,  D)  FIX  Aptamer,  E)  FXII  Aptamer.    The  
preliminary  data  represent  one  or  more  assays.  
  
  Next,  the  rate  of  thrombin  generation  upon  aptamer  administration  was  
analyzed.  This  parameter  measures  the  slope  of  the  amount  of  thrombin  formed  from  
the  first  amount  of  thrombin  generated  (lagtime)  to  the  maximum  amount  of  thrombin  
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generated  (peak).    Similarly  to  the  ETP  and  peak  amount  of  thrombin  generated,  
inhibition  of  the  common  pathway  (FII  and  FX)  exhibited  a  steep  dose-­‐‑response  
inhibition,  as  smaller  aptamer  doses  had  no  effect  on  the  rate  of  thrombin  generation,  
but  the  rate  of  thrombin  generation  was  suddenly  abolished  at  higher  doses  (Figure  38).    
Inhibition  of  the  intrinsic  pathway  (FIX,  FXI,  FXII)  exhibited  a  much  slower  rate  of  
reduction  of  thrombin  generation.    For  every  aptamer,  administration  of  the  control  
aptamer  was  able  to  increase  the  rate  of  thrombin  generation  dose-­‐‑dependently,  while  
having  differing  affects  on  the  other  parameters.      
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Figure  38.    Comparison  of  the  rate  of  thrombin  generation  during  aptamer  
inhibition  in  the  modified  ellagic  acid-­‐‑activated  TGA  
Normal  pooled  plasma  was  mixed  with  either  the  indicated  aptamer    (n)  or  a  size-­‐‑
matched  control  RNA  (p)  and  activated  with  200x-­‐‑diluted  ellagic  acid.    The  rate  of  
thrombin  generation  was  calculated  using  the  Thrombinoscope  software.    A)  FII  
Aptamer,  B)  FX  Aptamer,  C)  FIX  Aptamer,  D)  FIX  Aptamer,  E)  FXII  Aptamer.    The  
preliminary  data  represent  one  or  more  assays.  
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The  lagtime  measures  the  time  it  takes  for  the  first  amount  of  thrombin  to  be  
formed,  thus  it  is  considered  to  be  the  time  at  which  clotting  first  occurs.    Full  inhibition  
of  the  common  pathway  does  not  form  thrombin,  thus,  the  lagtime  cannot  be  computed  
at  the  higher  aptamer  concentrations  and  these  data  points  are  missing  (Figure  39A  and  
B).    Inhibition  of  FIX  greatly  increases  the  lagtime,  while  inhibition  of  FXI  and  FXII  does  
not  prolong  the  lagtime  as  severely  compared  to  the  other  aptamers  (Figure  39).    
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Figure  39.    Comparison  of  the  lagtime  during  aptamer  inhibition  in  the  
modified  ellagic  acid-­‐‑activated  TGA  
Normal  pooled  plasma  was  mixed  with  either  the  indicated  aptamer    (n)  or  a  size-­‐‑
matched  control  RNA  (p)  and  activated  with  200x-­‐‑diluted  ellagic  acid.    The  lagtime  was  
calculated  using  the  Thrombinoscope  software.    A)  FII  Aptamer,  B)  FX  Aptamer,  C)  FIX  
Aptamer,  D)  FIX  Aptamer,  E)  FXII  Aptamer.    The  preliminary  data  represent  one  or  
more  assays.  
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4.3.3 Comparison of aptamer inhibition and mTGA validation in 
human plasma and blood-based coagulation assays 
Two  common  coagulation  tests,  the  activated  partial  thromboplastin  time  (aPTT)  
and  the  thrombin  generation  assay  (TGA),  also  measure  the  lagtime  of  clot  formation  in  
plasma.  The  aPTT  assay  uses  the  same  activator,  ellagic  acid,  to  activate  FXII  and  thus  
initiate  clotting  through  the  intrinsic  pathway.    The  PT  uses  TF  to  activate  the  extrinsic  
pathway,  and  thus  measures  the  function  of  the  extrinsic  pathway  of  coagulation.    All  
aptamers  prolonged  the  clotting  time  in  the  aPTT,  with  inhibition  of  the  common  
pathway  having  a  maximum  effect  (Figure  40A).    Similar  to  the  mTGA,  inhibition  of  the  
intrinsic  pathway  could  prolong  clot  time  maximally  with  FIX,  intermediately  with  FXII,  
and  only  slightly  with  FXI  (Figure  40A).    In  the  PT,  inhibition  of  the  intrinsic  pathway  
did  not  have  an  effect,  while  inhibition  of  the  common  pathway  produced  a  robust  effect  
in  clot  time,  with  the  FII  aptamer  inhibiting  clot  formation  past  the  assay  maximum  
(Figure  40B).    
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Figure  40.    Comparison  of  clotting  times  during  aptamer  inhibition  in  an  aPTT  
and  PT  with  human  plasma  
Normal  pooled  plasma  was  mixed  with  the  indicated  aptamer  and  activated  with  either  
A)  aPTT  reagent  or  B)  PT  reagent.    The  data  represent  one  or  more  assays.  
  
  
In  addition  to  the  plasma  based  assays,  an  experiment  utilizing  whole  blood  and  
the  presence  of  platelets  would  also  give  detailed  information  about  the  dynamics  of  
inhibition  in  a  complete  setting.    Thromboelastography  uses  whole  blood  to  study  the  
kinetics  of  clot  formation  by  using  mechanical  motion  to  analyze  clot  strength.    The  two  
parameters  studied  included  the  lagtime  (the  time  until  clot  formation)  and  the  
maximum  amplitude  (the  strength  of  the  clot  formed).    Table  11  summarizes  the  data  
from  aptamer  dose-­‐‑titrations  performed  with  kaolin  as  the  intrinsic  pathway  activator.    
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Whereas  all  of  the  aptamers  except  the  FXII  aptamer  could  prolong  the  lagtime,  none  of  
the  aptamers  had  a  large  effect  on  the  maximum  amplitude  of  the  system.  
  
Table  11.  Summary  of  preliminary  TEG  parameters  with  the  panel  of  aptamers  
in  human  whole  blood  
Aptamer  Target   FII   FX   FIX   FXI   FXII  
Lagtime  
(Doubling  Time)  















In  order  to  determine  the  most  sensitive  coagulation  assay  for  target  and  
inhibitor  validation,  the  panel  of  aptamers  were  compared  in  the  TGA,  the  aPTT/PT,  and  
the  TEG  for  either  doubling  time  (aPTT/PT  and  TEG)  or  IC50  (calculated  from  the  peak  
amount  of  thrombin  generated  in  the  modified  TGA)  (Table  12).    Importantly,  the  
modified  TGA  was  the  only  assay  in  which  CTI  was  added  to  the  collection  tube  during  
the  blood  draw  so  as  to  inhibit  contact  activation  of  the  sample,  resulting  in  more  
sensitivity  to  aptamer  inhibition  with  all  but  the  FII  aptamer.  
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Table  12.    Summary  of  aptamer  effects  in  clinical  coagulation  assays  on  human  
plasma  or  blood  
Aptamer  Target   FII   FX   FIX   FXI   FXII  
aPTT    
(Doubling  Time)  
0.7µμM   0.4µμM   0.1µμM   5µμM   1µμM  
PT    
(Doubling  Time)  
0.15µμM   0.5µμM   No  effect   No  effect   No  effect  
TEG    
(Doubling  Time)  
4µμM   2.6µμM   0.17µμM   5.1µμM   No  effect  
mTGA    
(IC50)  
3.0µμM   0.3µμM   <0.1µμM   <1.0µμM   0.2µμM  
  
4.3.4 Comparison of aptamer inhibition and mTGA validation in 
animal plasma and blood-based coagulation assays 
Before  a  drug  can  proceed  into  human  clinical  trials,  it  must  first  be  extensively  
studied  in  animals  for  safety  and  efficacy.    Because  most  coagulation  assays  are  blood  or  
plasma  based,  they  are  easily  adapted  for  assessing  drug  inhibition  with  animal  
plasmas.    All  of  the  aptamers  used  here  are  isolated  solely  against  the  human  form  of  the  
coagulation  factor;  thus,  analysis  for  cross  reactivity  in  animal  plasma  is  a  must  before  
proceeding  into  pre-­‐‑clinical  trials.    In  general,  aptamers  have  exhibited  some  efficacy  in  
a  variety  of  species;  however,  the  cross-­‐‑reactive  species  varies  from  aptamer  to  aptamer.    
The  panel  of  aptamers  was  tested  in  rabbit  plasma  or  blood  in  the  aPTT/PT,  TEG,  and  
mTGA  assays  for  cross-­‐‑reactivity  (Table  13).    Only  the  FII  and  FX  aptamers  were  able  to  
exhibit  cross  reactivity  in  rabbit  plasma  as  determined  by  the  aPTT  and  the  mTGA;  
however,  these  aptamers  did  not  exhibit  high  efficacy  in  either  the  PT  or  the  TEG.    
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Aptamers  targeting  the  intrinsic  pathway  (FIX,  FXI  and  FXII)  did  not  show  reproducible  
efficacy  in  rabbit  plasma.    
  
Table  13.  Summary  of  aptamer  effects  in  clinical  coagulation  assays  on  rabbit  
plasma  or  blood  
  *Doubling  time  was  not  reached  at  the  highest  concentration  tested.  
Aptamer  Target   FII   FX   FIX   FXI   FXII  
aPTT    
(Doubling  Time)  
1.5µμM   1.5µμM   No  effect   No  effect   8µμM  
PT    
(Doubling  Time)  
>8µμM*   >4µμM*   No  effect   No  effect   No  effect  
TEG    
(Doubling  Time)  
  2.7µμM  (IC50)   No  effect   No  effect   No  effect   No  effect  
mTGA    
(IC50)  
5µμM   1.2µμM   No  effect   No  effect   No  effect  
  
4.4 Discussion  
The  standard  TF-­‐‑activated  TGA  offers  a  comprehensive  view  of  thrombin  
dynamics,  generating  more  information  on  how  deficiencies  or  drug-­‐‑inhibition  of  
coagulation  factors  affect  thrombin  generation  than  any  other  common  clinical  
coagulation  test.  However,  the  standard  TGA  proceeds  without  contribution  of  the  
intrinsic  pathway  of  coagulation  (FXII).    While  physiologic  hemostasis  is  thought  to  
occur  mainly  through  the  extrinsic  pathway,  thus  mirroring  the  standard  TGA,  intrinsic  
pathway  activation  is  thought  to  occur  through  continued  thrombin  generation  at  the  
site  of  the  growing  thrombus  (39).    To  this  end,  a  modified  TGA  assay  that  stimulates  
thrombin  generation  through  the  intrinsic  pathway  was  developed  in  order  to  study  
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thrombin  generation  during  intrinsic  pathway  inhibition  as  well  as  identify  potent  
inhibitors  of  this  pathway.    
   Aptamers  targeting  both  the  common  pathway  (FII  and  FX)  and  the  intrinsic  
pathway  (FIX,  FXI,  and  FXII)  were  used  to  validate  the  modified  TGA,  compare  the  
inhibition  of  thrombin  generation  in  both  assays,  as  well  as  compare  thrombin  
generation  during  inhibition  of  each  pathway  and  individual  clotting  factor.    First,  the  
strength  of  activator  used  to  initiate  the  intrinsic  pathway  was  calibrated  to  exhibit  a  
similar  pattern  of  thrombin  generation  seen  in  the  standard  TF-­‐‑activated  TGA.    The  
mTGA  was  able  to  detect  significant  decreases  in  thrombin  generation  upon  inhibition  
of  all  targets  tested,  in  both  the  intrinsic  and  common  pathways.    Inhibition  of  FII  and  
FX  of  the  common  pathway  completely  abolished  thrombin  generation  as  expected  since  
these  factors  are  essential  for  thrombin  and  fibrin  clot  formation  (1).    Thrombin  
generation  during  inhibition  of  the  intrinsic  pathway  varied  depending  upon  the  target.    
While  inhibition  of  FIX  and  FXI  severely  reduced  thrombin  generation  to  negligible  
amounts,  inhibition  of  FXII  could  only  lower  the  amount  of  thrombin  formed.    Like  FXII,  
FXI  has  been  shown  to  be  autoactivated  upon  contacting  certain  negative  surfaces,  such  
as  dextran  sulfate.    While  it  was  not  tested  whether  ellagic  acid  could  autoactivate  FXI  
itself,  some  FXI  activation  would  bypass  the  need  for  FXII  to  generate  thrombin.    In  
addition,  some  contact  activation  of  the  plasma  sample,  as  occurs  during  the  blood  
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drawing  process,  could  also  contribute  to  downstream  activation  of  clotting  factors  that  
would  affect  thrombin  generation  upon  inhibition  of  FXII.  
   The  standard  TF-­‐‑activated  TGA  was  compared  to  the  ellagic  acid-­‐‑activated  
mTGA  during  inhibition  of  the  common  pathway  (FX)  and  the  intrinsic  pathway  (FIX).    
Comparison  of  the  ETP  and  peak  amount  of  thrombin  formed  during  inhibition  of  FX  
was  similar  between  the  two  assays.    As  the  intrinsic  and  extrinsic  pathway  converge  
upon  activation  of  FX,  this  result  suggests  that  both  assays  proceed  similarly  once  the  
common  pathway  is  activated.    On  the  other  hand,  there  were  differences  in  thrombin  
generation  upon  inhibition  of  FIX.    FIX  is  thought  to  be  primarily  activated  by  FXI,  
however,  the  TF/FVIIa  complex  can  activate  small  amounts  of  FIX  in  the  initiation  phase  
of  thrombin  generation  as  well  as  directly  activating  FX.    This  was  mirrored  during  
comparison  of  the  two  assays,  as  the  TF-­‐‑activated  TGA  only  lowered  thrombin  
generation,  with  a  substantial  amount  of  thrombin  still  able  to  be  formed.    In  the  mTGA,  
which  is  activated  through  the  intrinsic  pathway,  thrombin  generation  was  essentially  
abolished,  as  only  negligible  amounts  of  thrombin  were  able  to  be  detected  upon  full  
FIX  inhibition.    This  result  highlights  the  differences  in  the  two  assays,  and  validates  the  
mTGA  in  proceeding  primarily  through  the  intrinsic  pathway.  
   Further  analysis  into  the  individual  parameters  of  the  mTGA  upon  inhibition  
with  each  aptamer  exhibited  certain  trends  consistent  with  the  roles  of  each  factor  in  
thrombin  generation.    Inhibition  of  FII  and  FX  of  the  common  pathway  was  able  to  
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completely  abolish  thrombin  generation  to  the  point  where  no  parameters  could  be  
computed.    Both  of  these  aptamers  exhibited  a  steep  dose  titration  curve,  as  thrombin  
generation  seemingly  was  either  all-­‐‑on  or  all-­‐‑off.    This  result  was  in  part  mirrored  in  an  
assay  utilizing  a  cell-­‐‑based  model  of  thrombin  generation,  an  in  vitro  system  using  
cultured  macrophages  as  a  source  of  tissue  factor,  physiologic  amounts  of  purified  
proteins,  and  platelets  that  serve  as  the  surface  for  thrombin  generation  to  occur.  In  this  
assay,  only  small  levels  of  FX  were  needed  to  normalize  parameters,  similar  to  the  steep  
dose  titration  seen  here  as  well  as  previous  data  using  the  extrinsic  activated  TGA  (64)  
(217).      
     As  FIX  has  roles  in  both  the  intrinsic  and  extrinsic  pathway,  its  thrombin  
generation  profile  was  comparatively  “in  the  middle”  between  common  pathway  
inhibitors  and  other  intrinsic  pathway  inhibitors.    Inhibition  of  FIX  led  to  a  marked  
increased  in  the  lagtime,  and  high  concentrations  of  the  aptamer  were  able  to  completely  
inhibit  thrombin  generation.    However,  this  aptamer  had  a  slightly  slower  onset  of  
action  compared  to  the  FII  and  FX  aptamers.    In  contrast,  inhibition  of  FXI  and  FXII  
could  not  completely  inhibit  thrombin  generation,  although  both  aptamers  severely  
impaired  the  peak  and  rate  of  thrombin  generation,  consistent  with  the  finding  that  
inhibition  of  factors  contributing  to  tenase  complex  formation  primarily  affects  these  
parameters  (64).    While  FXI  could  also  greatly  inhibit  the  ETP,  FXII  had  a  much  smaller  
effect  on  the  ETP,  perhaps  reflecting  that  FXI  could  be  activated  in  the  plasma  sample  by  
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several  ways.    In  contrast  to  the  other  aptamers,  inhibition  of  FXI  and  FXII  only  slightly  
increased  the  lagtime  of  the  sample,  the  parameter  that  is  solely  measured  in  the  aPTT.    
Thus,  it  seems  that  inhibition  of  FXI  and  FXII  is  better  analyzed  in  the  mTGA  than  
traditional  clotting  time  assays,  as  both  of  these  aptamers  could  maximally  affect  other  
thrombin  generation  parameters  with  minimal  disturbance  of  the  lagtime.      
Because  of  the  sensitivity  of  this  assay  to  contact  activation,  a  standardized  
amount  of  CTI  was  included  in  the  collection  tube  during  the  blood  draw  in  order  to  
inhibit  contact  activation  during  the  blood  drawing  and  plasma  preparation  process.    
While  human  blood  is  easily  activated  during  the  blood  drawing  process,  rodent  blood  
is  highly  attune  to  contact  activation  as  well.    In  our  experience,  each  animal  species  
requires  a  certain  amount  of  CTI  present  during  the  blood  draw  to  inhibit  contact  
pathway  activation.    Rabbit  was  chosen  as  the  species  of  choice  due  to  quantity  of  blood  
drawn  and  regularity  in  the  blood  drawing  process,  so  as  to  obtain  a  decent  number  of  
plasma  samples  that  have  not  been  contact  activated.    In  comparison,  it  is  difficult  to  
obtain  the  volume  of  plasma  needed  that  is  not  contact  activated  in  rats,  as  more  than  
half  of  the  samples  drawn  are  contact  activated  (verbal  communication).    
In  comparing  aptamer  efficacy  across  the  panel  of  coagulation  assays  performed  
with  rabbit  blood  or  plasma,  only  the  common  pathway  inhibitors  (FII  or  FX)  were  able  
to  exhibit  cross-­‐‑reactivity.    Intriguingly,  both  aptamers  were  only  able  to  inhibit  
thrombin  generation  effectively  in  the  aPTT  or  mTGA  in  rabbit  plasma  -­‐‑  both  assays  that  
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are  activated  by  ellagic  acid.  Inhibition  of  FII  in  the  kaolin-­‐‑activated  TEG  was  able  to  
prolong  the  time  for  a  clot  to  occur,  but  did  not  reach  doubling  time  at  the  
concentrations  tested.    The  FX  aptamer,  however,  did  not  show  any  effect  in  the  TEG  in  
rabbit  plasma.    In  addition,  both  aptamers  did  not  have  an  effect  in  the  TF-­‐‑activated  PT  
assay.    This  suggests  that  rabbit  plasma  may  act  differently  than  humans,  with  the  
extrinsic  system  perhaps  not  being  as  important  in  initiating  coagulation.    In  addition,  
the  fact  that  none  of  the  three  intrinsic  pathway  aptamers  were  able  to  cross  react  in  this  
species  suggests  that  these  proteins  may  be  quite  different  from  the  human  proteins,  and  
perhaps  act  in  a  different  manner.    Studies  of  cross-­‐‑reactivity  with  the  entire  panel  of  
aptamers  in  rat  and  non-­‐‑human  primates  are  currently  underway.      
Overall,  the  modified  TGA  is  the  most  sensitive  and  informative  assay  used  to  
study  both  intrinsic  and  common  pathway  inhibition.    Inhibition  of  any  of  these  
coagulation  factors  can  affect  a  number  of  parameters  that  are  easily  analyzed  using  the  
mTGA,  while  each  of  the  other  assays  tested  here  primarily  measure  the  lagtime.    While  
this  study  focused  on  the  use  of  RNA  aptamers  targeting  each  specific  coagulation  
factor,  data  with  small  molecule  and  antibody  inhibitors  also  exhibited  similar  trends,  
albeit  with  different  mechanisms  of  inhibition  (data  not  shown).    Further  analysis  and  
comparison  between  thrombin  inhibition  patterns  and  mechanism  of  small  molecules  
versus  aptamer  could  give  insight  into  coagulation  target  validation  for  the  type  of  
therapy  being  developed.    In  addition,  further  validation  and  analysis  of  coagulation  
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factor  inhibitors  in  animal  models  versus  mTGA  assessment  will  also  aide  in  the  ability  
of  this  assay  to  identify  potent  antithrombotics.    
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5. Conclusions and Perspectives 
5.1 The rationale behind developing aptamer inhibitors of the 
intrinsic pathway of coagulation   
Traditionally,  the  hemostatic  system  of  proteins  and  zymogens  involved  in  
maintaining  the  integrity  of  the  vasculature  has  been  organized  into  a  cascade  model  
hallmarked  by  two  converging  pathways  initiated  by  either  the  extrinsic  or  the  intrinsic  
pathway  and  resulting  in  thrombin  and  fibrin  clot  formation.    While  the  extrinsic  
pathway  is  triggered  by  the  binding  and  subsequent  activation  of  circulating  FVII  to  
exposed  TF  on  a  damaged  vessel  wall  and  thought  to  be  the  dominant  cause  of  
coagulation,  the  intrinsic,  or  ‘contact’  pathway,  is  activated  when  FXII  is  exposed  to  any  
number  of  artificial  or  physiologic  negatively  charged  surfaces  circulating  in  the  blood  
and  subsequently  activates  FXI  to  initiate  the  cascade.    
Although  the  intrinsic  pathway  can  activate  clotting  efficiently  in  vitro,  such  as  in  
clotting  assays  that  use  glass  to  activate  FXII  and  initiate  clotting,  these  tests  do  not  
necessarily  correlate  with  in  vivo  observations  from  hemophilic  or  factor  deficient  
patients.    While  patients  with  hemophilia  A  or  B  (FVIII  or  IX  deficiency)  or  common  
factor  deficiencies  (X,  V,  or  II)  have  severe  bleeding  phenotypes  or  are  incompatible  with  
life  (77),  patients  with  deficiencies  of  FXII  and  FXI  either  have  no  bleeding  tendencies  or  
an  injury-­‐‑related  variable  bleeding  tendency,  respectively  (219),  suggesting  that  FXII  and  
FXI  are  not  required  in  hemostasis.    Mice  lacking  FXI  or  FXII  exhibit  no  bleeding  
phenotype,  and,  interestingly,  both  are  protected  against  thrombus  formation  in  several  
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models  of  arterial  thrombotic  injury.    These  studies  suggest  that,  while  thrombus  
initiation  is  not  interrupted  on  the  vessel  wall  after  injury  in  both  FXI  and  FXII  deficient  
mice,  thrombi  that  are  formed  are  unstable  and  break  up  before  occlusion  of  a  blood  
vessel  can  occur  (40,  72,  73,  91).      Protection  from  thrombosis  is  not  limited  to  arterial  
injury,  as  FXII  or  FXI  deficiency  also  confer  a  thromboprotective  effect  in  a  transient  
middle  cerebral  artery  stroke  model  (MCAO)  (41,  92).    The  antithrombotic  effect  of  FXI  
deficiency  is  also  apparent  across  species,  as  inhibition  of  FXI  with  antibodies  in  rabbits  
and  baboons  resulted  in  reduced  thrombus  propagation  and  prevented  growth  of  
occlusive  thrombi  in  either  injured  arteries  or  on  arterio-­‐‑venous  shunts,  respectively    
(74-­‐‑77,  93).  Taken  together,  this  work  increasingly  suggests  that  inhibition  of  the  
upstream,  intrinsic  coagulation  factors  XI  and  XII  can  hinder  thrombosis  without  
affecting  normal  hemostatic  events  (220).  It  then  follows  that  the  pharmacological  
inhibition  of  FXI  and  FXII  in  humans  could  produce  a  safe  and  effective  anticoagulant  to  
treat  and  prevent  thromboembolic  disorders  (Figure  41).    
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Figure  41.  Decoupling  hemostasis  and  thrombosis  
While  the  extrinsic  pathway  is  essential  for  initiating  hemostasis  at  the  site  of  blood  
vessel  wall  injury,  continued  thrombin  generation  on  the  clot  surface  due  to  the  intrinsic  
pathway  contributes  to  the  stability  of  the  blood  clot.  Pharmacologic  inhibition  of  FXI  
and  FXII  of  the  intrinsic  pathway  could  lead  to  a  safe  and  effective  antithrombotic  that  
interrupts  thrombosis  without  interrupting  hemostasis.  
  
The  overall  goal  of  this  project  was  to  develop  potent  and  specific  inhibitors  of  
the  intrinsic  pathway  utilizing  the  aptamer  platform  of  therapeutics  and  evaluate  this  
inhibition  as  a  potential  anticoagulant  strategy.    Currently  approved  anticoagulants  
inhibit  either  downstream  or  multiple  members  of  the  coagulation  pathway.    While  
these  drugs  are  effective  anticoagulants,  they  are  not  always  safe,  and  drug  
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administration  without  a  direct  antidote  can  require  constant  monitoring  and  confer  a  
higher  risk  of  bleeding  complications.    Striking  the  correct  balance  between  inhibiting  
thrombus  formation  (efficacy)  and  reducing  the  risk  of  severe  bleeding  (safety)  is  crucial  
in  developing  a  novel  anticoagulant.    This  ratio  of  efficacy  to  safety  can  be  achieved  by  
two  ways:  targeting  factors  that  cause  bleeding,  but  having  the  ability  to  reverse  the  
drug’s  action,  or  targeting  factors  involved  in  pathological  thrombus  formation  that  do  
not  play  a  major  part  in  hemostasis.    While  aptamer-­‐‑antidote  pairs  targeting  
downstream  members  of  the  coagulation  pathway  (including  FII,  FX,  and  FIX)  have  
previously  been  described  to  be  effective  anticoagulants  yet  will  require  antidotes  to  be  
safely  administered,  this  project  was  successful  in  isolating  effective  aptamer  inhibitors  
of  two  upstream  members  of  the  intrinsic  pathway,  FXI  and  FXII,  which  may  not  require  
antidotes  to  be  safe  and  effective  anticoagulants.  
5.2 Discovery and pre-clinical development of intrinsic pathway 
aptamer inhibitors  
The  discovery  and  initial  development  phase  of  aptamer  therapeutics  includes  
performing  a  directed  evolution  selection  to  isolate  a  specific,  high  affinity  aptamer,  and  
subsequently  testing  this  aptamer  in  a  number  of  biochemical  assays  to  identify  its  mode  
of  action,  as  well  as  plasma  or  blood  based  assay  to  asses  its  anticoagulant  potential.    
Both  aptamers  described  in  this  process  were  able  to  be  initially  biochemically  
characterized,  as  well  as  demonstrated  anticoagulant  ability  and  reduction  of  thrombin  
generation  in  a  plasma-­‐‑based  assay  (Figure  42).      
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Figure  42.    Inhibiting  the  intrinsic  pathway  of  coagulation  with  RNA  
aptamers.  
Both  FXII  and  FXIa  aptamers  specifically  inhibit  their  respective  targets  to  decrease  
thrombin  generation  and  fibrin  clot  formation.    
  
While  this  strategy  has  been  used  successfully  to  identify  aptamer  anticoagulants  
specifically  targeting  a  number  of  other  coagulation  factors,  the  plasma-­‐‑based  
characterization  of  intrinsic  pathway  inhibitors  was  hindered  by  several  circumstances.    
The  first  issue  has  been  discussed  at  length  in  the  above  chapters:  the  ability  of  the  
contact  pathway  to  be  readily  activated  during  the  blood  drawing  process.    This  
property  hindered  the  use  of  in  vitro,  plasma-­‐‑based  assays  to  be  utilized  to  screen  a  large  
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number  of  intrinsic  pathway  inhibitory  aptamers  for  anticoagulant  activity.    Instead,  
more  time  intensive  biochemical  assays  were  employed  to  screen  these  aptamers  for  
functionality  before  moving  into  more  complex  plasma-­‐‑based  assays.  It  was  not  until  the  
introduction  of  the  use  of  CTI,  which  inhibits  contact  activation  in  the  sample  during  the  
blood  drawing  process,  that  we  were  able  to  see  potent  inhibitory  effects  upon  aptamer  
administration  in  a  plasma-­‐‑based  setting.    It  was  hypothesized  that  previous  contact  
activation  of  the  plasma  sample  led  to  downstream  activation  of  coagulation  factors,  
perhaps  culminating  with  FXIa  binding  to  FIX.    It  has  been  determined  that  only  a  small  
amount  of  thrombin  formed  can  lead  to  the  fibrin  clot  formation  measured  in  clotting  
time  assays.    Upon  re-­‐‑calcification,  any  residual  FXIa  bound  to  FIX  can  now  activate  FIX;  
however,  inhibition  of  FXII/FXIIa  or  FXI/FXIa  would  not  have  a  large  effect  on  clotting  
times  in  a  plasma  sample  that  can  already  produce  a  small  amount  of  thrombin  due  to  
basal  activation.    Further  studies  into  the  difference  of  using  contact  pathway  inhibited  
plasma  versus  untreated  plasma  will  continue  to  clarify  these  differences  and  allow  us  
to  better  screen  and  characterize  our  aptamer  libraries  against  FXI,  FXII  and  kallikrein.    
Aside  from  hindrances  during  the  blood  drawing  process,  in  vitro  plasma  or  
blood-­‐‑based  assays  that  closely  mimic  physiologic  responses  are  lacking  in  the  
laboratory  and  the  field.    While  it  is  widely  accepted  that  the  extrinsic  pathway  is  the  
main  contributor  to  coagulation  in  vivo,  the  aPTT  and  PT  use  extreme  amounts  of  either  
intrinsic  or  extrinsic  pathway  activators  in  order  to  reach  a  standardized  clotting  time  
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utilized  in  the  clinic  for  reproducibility.    These  activators  are  mostly  non-­‐‑physiologic  
substances  or  are  more  concentrated  than  in  any  physiologic  setting;  thus,  they  fully  and  
quickly  activate  the  clotting  cascade.    As  these  assays  were  primarily  based  off  the  initial  
cascade  model  of  coagulation,  they  do  not  take  into  account  the  importance  of  surfaces  
for  clotting  to  occur,  as  platelets  are  replaced  by  phospholipids  and  endothelial  cells  are  
presumably  not  present.    It  is  our  observation  that  inhibition  of  the  common  pathway  
proteases  (FII  and  FX)  can  completely  disrupt  clotting  in  these  assays,  while  intrinsic  
pathway  inhibitors  have  a  lesser  effect  on  clotting  times,  with  clots  eventually  being  able  
to  form.    Therefore,  while  this  assay  can  easily  identify  common  pathway  inhibitors,  the  
use  of  intrinsic  pathway  inhibitors  may  not  cause  a  large  effect  on  clotting  times,  and  
thus  it  might  be  harder  to  identify  inhibitors  of  these  targets.    
In  addition,  the  traditional  clotting  assays  and  other  plasma  or  blood  based  in  
vitro  assays  used  in  this  study  do  not  take  into  account  the  influence  of  blood  flow  on  the  
system.    Blood  flow  continuously  supplies  the  area  of  clotting  with  new  material,  
including  zymogens,  platelets,  and  inhibitors,  as  well  as  carrying  away  activated  
proteases,  platelets,  and  inhibitors.    Blood  flow  is  a  currently  underexplored  but  
important  mediated  of  fibrin  deposition  and  can  greatly  influence  the  stability  of  the  clot  
(5).    As  it  is  hypothesized  that  FXI  and  FXII  might  play  a  larger  role  in  continued  
thrombin  generation  than  initial  clot  formation,  inhibitors  of  these  two  proteases  in  a  
flow-­‐‑based  system  might  play  a  larger  role  than  indicated  using  non-­‐‑flow  assays.    As  
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more  is  known  about  the  difference  between  thrombotic  environments  versus  
hemostatic  environments,  in  vitro  assays  need  to  be  developed  to  mimic  these  settings.      
In  addition  to  choosing  the  most  physiologic  in  vitro  assays  to  more  effectively  
examine  thrombosis  versus  hemostasis,  the  choice  of  animal  species  and  animal  model  
during  pre-­‐‑clinical  drug  development  can  greatly  influence  the  result.    Because  aptamers  
bind  tightly  over  a  large  surface  area  on  the  protein’s  surface,  they  do  not  always  exhibit  
a  high  rate  of  cross-­‐‑reactivity  to  other  species,  where  even  one  amino  acid  change  over  
the  binding  region  can  disrupt  aptamer-­‐‑protein  binding.    Anecdotally,  it  is  thought  that  
if  the  aptamer  inhibits  an  established  coagulation  reaction  found  across  species,  such  as  
the  binding  of  FV  to  FX  to  form  the  prothrombinase  complex,  then  this  reaction,  and  
thus  the  specific  exosites  on  each  protein,  should  be  highly  conserved.    Therefore,  an  
aptamer  that  binds  to  that  exosite  and  inhibits  that  reaction  theoretically  has  a  higher  
chance  of  cross-­‐‑reacting  with  different  species.    In  general,  aptamers  tend  to  target  
exosites  on  the  surfaces  of  proteins.    We  found  (summarized  in  Chapter  4,  as  well  as  
unpublished  data)  that  aptamers  targeting  the  downstream  coagulation  factors  (FII,  FX  
and  FIX),  all  which  block  exosites  on  their  target  protein,  have  a  higher  rate  of  cross-­‐‑
reactivity  over  the  animal  species  tested  than  the  intrinsic  pathway-­‐‑targeting  aptamers.    
This  mirrors  what  is  thought  to  have  occurred  evolutionarily  –  with  the  emergence  of  
the  common  pathway  proteases  first,  followed  by  the  more  recent  emergence  of  the  
intrinsic  pathway.    Thus,  our  data  indirectly  hints  that  the  protein  exosites  on  proteins  
     203  
higher  up  the  cascade  may  not  be  as  conserved  across  species.    Further  biochemical  
studies,  including  crystal  structures  of  aptamers  bound  to  proteins,  would  be  needed  to  
examine  this  theory.    
Because  the  proteins  for  FXI  and  FXII  may  not  be  as  conserved  across  species,  
established  animal  models  of  thrombosis  or  hemostasis  used  to  evaluate  inhibition  of  
FXI  and  FXII  are  brought  into  question.    If  the  function  of  FXI  and/or  FXII  are  slightly  
different  in  an  animal  than  a  human,  then  determination  of  the  therapeutic  potential  of  
an  inhibitor  may  not  correlate.    Animals  may  not  be  “small  humans”  where  the  
pathways  are  identical  between  the  two  species.    In  this  instance,  it  has  been  observed  
that  different  species  have  different  clotting  times,  with  rabbits  and  rats  clotting  very  
quickly  compared  with  humans  or  non-­‐‑human  primates.    This  indicates  that  the  
coagulation  system  may  have  some  very  real  differences,  if  not  just  the  concentration  of  
protein  present  in  the  blood.    Both  of  these  species  need  to  have  higher  amounts  of  CTI  
present  in  order  to  prevent  the  contact  pathway  from  becoming  activated,  indicating  
that  this  pathway  might  play  a  greater  role  in  coagulation  than  in  humans.  Therefore,  
the  use  of  these  animal  models  to  characterize  inhibitors,  as  well  as  the  murine  data  
using  FXI  or  FXII  deficient  mice,  may  not  replicate  what  is  or  will  be  seen  in  humans.    
The  selection  of  the  right  animal  model  is  key  in  developing  these  aptamers  further  as  
therapeutics.    Currently,  the  FXI  and  FXII  aptamers  do  not  potently  cross  react  in  any  
animal  species  besides  human.    Additional  experiments  using  correct  blood  drawing  
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processes  are  underway  to  test  these  aptamers  in  more  closely  related  species  where  the  
cost  to  do  animal  model  experiments  have  been  decreasing,  including  non-­‐‑human  
primates.  
Aside  from  testing  the  aptamers  against  different  animal  serums,  strategies  to  re-­‐‑
design  the  aptamer  to  be  cross-­‐‑reactive  can  be  undertaken.    The  human  binding  aptamer  
can  be  partially  randomized  and  re-­‐‑selected  against  the  animal  protein  in  a  “doped-­‐‑
pool”  SELEX.      The  goal  of  this  SELEX  would  be  that  slight  changes  in  the  final  aptamer  
sequence  will  bind  to  the  same  exosite  on  the  human  protein  and  with  a  higher  affinity  
to  the  animal  protein.    This  selection  assumes  that  high-­‐‑quality,  purified  animal  proteins  
are  available.    Unfortunately,  these  are  not  currently  available  commercially  for  FXI  or  
FXII.    
In  subsequent  selections,  the  consideration  of  cross-­‐‑reactivity  can  be  included  in  
the  selection  protocol,  therefore  considering  pre-­‐‑clinical  studies  during  the  drug  
discovery  process.    The  first  instance  of  this  was  demonstrated  using  a  toggle  selection  
approach,  whereby  a  thrombin  aptamer  was  isolated  that  could  bind  to  both  human  and  
pig  thrombin  by  alternating  selection  rounds  with  each  purified  protein  (151).    Again,  
while  this  strategy  is  effective,  it  is  limited  with  the  ability  to  obtain  highly  purified  
animal  protein.    
Aside  from  toggle  SELEX,  there  are  other  strategies  that  can  be  employed  to  
increase  cross-­‐‑reactivity.  If  no  purified  protein  is  available,  a  complex  convergent  toggle  
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selection  may  be  employed.    The  complex  SELEX  approach  has  previously  been  utilized  
to  select  for  a  library  of  aptamers  that  bind  to  a  mixture  of  proteins  including  the  plasma  
proteome  (152).    Theoretically,  a  complex  toggle  approach  would  alternate  selection  
rounds  between  human  and  animal  plasma  proteomes,  with  a  resulting  pool  of  aptamer  
sequences  that  can  bind  to  both  proteomes.    This  strategy  can  be  employed  in  several  
different  ways  to  increase  the  probability  of  isolating  an  aptamer  that  can  bind  to  both  
species  –  the  plasma  proteomes  can  be  combined  to  form  a  mixture  of  human  and  
animal  proteins,  or  a  complex  selection  can  be  performed  on  the  animal  proteome  
followed  by  a  convergent  selection  with  the  purified  human  target  protein.    Any  number  
of  these  selections  could  1)  increase  the  chance  of  obtaining  a  species  cross-­‐‑reactive  
aptamer  and  2)  not  require  the  use  of  high  quantities  of  purified  animal  proteins.      
5.3 Clinical development of aptamer therapeutics  
Before  aptamers  begin  preclinical  and  clinical  trials,  several  optimization  steps  
must  occur  in  order  to  make  the  compound  cost-­‐‑effective  and  able  to  be  stably  
administered.    First,  in  order  to  decrease  manufacturing  and  material  costs,  as  well  as  
potentially  decrease  any  non-­‐‑specific,  RNA  length  dependent  issues,  the  aptamer  is  
truncated  to  the  shortest  length  possible  that  retains  binding  affinity  and  anticoagulant  
function.    The  FXII  and  FXI  aptamers  were  isolated  using  an  80  and  71  nucleotide  
modified  RNA  library,  respectively.    While  these  libraries  are  able  to  isolate  functional  
aptamers,  the  functional  portion  of  the  aptamer  may  not  include  all  nucleotides.    
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Truncation  is  aided  by  comparing  each  family  of  aptamer  sequences  within  a  selection.    
While  these  families  differ  considerably  in  base  composition,  there  may  be  conserved  
strings  of  bases  found  throughout  several  different  families.    Using  this  strategy,  the  
FXII  aptamer  was  truncated  from  80  nucleotide  to  52  nucleotide  while  keeping  intact  a  
conserved  string  of  bases.    Previously,  40  nucleotides  was  the  maximum  length  for  a  
cost-­‐‑effective  aptamer,  that  length  has  gone  up  as  manufacturing  costs  have  been  
reduced,  and  a  50-­‐‑mer  is  possible  for  cost-­‐‑effect,  large  scale  production.    The  FXI  
aptamer  has  not  yet  been  truncated.    
In  addition  to  truncation,  the  aptamer  is  further  optimized  by  replacing  as  many  
2’F  pyrimidine  modifications  and  2’hydroxyl  nucleotides  to  a  2’O-­‐‑methyl  modification  
in  order  to  further  increase  stability  as  well  as  reduce  the  likelihood  of  activating  innate  
immune  responses.    This  reduces  production  costs  while  still  protecting  the  aptamer  
from  endonuclease  cleavage.    In  addition,  stabilization  of  the  aptamer  by  optimizing  the  
stems  present  in  the  RNA  structure,  such  as  switching  a  U-­‐‑A  base  pair  to  the  more  stable  
G-­‐‑C  base  pair,  can  also  be  performed  if  needed.    Oftentimes,  this  can  aid  in  truncation,  
as  two  consecutive  U-­‐‑A  base  pairs  making  up  a  stem  can  sometimes  be  altered  to  one  G-­‐‑
C  base  pair  without  disrupting  the  stability  of  the  aptamer.      
In  preparation  for  animal  or  human  administration,  a  high  molecular  weight  
moiety,  such  as  PEG,  will  be  appended  to  the  end  of  the  aptamer  in  order  to  increase  the  
size  of  the  aptamer  and  thus  reduce  clearance  time  facilitated  by  the  kidneys.    While  this  
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modification  does  not  usually  alter  the  structure  of  the  aptamer,  there  have  been  
instances  where  addition  of  a  PEG  can  partially  disrupt  aptamer  binding.    While  this  is  
rare,  the  PEG  can  be  appended  to  the  other  end  of  the  aptamer,  or  a  longer  linker  can  be  
added  to  retain  proper  aptamer  folding  and  function.    In  this  way,  the  half-­‐‑life  of  the  
aptamer  can  be  increased  from  minutes  to  days.    Overall,  this  strategy  has  been  
successful  in  optimizing  aptamers  for  animal  studies,  and  an  anticoagulant  aptamer  
targeting  FIX  modified  with  this  scheme  is  currently  in  Phase  2  clinical  trials.      
5.4 Applications and the therapeutic potential of an intrinsic 
pathway inhibitor 
Overall,  inhibition  of  the  intrinsic  pathway  could  be  the  “holy  grail”  of  
anticoagulant  therapy,  as  inhibition  of  either  FXI  or  FXII  seems  promising  in  inhibiting  
thrombosis  without  affecting  hemostasis.    There  is  some  debate  that  FXI  may  be  the  
preferred  target,  as  it  is  thought  to  be  primarily  a  coagulation  protein  with  no  known  
large  roles  in  other  physiologic  processes.  FXII,  on  the  other  hand,  has  emerging  roles  in  
inflammation  as  well  as  potential  basal  growth  factor  activity  stemming  from  low  levels  
of  zymogen  activity.    In  this  setting,  an  aptamer  therapeutic  might  be  beneficial,  as  
aptamers  can  block  distinct  functions  based  on  the  binding  site  location  on  the  target  
protein.    To  this  end,  while  the  FXII  aptamer  described  here  inhibits  FXI  activation,  it  
does  not  effect  prekallikrein  activation,  and  thus  potentially  might  affect  coagulation  but  
not  inflammatory  processes.    As  other  roles  of  FXII  are  elucidated,  aptamer  effects  can  be  
studied,  including  FXII’s  emerging  role  as  a  growth  factor.    Because  of  the  low  risk  of  
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bleeding  and  central  role  as  a  contact  activator,  inhibition  of  FXI  or  FXII  can  be  utilized  a  
drug  therapy  in  many  ways,  including  long  term  therapy  to  prevent  thrombosis  in  at-­‐‑
risk  patient  populations  or  in  combination  therapy  to  inhibit  blood  contact  activation  
when  using  artificial  surfaces,  such  as  catheters  or  a  heart-­‐‑lung  machine.  
The  development  of  an  intrinsic  pathway  aptamer  as  a  long-­‐‑term  anticoagulant  
has  several  benefits  and  drawbacks.  Although  inhibition  of  FXI  or  FXII  is  not  anticipated  
to  be  correlated  with  major  bleeding  events,  some  bleeding  events  associated  with  
surgical  procedures  in  specific  tissues  have  been  reported  in  FXI-­‐‑deficient  patients.    
Aptamers  inherently  have  the  ability  to  be  reversed,  and  this  technology  has  been  tested  
in  humans  to  be  fast-­‐‑acting  and  effective  (163).    While  minimal  events  are  expected  with  
intrinsic  pathway  inhibition,  a  readily  available  antidote  can  further  increase  the  safety  
of  these  drugs  by  rendering  the  target  protein  completely  functional  within  minutes  of  
antidote  administration.    
While  long-­‐‑term  anticoagulation  has  traditionally  been  effectively  administered  
orally,  aptamers  are  currently  only  parentally  available,  which  limits  their  use  to  
injections  or  intravenous  use,  especially  during  surgical  procedures.    Preliminary  data  
has  suggested  that  aptamers  can  also  be  administered  subcutaneously  with  a  longer  
onset  of  action,  which  is  an  acceptable  mode  of  administration  for  a  long-­‐‑term  
anticoagulant  (189).    However;  while  aptamer  effects  can  be  seen  for  weeks  after  
subcutaneous  administration,  a  rebound  anticoagulant  effect  is  exhibited  after  antidote  
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use.    However,  this  should  not  be  a  hindrance  to  an  intrinsic  pathway  inhibitor  where  
antidote  use  is  expected  to  be  minimal  or  for  acute  settings  where  re-­‐‑dosing  of  antidote  
is  possible.    
Aptamers  inhibiters  of  other  major  coagulation  proteases  have  previously  been  
described  (164,  181,  182).    While  all  are  functional  inhibitors  of  their  protease  target  and  
can  independently  anticoagulate  blood  or  plasma,  their  concurrent  administration  
synergizes  with  greatly  increased  anticoagulant  effects  (data  not  published).    Current  
studies  are  ongoing  to  determine  an  effective  anticoagulant  strategy  for  use  in  cardio-­‐‑
pulmonary  bypass,  with  preliminary  data  suggesting  that  inhibiting  two  sequential  
steps  in  the  coagulation  cascade  is  the  most  potent  anticoagulation  combination.    The  
addition  of  an  intrinsic  pathway  aptamer  inhibitor  could  also  be  beneficial  in  this  highly  
thrombogenic,  artificial  setting,  where  blood  flows  through  tubing  and  over  an  
oxygenator.    Use  of  the  FXII  aptamer  to  inhibit  contact  activation  by  these  materials  
could  lead  to  reduced  activation  of  coagulation  factors,  and  potentially  lower  dosing  
requirements  for  other  aptamers.    Currently,  the  use  of  two  highly  potent,  non-­‐‑aptamer  
anticoagulants  is  limited,  as  synergy  can  oftentimes  result  in  uncontrollable  hemorrhage.    
Importantly,  concomitant  use  of  several  aptamers  is  ultimately  safer,  as  you  can  quickly  
reverse  all  aptamers  using  an  universal  antidote,  or  reverse  the  action  of  just  one  
aptamer  by  using  a  sequence  specific  antidote.    In  addition,  full  or  partial  reversal  of  
aptamer  function  can  be  reproducibly  performed.    This  level  of  control  with  an  
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anticoagulant  therapeutic  is  unparalleled,  and  can  lead  to  multiple  applications  in  the  
surgical  field.  
In  the  laboratory,  aptamers  are  useful  tools  to  examine  diverging  functions  of  a  
protease,  as  they  can  inhibit  specific  functions  while  leaving  others  intact.    The  FXII  
aptamer  described  in  this  project  inhibits  coagulation  (FXI  activation)  but  not  
inflammation  (prekallikrein  activation).    While  in  vivo  the  aptamer  may  effect  both  
functions  of  FXII  because  it  inhibits  the  first  step  of  FXII  autoactivation,  this  aptamer  can  
be  used  to  examine  the  difference  between  FXIIa-­‐‑mediated  reactions  in  the  laboratory.  
As  FXII  and  FXIIa  has  increasingly  been  shown  to  be  involved  in  a  number  of  different  
processes,  this  aptamer  could  be  valuable  in  discerning  the  influence  of  its  separate  
functions.    Similarly,  FXI  has  binding  sites  for  multiple  coagulation  proteins,  including  
the  platelet  receptor  GP1bα,  and  can  be  activated  by  other  proteases  other  than  FXII.    
While  aptamer  effects  on  these  interaction  has  not  yet  been  assessed,  further  biochemical  
characterization  will  allow  for  detailed  mechanisms  in  aptamer  inhibition,  and  the  
potential  to  aid  in  further  discerning  the  biologic  function  of  FXI.  
5.5 Summary 
Overall,  the  novel  aptamer  inhibitors  of  FXII  and  FXI  described  here  are  
promising  as  potential  therapeutics.  As  both  of  these  aptamers  can  decrease  thrombin  
generation  in  plasma-­‐‑based  assays,  further  in  vivo  analysis  will  determine  if  these  
aptamers  can  affect  the  FXII-­‐‑mediated  FXI  activation  that  contributes  to  attenuated  
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thrombin  generation  in  a  thrombotic  environment.    As  a  class  of  drugs,  aptamers  lend  
themselves  well  to  anticoagulation,  as  they  can  inhibit  specific  protein-­‐‑mediated  
reactions,  thus  eliminating  off  target  effects  for  a  protein,  especially  FXII,  whose  role  in  
several  pathways  is  not  yet  elucidated.  In  addition,  aptamers  have  the  ability  to  be  
quickly  reversed  while  leaving  their  target  protein  intact,  thus  increasing  their  safety  
during  potential  bleeding  events.    In  the  setting  of  FXII  and  FXI,  this  is  attractive  not  
only  for  FXI  aptamer  therapy,  where  mild  bleeding  events  may  occur,  but  also  for  
potential  combination  therapy  with  a  more  potent  antiplatelet  agent  or  antithrombotic  
agent,  which,  while  effective,  has  been  hindered  by  a  lack  of  safety  due  to  increased  
bleeding  events.    Lastly,  this  project  highlights  the  need  for  better  physiologic  laboratory  
assays  in  which  to  study  potential  drug  therapeutics.    We  were  successful  in  developing  
a  standardized  assay  that  can  detect  changes  in  thrombin  generation  during  inhibition  of  
the  common  or  intrinsic  pathway  of  coagulation.    As  many  common  coagulation  tests  
were  based  off  of  outdated  coagulation  models,  the  introduction  of  new  or  updated  tests  
should  be  welcomed  to  the  laboratory.  
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Appendix A 
Throughout  this  project,  it  was  noticed  that  the  aptamer  controls  could  exhibit  
nonspecific  effects  in  plasma-­‐‑based  assays,  notably  the  aPTT  and  TGA.    These  effects,  
however,  were  completely  opposite  in  each  assay,  as  control  RNA  acted  as  an  
anticoagulant  in  an  aPTT  and  an  agonist  in  a  TGA.    The  data  and  some  speculation  as  to  
why  this  occurs  are  found  here.    
In  an  aPTT,  2’F  pyrimidine  modified,  nonspecific  RNA  can  dose-­‐‑dependently  
increase  clotting  times  in  an  aPTT  activated  by  either  micronized  silica  or  ellagic  acid  
(Figure  43).    This  activation  is  also  length  dependent,  as  shorter  RNA’s  exhibit  less  of  an  
effect  on  clotting  times,  with  a  steep  drop  off  in  nonspecific  prolongation  for  RNAs  less  
than  70  nucleotides.    Therefore,  our  aptamers  were  truncated  whenever  possible  to  less  
than  70  nucleotides  to  decrease  nonspecific  effects.    
  
Figure  43.    Control  RNA  comparison  in  an  aPTT  assay  
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Normal  plasma  was  incubated  with  indicated  control  aptamers,  and  activated  with  
micronized  silica  to  obtain  clotting  times.    The  data  represent  the  mean  ±  SEM  of  
duplicate  measures.  
  
It  was  quickly  noticed  that  the  same  RNA  constructs  used  in  the  aPTT  acted  as  
agonists  in  the  modified  TGA,  as  they  also  could  dose-­‐‑dependently  increase  the  rate  and  
peak  amount  of  thrombin  generated  (Figure  44).  This  agonist  effect,  however,  did  not  
alter  the  ETP  of  the  sample.  Anecdotally,  the  control  RNA  had  a  larger  effect  when  the  
baseline  peak  thrombin  generation  of  the  sample  was  low  (around  100nM),  and  it  also  
seems  that  size  has  an  inverse  effect,  with  the  longer  RNA’s  exhibiting  less  of  an  effect  
than  the  shorter  RNA’s.    This  data,  however,  needs  to  be  repeated.    
  
Figure  44.  An  RNA  control  exhibits  antagonistic  effects  in  a  modified  TGA  
assay  
A  50  nucleotide  scrambled  control  RNA  was  incubated  with  plasma  at  the  indicated  
concentrations  before  addition  of  diluted  ellagic  acid  activator  to  begin  thrombin  
generation.  The  data  are  representative  of  three  independent  measures.  
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It  was  determined  that  these  opposite,  nonspecific  effects  depends  on  the  
potency  of  the  activator  (data  not  shown).    The  TGA  uses  200x  diluted  ellagic  acid  to  
initiate  thrombin  generation  with  the  aPTT  uses  “full  strength”  ellagic  acid.    As  tested  by  
an  aPTT  analyzing  lag  times,  as  the  concentration  of  ellagic  acid  increases,  less  agonistic  
effects  of  control  RNA  were  seen,  with  a  switch  to  a  prolongation  of  lag  time  as  the  
reagent  neared  full  strength  (personal  communication  with  Merck).    This  hints  at  
possibly  two  different  mechanisms  of  nonspecific  interactions.      
Control  aPTT  experiments  looking  at  FXIIa  and  FXIa  activated  clotting  times  
suggested  that  the  agonist  effect  may  be  mediated  by  FXIa.    It  is  known  that  polyanions,  
such  as  polyphosphates,  can  act  as  a  cofactor  to  enhance  FXI  activation  by  thrombin  
(111).    Similarly,  incubation  of  either  purified  protein  or  plasma  with  control  aptamer  or  
polyphosphate  accelerated  clotting  times  in  a  FXIa-­‐‑dependent  manner,  while  no  
difference  in  lagtime  was  seen  in  FXIIa-­‐‑initiated  clotting  times  (Figure  45).    As  a  control,  
the  FXII  aptamer  inhibited  clotting  times  in  FXIIa  activated  plasma,  but  acted  similarly  
to  nonspecific  RNA  in  FXIa  activated  plasma.    
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Figure  45.    Analysis  of  polyanions  on  FXIIa  or  FXIa  clotting  times  
The  effect  of  R4cXII-­‐‑1(n),  scrambled  control  RNA  (p)  or  polyphosphates  (q)  in  a  
clotting  assay  activated  with  A)  250nM  FXIIa    or  B)  40nM  FXIa.    The  data  represent  the  
mean  ±  SEM  of  duplicate  measures.  
  
While  the  general  mechanism  on  why  these  nonspecific  effects  occur  is  not  
known,  the  data  hints  at  two  different  mechanisms  that  depend  on  the  concentration  of  
activation  reagent  used.    At  high  concentrations  of  activator  where  activation  is  forced  to  
proceed  through  the  intrinsic  pathway,  nonspecific  RNA  could  interfere  with  binding  
properties  of  the  activator  to  FXII  (it  is  well  established  that  nonspecific  RNA  binds  to  
FXII),  and  thus  slightly  inhibit  clotting.    When  the  activator  is  diluted,  perhaps  allowing  
for  other  feedback  mechanisms  to  contribute  to  thrombin  generation,  nonspecific  RNA  
could  be  acting  as  an  agonist  in  a  FXI-­‐‑dependent  manner.    Further  analysis  will  help  to  
determine  the  specifics  of  these  nonspecific,  yet  assay-­‐‑specific,  RNA  effects.
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